

# ABALOPARATIDE

---

## Products Affected

- TYMLOS

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 24 MONTHS  |
| Other Criteria                | OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# ABATACEPT IV

## Products Affected

- ORENCIA INTRAVENOUS

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> |  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.  |
| <b>Coverage Duration</b>            | RA, PJIA, PSA: INITIAL: 6 MOS, RENEWAL: 12 MOS. ACUTE GRAFT VERSUS HOST DISEASE (AGVHD): 1 MO.   |
| <b>Other Criteria</b>               | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA, PJIA, PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

# ABATACEPT SQ

**Products Affected**

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Exclusion Criteria           |  |
| Required Medical Information |  |
| Age Restrictions             |  |
| Prescriber Restrictions      | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.  |
| Coverage Duration            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| Other Criteria               | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PJIA, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications                  | All FDA-approved Indications.  |
| Off Label Uses               |  |
| Part B Prerequisite          | No   |

Formulary ID: 26382  
 Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# ABEMACICLIB

---

## Products Affected

- VERZENIO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ABIRATERONE

## Products Affected

- *abiraterone acetate*
- *abirtega*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# ABIRATERONE SUBMICRONIZED

## Products Affected

- ABIRATERONE ACETATE  
MICRONIZED
- YONSA

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  |   |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       |   |
| <b>Coverage Duration</b>             | 12 MONTHS   |
| <b>Other Criteria</b>                | METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# ACALABRUTINIB

---

## Products Affected

- CALQUENCE

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ACORAMIDIS

## Products Affected

- ATTRUBY

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | CARDIOMYOPATHY OF WILD TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM): INITIAL: 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS I, II, OR III HEART FAILURE, AND 2) DIAGNOSIS CONFIRMED BY (A) BONE SCAN (SCINTIGRAPHY) STRONGLY POSITIVE FOR MYOCARDIAL UPTAKE OF TC-99M-PYP, OR (B) BIOPSY OF TISSUE OF AFFECTED ORGAN(S) (CARDIAC AND POSSIBLY NON-CARDIAC SITES) TO CONFIRM AMYLOID PRESENCE AND CHEMICAL TYPING TO CONFIRM PRESENCE OF TRANSTHYRETIN (TTR) PROTEIN. |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | ATTR-CM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ATTR SPECIALIST, OR MEDICAL GENETICIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>                | ATTR-CM: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER ATTR-CM TTR STABILIZERS (E.G., TAFAMIDIS).   |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# ADAGRASIB

---

## Products Affected

- KRAZATI

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ADALIMUMAB

## Products Affected

- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA-PED>=40KG CROHNS START
- HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST. |
| <b>Coverage Duration</b>            | INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING   |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
|                                      | <p>ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# ADALIMUMAB-AATY

## Products Affected

- *adalimumab-aaty (1 pen) auto-injector kit 40 mg/0.4ml subcutaneous*
- *adalimumab-aaty (1 pen) subcutaneous auto-injector kit 80 mg/0.8ml*
- *adalimumab-aaty (2 pen)*
- *adalimumab-aaty (2 syringe)*
- *adalimumab-aaty cd/uc/hs start*
- YUFLYMA (1 PEN)
- YUFLYMA (2 SYRINGE)
- YUFLYMA-CD/UC/HS STARTER

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST. |
| <b>Coverage Duration</b>            | INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA           |

Formulary ID: 26382  
 Effective: 05/01/2026

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
|                                      | (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

# ADALIMUMAB-ADBIM

## Products Affected

- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: RA, PJA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL: RA, PSO, PJA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, |

Formulary ID: 26382  
 Effective: 05/01/2026

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
|                                      | OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

# ADALIMUMAB-BWWD

## Products Affected

- HADLIMA
- HADLIMA PUSH TOUCH

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: RA, PJA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL: RA, PSO, PJA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES |

Formulary ID: 26382  
 Effective: 05/01/2026

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
|                                      | NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# AFATINIB

---

## Products Affected

- GILOTRIF

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION; NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# ALECTINIB

---

## Products Affected

- ALECENSA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

# ALPELISIB-PIQRAY

## Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

# AMIKACIN LIPOSOMAL INH

## Products Affected

- ARIKAYCE

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE: RENEWAL: 1) NO POSITIVE MAC SPUTUM CULTURE AFTER CONSECUTIVE NEGATIVE CULTURES, AND 2) IMPROVEMENT IN SYMPTOMS. ADDITIONALLY, FOR FIRST RENEWAL, APPROVAL REQUIRES AT LEAST ONE NEGATIVE SPUTUM CULTURE FOR MAC BY SIX MONTHS OF ARIKAYCE TREATMENT. FOR SECOND AND SUBSEQUENT RENEWALS, APPROVAL REQUIRES AT LEAST THREE NEGATIVE SPUTUM CULTURES FOR MAC BY 12 MONTHS OF ARIKAYCE TREATMENT. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | MAC LUNG DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR INFECTIOUS DISEASE SPECIALIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 6 MONTHS.   |
| <b>Other Criteria</b>                |  |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# AMIVANTAMAB-HYALURONIDASE-LPUJ

## Products Affected

- RYBREVANT FASPRO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# AMIVANTAMAB-VMJW

---

## Products Affected

- RYBREVANT

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ANAKINRA

## Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS.   |
| <b>Required Medical Information</b> | INITIAL: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES. DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS. |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.   |
| <b>Coverage Duration</b>            | RA: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. CAPS, DIRA: LIFETIME.  |
| <b>Other Criteria</b>               | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: RA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b>  |
|--------------------------------------|--|
|                                      | ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# APALUTAMIDE

## Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# APOMORPHINE - ONAPGO

## Products Affected

- ONAPGO

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS.  |
| Other Criteria                | PD: RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.                           |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# APOMORPHINE - SL

## Products Affected

- KYNMOBI

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              | PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OF AGE OR OLDER.                                   |
| Prescriber Restrictions       | PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.                             |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS   |
| Other Criteria                | PD: RENEWAL: IMPROVEMENT WITH MOTOR FLUCTUATIONS DURING OFF EPISODES WITH THE USE OF THERAPY. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# APREMILAST

## Products Affected

- OTEZLA
- OTEZLA XR
- OTEZLA/OTEZLA XR INITIATION PK

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: MILD PLAQUE PSORIASIS (PSO): 1) PSORIASIS COVERING LESS THAN 3 PERCENT OF BODY SURFACE AREA (BSA), 2) STATIC PHYSICIAN GLOBAL ASSESSMENT (SPGA) SCORE OF 2, OR 3) PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORE OF 2 TO 9. MODERATE TO SEVERE PSO: PSORIASIS COVERING 3 PERCENT OR MORE OF BSA, OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. BEHCETS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: MILD PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL SYSTEMIC THERAPY (E.G., METHOTREXATE, ACITRETIN, CYCLOSPORINE) OR ONE CONVENTIONAL TOPICAL THERAPY (E.G., TOPICAL CORTICOSTEROIDS). MODERATE TO SEVERE PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. BEHCETS DISEASE: 1) HAS ORAL ULCERS OR A HISTORY OF RECURRENT ORAL ULCERS BASED ON CLINICAL SYMPTOMS, AND 2) TRIAL |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
|                                      | OF OR CONTRAINDICATION TO ONE OR MORE CONSERVATIVE TREATMENTS (E.G., COLCHICINE, TOPICAL CORTICOSTEROID, ORAL CORTICOSTEROID). INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

# ARIMOCLOMOL

## Products Affected

- MIPLYFFA

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | NIEMANN-PICK DISEASE TYPE C (NPC): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH NEUROLOGIST OR GENETICIST. |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| Other Criteria                | NPC: RENEWAL: IMPROVEMENT OR SLOWING OF DISEASE PROGRESSION.   |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# ASCIMINIB

## Products Affected

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>  |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | PREVIOUSLY TREATED OR T315I MUTATION PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML); MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SCEMBLIX IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | 12 MONTHS  |
| <b>Other Criteria</b>                |  |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# ASFOTASE ALFA

## Products Affected

- STRENSIQ

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Exclusion Criteria           |  |
| Required Medical Information |  |
| Age Restrictions             |  |
| Prescriber Restrictions      | HYPOPHOSPHATASIA (HPP): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, GENETICIST, OR METABOLIC SPECIALIST.  |
| Coverage Duration            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| Other Criteria               | INITIAL: PERINATAL/INFANTILE-ONSET HPP: 1) 6 MONTHS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC CHEST DEFORMITY, (II) CRANIOSYNOSTOSIS, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OF VITAMIN B6 DEPENDENT SEIZURES, (V) NEPHROCALCINOSIS OR HISTORY OF ELEVATED SERUM CALCIUM, (VI) HISTORY OR PRESENCE OF NON-TRAUMATIC POSTNATAL FRACTURE AND DELAYED FRACTURE HEALING. JUVENILE-ONSET HPP: 1) 18 YEARS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TNSALP ALPL GENE MUTATION AS CONFIRMED BY GENETIC |

Formulary ID: 26382

Effective: 05/01/2026

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
|                                      | <p>TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALP LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PLP LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PEA LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC DEFORMITIES, (II) PREMATURE LOSS OF PRIMARY TEETH PRIOR TO 5 YEARS OF AGE, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OR PRESENCE OF NON-TRAUMATIC FRACTURES OR DELAYED FRACTURE HEALING. ALL INDICATIONS: 1) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE, 2) CALCIUM OR PHOSPHATE LEVELS ARE NOT BELOW THE NORMAL RANGE, 3) NOT HAVE A TREATABLE FORM OF RICKETS. RENEWAL: ALL INDICATIONS: 1) IMPROVEMENT IN THE SKELETAL CHARACTERISTICS OF HPP, AND 2) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE.</p> |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# ATOGEPANT

## Products Affected

- QULIPTA

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| Other Criteria                | MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# AVACOPAN

## Products Affected

- TAVNEOS

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  | ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS: INITIAL: ANCA SEROPOSITIVE (ANTI-PR3 OR ANTI-MPO). |
| Age Restrictions              |   |
| Prescriber Restrictions       | ANCA-ASSOCIATED VASCULITIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.              |
| Coverage Duration             | INITIAL/RENEWAL: 6 MONTHS.  |
| Other Criteria                | ANCA-ASSOCIATED VASCULITIS: RENEWAL: CONTINUES TO BENEFIT FROM THERAPY.   |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# AVAPRITINIB

---

## Products Affected

- AYVAKIT

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# AVUTOMETINIB-DEFACTINIB

---

## Products Affected

- AVMAPKI FAKZYNJA CO-PACK

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# AXATILIMAB-CSFR

## Products Affected

- NIKTIMVO

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | CHRONIC GRAFT VS HOST DISEASE (CGVHD): 1) FAILURE OF AT LEAST TWO LINES OF SYSTEMIC THERAPY, ONE OF WHICH MUST BE A TRIAL OF OR CONTRAINDICATION TO JAKAFI, AND 2) NO CONCURRENT USE WITH JAKAFI, REZUROCK, OR IMBRUVICA. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# AXITINIB

---

## Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# AZACITIDINE

---

## Products Affected

- ONUREG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# AZTREONAM INHALED

---

## Products Affected

- CAYSTON

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              | 7 YEARS OF AGE OR OLDER       |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# BEDAQUILINE

---

## Products Affected

- SIRTURO

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 24 WEEKS                      |
| <b>Other Criteria</b>                | N/A                           |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# BELIMUMAB

## Products Affected

- BENLYSTA SUBCUTANEOUS

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | INITIAL: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. LUPUS NEPHRITIS (LN): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.  |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS   |
| Other Criteria                | INITIAL: SLE: CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. RENEWAL: SLE: PATIENT HAD CLINICAL IMPROVEMENT. LN: IMPROVEMENT IN RENAL RESPONSE FROM BASELINE LABORATORY VALUES (I.E., EGFR OR PROTEINURIA) AND/OR CLINICAL PARAMETERS. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# BELUMOSUDIL

## Products Affected

- REZUROCK

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | CHRONIC GRAFT VS HOST DISEASE (CGVHD): 1) FAILURE OF AT LEAST TWO LINES OF SYSTEMIC THERAPY, ONE OF WHICH MUST BE A TRIAL OF OR CONTRAINDICATION TO JAKAFI, AND 2) NO CONCURRENT USE WITH JAKAFI, NIKTIMVO, OR IMBRUVICA. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
 Effective: 05/01/2026

# BELZUTIFAN

---

## Products Affected

- WELIREG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# BENDAMUSTINE

## Products Affected

- BENDAMUSTINE HCL  
INTRAVENOUS SOLUTION
- *bendamustine hcl intravenous solution  
reconstituted*
- BENDEKA
- VIVIMUSTA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# BENRALIZUMAB

## Products Affected

- FASENRA
- FASENRA PEN

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.  |
| <b>Coverage Duration</b>            | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE, OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ASTHMA: 1) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
|                                      | EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# BETAINE

---

## Products Affected

- *betaine*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# BEVACIZUMAB-BVZR

---

## Products Affected

- ZIRABEV

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# BEXAROTENE

---

## Products Affected

- *bexarotene*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# BINIMETINIB

---

## Products Affected

- MEKTOVI

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# BORTEZOMIB

## Products Affected

- BORTEZOMIB INJECTION SOLUTION RECONSTITUTED 1 MG, 2.5 MG
- *bortezomib injection solution reconstituted 3.5 mg*
- BORUZU

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
 Effective: 05/01/2026

# BOSENTAN

## Products Affected

- *bosentan oral tablet*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>                | PAH: INITIAL: 1) DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASE IN BILIRUBIN BY 2 OR MORE TIMES ULN, AND 2) NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE. RENEWAL: NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE.  |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# BOSUTINIB

## Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND BOSULIF IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       |   |
| <b>Coverage Duration</b>             | 12 MONTHS   |
| <b>Other Criteria</b>                |   |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# BRIGATINIB

## Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# C1 ESTERASE INHIBITOR-HAEGARDA

## Products Affected

- HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | HEREDITARY ANGIOEDEMA (HAE): INITIAL: 1) TYPE III HAE, OR 2) TYPE I OR II HAE CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTS: C1-INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, IMMUNOLOGIST, ALLERGIST OR PULMONOLOGIST.  |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>                | HAE: INITIAL/RENEWAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS.   |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# CABOZANTINIB CAPSULE

**Products Affected**

- COMETRIQ (100 MG DAILY DOSE)  
ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE)  
ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

| PA Criteria                          | Criteria Details              |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# CABOZANTINIB TABLET

## Products Affected

- CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# CANNABIDIOL

## Products Affected

- EPIDIOLEX

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | INITIAL: DRAVET SYNDROME (DS), LENNOX-GASTAUT SYNDROME (LGS), TUBEROUS SCLEROSIS COMPLEX (TSC): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.                |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS.   |
| Other Criteria                | INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# CAPIVASERTIB

## Products Affected

- TRUQAP ORAL TABLET 200 MG
- TRUQAP ORAL TABLET THERAPY PACK 160 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# CAPMATINIB

---

## Products Affected

- TABRECTA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# CARGLUMIC ACID

## Products Affected

- carglumic acid oral tablet soluble*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | INITIAL: ACUTE OR CHRONIC HYPERAMMONEMIA (HA) DUE TO N ACETYLGLUTAMATE SYNTHASE (NAGS) DEFICIENCY: NAGS GENE MUTATION IS CONFIRMED BY BIOCHEMICAL OR GENETIC TESTING. ACUTE HA DUE TO PROPIONIC ACIDEMIA (PA): 1) CONFIRMED BY ELEVATED METHYLCITRIC ACID AND NORMAL METHYLMALONIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE PCCA OR PCCB GENE. ACUTE HA DUE TO METHYLMALONIC ACIDEMIA (MMA): 1) CONFIRMED BY ELEVATED METHYLMALONIC ACID, METHYLCITRIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE MMUT, MMA, MMAB OR MMADHC GENES. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | ACUTE HA DUE TO NAGS/PA/MMA: 7 DAYS. CHRONIC HA DUE TO NAGS: INITIAL: 6 MOS, RENEWAL: 12 MOS.  |
| <b>Other Criteria</b>                | RENEWAL: CHRONIC HA DUE TO NAGS: PATIENT HAS SHOWN CLINICAL IMPROVEMENT.   |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# CERITINIB

---

## Products Affected

- ZYKADIA ORAL TABLET

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# CERTOLIZUMAB PEGOL

## Products Affected

- CIMZIA (1 SYRINGE)
- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG
- CIMZIA-STARTER

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA. AS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING                    |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
|                                      | <p>PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ. CD: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, RINVOQ, SKYRIZI, TREMFYA. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, SKYRIZI, TREMFYA, OTEZLA. NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PJA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL FOR RA, PSA, PSO, AS, CD, PJA: TRIAL OF OR CONTRAINDICATION TO THE STEP AGENTS IS NOT REQUIRED IF THE PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL FOR RA, PSA, AS, PSO, NR-AXSPA, PJA: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# CETUXIMAB

---

## Products Affected

- ERBITUX

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# CLADRIBINE

## Products Affected

- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  |   |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       |   |
| <b>Coverage Duration</b>             | 48 WEEKS.   |
| <b>Other Criteria</b>                | RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF TWO CYCLES IN EACH). |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# CLOBAZAM-SYMPAZAN

## Products Affected

- SYMPAZAN

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | INITIAL: LENNOX-GASTAUT SYNDROME (LGS): THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS  |
| Other Criteria                | LGS: INITIAL: CONTRAINDICATION TO OR UNABLE TO SWALLOW CLOBAZAM TABLETS OR SUSPENSION.                  |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# COBIMETINIB

---

## Products Affected

- COTELLIC

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# CORTICOTROPIN

## Products Affected

- CORTROPHIN

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | INITIAL: NOT APPROVED FOR DIAGNOSTIC PURPOSES.  |
| <b>Required Medical Information</b> |   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MULTIPLE SCLEROSIS (MS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, ALLERGIST/IMMUNOLOGIST, OPHTHALMOLOGIST, PULMONOLOGIST OR NEPHROLOGIST.   |
| <b>Coverage Duration</b>            | INFANTILE SPASMS AND MS: 28 DAYS. ALL OTHER FDA APPROVED INDICATIONS: INITIAL/RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS: TRIAL OF OR CONTRAINDICATION TO INTRAVENOUS (IV) CORTICOSTEROIDS. RENEWAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MS: DEMONSTRATED CLINICAL BENEFIT WHILE ON THERAPY AS INDICATED BY SYMPTOM RESOLUTION AND/OR NORMALIZATION OF LABORATORY TESTS. PART B BEFORE PART D STEP THERAPY, APPLIES ONLY TO BENEFICIARIES IN AN MA-PD PLAN. |
| <b>Indications</b>                  | All FDA-approved Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# CRIZOTINIB CAPSULE

---

## Products Affected

- XALKORI ORAL CAPSULE

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# CRIZOTINIB PELLETS

## Products Affected

- XALKORI ORAL CAPSULE SPRINKLE  
150 MG, 20 MG, 50 MG

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | NON-SMALL CELL LUNG CANCER (NSCLC), ANAPLASTIC LARGE CELL LYMPHOMA (ALCL), INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT); UNABLE TO SWALLOW CAPSULES. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# DABRAFENIB CAPSULES

---

## Products Affected

- TAFINLAR ORAL CAPSULE

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# DABRAFENIB SUSPENSION

## Products Affected

- TAFINLAR ORAL TABLET SOLUBLE

| PA Criteria                   | Criteria Details                     |
|-------------------------------|--------------------------------------|
| Exclusion Criteria            |                                      |
| Required Medical Information  |                                      |
| Age Restrictions              |                                      |
| Prescriber Restrictions       |                                      |
| Coverage Duration             | 12 MONTHS                            |
| Other Criteria                | UNABLE TO SWALLOW TAFINLAR CAPSULES. |
| Indications                   | All FDA-approved Indications.        |
| Off Label Uses                |                                      |
| Part B Prerequisite           | No                                   |
| Prerequisite Therapy Required | No                                   |

Formulary ID: 26382  
Effective: 05/01/2026

# DACOMITINIB

---

## Products Affected

- VIZIMPRO

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# DALFAMPRIDINE

## Products Affected

- *dalfampridine er*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | MULTIPLE SCLEROSIS (MS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.  |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS  |
| Other Criteria                | MS: INITIAL: HAS SYMPTOMS OF A WALKING DISABILITY (E.G., MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS, UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA). RENEWAL: IMPROVEMENT IN WALKING ABILITY. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# DAROLUTAMIDE

## Products Affected

- NUBEQA

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# DASATINIB

## Products Affected

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND DASATINIB IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       |   |
| <b>Coverage Duration</b>             | 12 MONTHS   |
| <b>Other Criteria</b>                |   |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# DATOPOTAMAB DERUXTECAN-DLNK

---

## Products Affected

- DATROWAY

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# DECITABINE/CEDAZURIDINE

## Products Affected

- INQOVI

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# DEFERASIROX

## Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L. CHRONIC IRON OVERLOAD IN NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT): 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS), AND 2) LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G OF LIVER DRY WEIGHT OR GREATER. RENEWAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L. NTDT: 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) OR 2) LIC OF 3 MG FE/G OF LIVER DRY WEIGHT OR GREATER. |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS OR NTDT: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS OR NTDT: DEFERASIROX SPRINKLE PACKETS: TRIAL OF OR CONTRAINDICATION TO GENERIC DEFERASIROX ORAL TABLET OR TABLET FOR ORAL SUSPENSION.   |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

# DENOSUMAB-BMWO - OSENVELT

## Products Affected

- OSENVELT

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# DEUTETRABENAZINE

## Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR PATIENT TITRATION

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  |  |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | HUNTINGTON DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. TARDIVE DYSKINESIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. |
| <b>Coverage Duration</b>             | 12 MONTHS  |
| <b>Other Criteria</b>                | TARDIVE DYSKINESIA: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.   |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
 Effective: 05/01/2026

# DICLOFENAC TOPICAL SOLUTION

## Products Affected

- *diclofenac sodium external solution 2 %*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 6 MONTHS   |
| Other Criteria                | OSTEOARTHRITIS OF THE KNEE: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DICLOFENAC SODIUM 1.5% TOPICAL DROPS. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# DICLOFENAC-FLECTOR

---

## Products Affected

- *diclofenac epolamine external*

| PA Criteria                   | Criteria Details                    |
|-------------------------------|-------------------------------------|
| Exclusion Criteria            |                                     |
| Required Medical Information  |                                     |
| Age Restrictions              |                                     |
| Prescriber Restrictions       |                                     |
| Coverage Duration             | 12 MONTHS                           |
| Other Criteria                |                                     |
| Indications                   | All Medically-accepted Indications. |
| Off Label Uses                |                                     |
| Part B Prerequisite           | No                                  |
| Prerequisite Therapy Required | No                                  |

# DIMETHYL FUMARATE

## Products Affected

- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*

| PA Criteria                          | Criteria Details              |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
 Effective: 05/01/2026

# DIROXIMEL FUMARATE

---

## Products Affected

- VUMERITY

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# DORDAVIPRONE

---

## Products Affected

- MODEYSO

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# DOSTARLIMAB-GXLY

## Products Affected

- JEMPERLI

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
 Effective: 05/01/2026

# DRONABINOL CAPSULE

## Products Affected

- *dronabinol*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 6 MONTHS   |
| Other Criteria                | NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY: TRIAL OF OR CONTRAINDICATION TO ONE ANTIEMETIC THERAPY. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# DROXIDOPA

## Products Affected

- *droxidopa*

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH): INITIAL: 1) BASELINE BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE POSITION. 2) A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION. |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | NOH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST.  |
| <b>Coverage Duration</b>             | INITIAL: 3 MONTHS RENEWAL: 12 MONTHS  |
| <b>Other Criteria</b>                | NOH: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.   |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# DUPILUMAB

## Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria                          | Criteria Details                  |
|--------------------------------------|-----------------------------------|
| <b>Exclusion Criteria</b>            | PA Criteria: Pending CMS Approval |
| <b>Required Medical Information</b>  | PA Criteria: Pending CMS Approval |
| <b>Age Restrictions</b>              | PA Criteria: Pending CMS Approval |
| <b>Prescriber Restrictions</b>       | PA Criteria: Pending CMS Approval |
| <b>Coverage Duration</b>             | PA Criteria: Pending CMS Approval |
| <b>Other Criteria</b>                | PA Criteria: Pending CMS Approval |
| <b>Indications</b>                   | PA Criteria: Pending CMS Approval |
| <b>Off Label Uses</b>                | PA Criteria: Pending CMS Approval |
| <b>Part B Prerequisite</b>           | PA Criteria: Pending CMS Approval |
| <b>Prerequisite Therapy Required</b> | PA Criteria: Pending CMS Approval |

Formulary ID: 26382  
Effective: 05/01/2026

# DUVELISIB

---

## Products Affected

- COPIKTRA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# EFLORNITHINE

---

## Products Affected

- IWILFIN

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 24 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ELACESTRANT

---

## Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ELAGOLIX

## Products Affected

- ORILISSA ORAL TABLET 150 MG, 200 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.  |
| <b>Age Restrictions</b>             | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 18 YEARS OF AGE OR OLDER.  |
| <b>Prescriber Restrictions</b>      | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS  |
| <b>Other Criteria</b>               | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 2) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND A PROGESTIN-CONTAINING PREPARATION. RENEWAL: 1) IMPROVEMENT IN PAIN ASSOCIATED WITH ENDOMETRIOSIS WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

# ELAPEGADEMASE-LVLR

## Products Affected

- REVCOVI

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | ADENOSINE DEAMINASE SEVERE COMBINED IMMUNE DEFICIENCY (ADA-SCID): INITIAL: ADA-SCID AS MANIFESTED BY: 1) CONFIRMATORY GENETIC TEST, OR 2) SUGGESTIVE LABORATORY FINDINGS (E.G., ELEVATED DEOXYADENOSINE NUCLEOTIDE [DAXP] LEVELS, LYMPHOPENIA) AND HALLMARK SIGNS/SYMPTOMS (E.G., RECURRENT INFECTIONS, FAILURE TO THRIVE, PERSISTENT DIARRHEA). |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | ADA-SCID: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH IMMUNOLOGIST, HEMATOLOGIST/ONCOLOGIST, OR PHYSICIAN SPECIALIZING IN INHERITED METABOLIC DISORDERS.  |
| <b>Coverage Duration</b>             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>                | ADA-SCID: RENEWAL: 1) IMPROVEMENT OR MAINTENANCE OF IMMUNE FUNCTION FROM BASELINE, AND 2) HAS NOT RECEIVED SUCCESSFUL HCT OR GENE THERAPY.   |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# ELEXACAFITOR-TEZACAFITOR-IVACAFITOR

## Products Affected

- TRIKAFTA ORAL TABLET THERAPY
- TRIKAFTA ORAL THERAPY PACK PACK

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  |   |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.   |
| <b>Coverage Duration</b>             | INITIAL: 6 MONTHS. RENEWAL: LIFETIME.   |
| <b>Other Criteria</b>                | CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# ELRANATAMAB-BCMM

## Products Affected

- ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| Other Criteria                | RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RENEWAL: 1) HAS RECEIVED AT LEAST 24 WEEKS OF TREATMENT WITH ELREXFIO, AND 2) HAS RESPONDED TO TREATMENT (PARTIAL RESPONSE OR BETTER), AND HAS MAINTAINED THIS RESPONSE FOR AT LEAST 2 MONTHS. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# ELTROMBOPAG - ALVAIZ

## Products Affected

- ALVAIZ

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT IS LESS THAN $30 \times 10^9/L$ , OR 2) PLATELET COUNT IS LESS THAN $50 \times 10^9/L$ AND HAD A PRIOR BLEEDING EVENT.  |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.   |
| <b>Coverage Duration</b>             | ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.   |
| <b>Other Criteria</b>                | INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNT FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# ELTROMBOPAG - PROMACTA

## Products Affected

- *eltrombopag olamine oral packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT OF LESS THAN $30 \times 10^9/L$ , OR 2) PLATELET COUNT OF LESS THAN $50 \times 10^9/L$ AND A PRIOR BLEEDING EVENT.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.  |
| <b>Coverage Duration</b>            | ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.  |
| <b>Other Criteria</b>               | INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR HAD AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). ALL INDICATIONS: ELTROMBOPAG ORAL SUSPENSION PACKETS: TRIAL OF A FORMULARY VERSION OF ELTROMBOPAG TABLET OR PATIENT IS UNABLE TO TOLERATE TABLET FORMULATION. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNTS FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

# ENASIDENIB

---

## Products Affected

- IDHIFA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ENCORAFENIB

---

## Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ENSARTINIB

## Products Affected

- ENSACOVE ORAL CAPSULE 100 MG,  
25 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ENTRECTINIB CAPSULES

---

## Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ENTRECTINIB PELLETS

## Products Affected

- ROZLYTREK ORAL PACKET

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), SOLID TUMORS: 1) TRIAL OF OR CONTRAINDICATION TO ROZLYTREK CAPSULES MADE INTO AN ORAL SUSPENSION, AND 2) DIFFICULTY OR UNABLE TO SWALLOW CAPSULES. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
 Effective: 05/01/2026

# ENZALUTAMIDE

## Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC): HIGH RISK FOR METASTASIS (I.E. PSA DOUBLING TIME OF 9 MONTHS OR LESS). METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), NON-METASTATIC CRPC (NMCRPC), METASTATIC CSPC (MCSPC), NMCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# EPCORITAMAB-BYSP

---

## Products Affected

- EPKINLY

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# EPOETIN ALFA-EPBX

## Products Affected

- RETACRIT INJECTION SOLUTION                      UNIT/ML, 4000 UNIT/ML, 40000  
10000 UNIT/ML, 10000 UNIT/ML(1ML),            UNIT/ML  
2000 UNIT/ML, 20000 UNIT/ML, 3000

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: CHRONIC KIDNEY DISEASE (CKD), ANEMIA RELATED TO ZIDOVUDINE, OR CANCER CHEMOTHERAPY: HEMOGLOBIN LEVEL IS LESS THAN 10G/DL. ELECTIVE, NON-CARDIAC, NON-VASCULAR SURGERY: HEMOGLOBIN LEVEL IS 13G/DL OR LESS. RENEWAL: 1) CKD IN ADULTS NOT ON DIALYSIS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS REACHED 10G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 2) CKD IN PEDIATRIC PATIENTS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS APPROACHED OR EXCEEDS 12G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 3) ANEMIA RELATED TO ZIDOVUDINE: HEMOGLOBIN LEVEL BETWEEN 10G/DL AND 12G/DL. 4) CANCER CHEMOTHERAPY: (A) HEMOGLOBIN LEVEL IS LESS THAN 10 G/DL, OR (B) HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION. |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | ANEMIA FROM CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE: INITIAL/RENEWAL: 12 MONTHS. SURGERY: 1 MONTH.  |
| <b>Other Criteria</b>               | RENEWAL: CKD: NOT RECEIVING DIALYSIS TREATMENT. THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.  |
| <b>Indications</b>                  | All FDA-approved Indications.   |

Formulary ID: 26382

Effective: 05/01/2026

| PA Criteria                   | Criteria Details |
|-------------------------------|------------------|
| Off Label Uses                |                  |
| Part B Prerequisite           | No               |
| Prerequisite Therapy Required | No               |

# ERDAFITINIB

## Products Affected

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ERENUMAB-AOOE

## Products Affected

- AIMOVIG

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| Other Criteria                | MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# ERLOTINIB

## Products Affected

- *erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# ESKETAMINE

## Products Affected

- SPRAVATO (56 MG DOSE)
- SPRAVATO (84 MG DOSE)

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | INITIAL: TREATMENT-RESISTANT DEPRESSION (TRD), MAJOR DEPRESSIVE DISORDER (MDD): PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST OR OTHER REMS-CERTIFIED PROVIDER.                         |
| Coverage Duration             | INITIAL: TRD: 3 MONTHS. MDD: 4 WEEKS. RENEWAL: TRD, MDD: 12 MONTHS.  |
| Other Criteria                | INITIAL: TRD, MDD: 1) NON-PSYCHOTIC, UNIPOLAR DEPRESSION, AND 2) NO ACTIVE SUBSTANCE ABUSE. RENEWAL: TRD, MDD: DEMONSTRATED CLINICAL BENEFIT (IMPROVEMENT IN DEPRESSION) COMPARED TO BASELINE. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# ETANERCEPT

## Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
|                                      | INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# EVEROLIMUS-AFINITOR

## Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
 Effective: 05/01/2026

# EVEROLIMUS-AFINITOR DISPERZ

---

## Products Affected

- *everolimus oral tablet soluble*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# FECAL MICROBIOTA CAPSULE

## Products Affected

- VOWST

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 30 DAYS  |
| Other Criteria                | CLOSTRIDIODES DIFFICILE INFECTION (CDI): 1) HAS NOT PREVIOUSLY RECEIVED VOWST: COMPLETION OF ANTIBIOTIC TREATMENT FOR RECURRENT CDI (AT LEAST 3 CDI EPISODES), OR 2) PREVIOUSLY RECEIVED VOWST: (A) TREATMENT FAILURE (DEFINED AS THE PRESENCE OF CDI DIARRHEA WITHIN 8 WEEKS OF FIRST DOSE OF VOWST AND A POSITIVE STOOL TEST FOR C. DIFFICILE), AND (B) HAS NOT RECEIVED MORE THAN ONE TREATMENT COURSE OF VOWST WHICH WAS AT LEAST 12 DAYS AND NOT MORE THAN 8 WEEKS PRIOR. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# FEDRATINIB

## Products Affected

- INREBIC

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS  |
| Other Criteria                | MYELOFIBROSIS: INITIAL: TRIAL OF OR CONTRAINDICATION TO JAKAFI (RUXOLITINIB). RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# FENFLURAMINE

## Products Affected

- FINTEPLA

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | INITIAL: DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME (LGS): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.   |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS.   |
| Other Criteria                | INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# FENTANYL CITRATE

## Products Affected

- *fentanyl citrate buccal lozenge on a handle*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | CANCER RELATED PAIN: 1) CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION, AND 2) TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT OR PATIENT HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# FEZOLINETANT

## Products Affected

- VEOZAH

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Exclusion Criteria           |  |
| Required Medical Information |  |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | INITIAL/RENEWAL: 12 MONTHS   |
| Other Criteria               | MENOPAUSAL VASOMOTOR SYMPTOMS (VMS): INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO HORMONAL THERAPY (E.G., ESTRADIOL TRANSDERMAL PATCH, ORAL CONJUGATED ESTROGENS), 2) LABORATORY TESTING TO ESTABLISH BASELINE HEPATIC FUNCTION AND CONTINUED MONITORING OF THESE VALUES IN ACCORDANCE WITH THE FDA CURRENT LABEL RECOMMENDATION, AND 3) NO CONCURRENT USE WITH ANOTHER HORMONAL (E.G., PREMPRO) OR NON-HORMONAL (E.G., BRISDELLE) AGENT FOR VMS. RENEWAL: 1) CONTINUED NEED FOR VMS TREATMENT (PERSISTENT HOT FLASHES), 2) REDUCTION IN VMS FREQUENCY OR SEVERITY DUE TO VEOZAH TREATMENT, AND 3) NO NEW SYMPTOMS OF LIVER INJURY AND/OR WORSENING LAB VALUES (E.G., ALT, AST, TOTAL BILIRUBIN). |
| Indications                  | All FDA-approved Indications.  |
| Off Label Uses               |  |
| Part B Prerequisite          | No   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# FILGRASTIM-AAFI

## Products Affected

- NIVESTYM

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.                                       |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# FINERENONE

## Products Affected

- KERENDIA

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | INITIAL: HEART FAILURE (HF): 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS II-IV, AND 2) LEFT VENTRICULAR EJECTION FRACTION OF AT LEAST 40 PERCENT NOT DUE TO AN UNDERLYING CAUSE (E.G., INFILTRATIVE CARDIOMYOPATHY, HYPERTROPHIC CARDIOMYOPATHY, VALVULAR DISEASE, PERICARDIAL DISEASE, HIGH-OUTPUT HEART FAILURE).  |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | INITIAL: HF: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST.  |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL:12 MONTHS   |
| <b>Other Criteria</b>                | CHRONIC KIDNEY DISEASE (CKD) ASSOCIATED WITH TYPE 2 DIABETES (T2D): INITIAL: HISTORY OF AND WILL CONTINUE ON, HAS A CONTRAINDICATION, OR INTOLERANCE TO AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE-I) OR AN ANGIOTENSIN RECEPTOR BLOCKER (ARB). HF: INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER MINERALOCORTICOID (ALDOSTERONE) RECEPTOR ANTAGONIST. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382

Effective: 05/01/2026

# FINGOLIMOD

---

## Products Affected

- *fingolimod hcl*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# FOSCARBIDOPA-FOSLEVODOPA

## Products Affected

- VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.  |
| Coverage Duration             | INITIAL: 12 MONTHS. RENEWAL: 12 MONTHS.   |
| Other Criteria                | PD: INITIAL: ONE OF THE FOLLOWING: 1) UNABLE TO SWALLOW EXTENDED-RELEASE (ER) TABLETS OR ADMINISTER ER CAPSULES VIA A FEEDING TUBE, OR 2) FAILURE TO ADHERE OR TOLERATE VIA A FEEDING TUBE AN ORAL CARBIDOPA/LEVODOPA REGIMEN. RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# FRUQUINTINIB

## Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# FUTIBATINIB

## Products Affected

- LYTGObI (12 MG DAILY DOSE)
- LYTGObI (16 MG DAILY DOSE)
- LYTGObI (20 MG DAILY DOSE)

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA): COMPLETE A COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS. |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       |   |
| <b>Coverage Duration</b>             | 12 MONTHS   |
| <b>Other Criteria</b>                |   |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# GALCANEZUMAB-GNLM

## Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | INITIAL: MIGRAINE PREVENTION: 6 MOS. EPISODIC CLUSTER HEADACHE: 3 MOS. RENEWAL (ALL): 12 MOS.   |
| Other Criteria                | MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. EPISODIC CLUSTER HEADACHE: RENEWAL: IMPROVEMENT IN EPISODIC CLUSTER HEADACHE FREQUENCY AS COMPARED TO BASELINE. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# GANAXOLONE

---

## Products Affected

- ZTALMY

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# GEFITINIB

## Products Affected

- *gefitinib*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION; NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# GEPIRONE

## Products Affected

- EXXUA
- EXXUA TITRATION PACK

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS.  |
| Other Criteria                | MAJOR DEPRESSIVE DISORDER: INITIAL: TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENTS: TRINTELLIX AND ONE GENERIC ANTIDEPRESSANT. INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER 5-HT1A RECEPTOR AGONIST (E.G., BUSPIRONE). RENEWAL: RESPONSE TO OR REMISSION OF DEPRESSIVE SYMPTOMS WITH THERAPY. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# GILTERITINIB

---

## Products Affected

- XOSPATA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# GLASDEGIB

---

## Products Affected

- DAURISMO ORAL TABLET 100 MG,  
25 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# GLATIRAMER

## Products Affected

- *glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# GLP1-DULAGLUTIDE

---

## Products Affected

- TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| PA Criteria                   | Criteria Details                    |
|-------------------------------|-------------------------------------|
| Exclusion Criteria            |                                     |
| Required Medical Information  |                                     |
| Age Restrictions              |                                     |
| Prescriber Restrictions       |                                     |
| Coverage Duration             | 12 MONTHS                           |
| Other Criteria                |                                     |
| Indications                   | All Medically-accepted Indications. |
| Off Label Uses                |                                     |
| Part B Prerequisite           | No                                  |
| Prerequisite Therapy Required | No                                  |

Formulary ID: 26382  
Effective: 05/01/2026

# GLP1-SEMAGLUTIDE

## Products Affected

- OZEMPIC (0.25 OR 0.5 MG/DOSE)
- OZEMPIC (1 MG/DOSE)  
SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- RYBELSUS (FORMULATION R2)

| PA Criteria                   | Criteria Details                    |
|-------------------------------|-------------------------------------|
| Exclusion Criteria            |                                     |
| Required Medical Information  |                                     |
| Age Restrictions              |                                     |
| Prescriber Restrictions       |                                     |
| Coverage Duration             | 12 MONTHS                           |
| Other Criteria                |                                     |
| Indications                   | All Medically-accepted Indications. |
| Off Label Uses                |                                     |
| Part B Prerequisite           | No                                  |
| Prerequisite Therapy Required | No                                  |

Formulary ID: 26382  
Effective: 05/01/2026

# GLP1-TIRZEPATIDE

## Products Affected

- MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| <b>PA Criteria</b>                   | <b>Criteria Details</b>             |
|--------------------------------------|-------------------------------------|
| <b>Exclusion Criteria</b>            |                                     |
| <b>Required Medical Information</b>  |                                     |
| <b>Age Restrictions</b>              |                                     |
| <b>Prescriber Restrictions</b>       |                                     |
| <b>Coverage Duration</b>             | 12 MONTHS.                          |
| <b>Other Criteria</b>                |                                     |
| <b>Indications</b>                   | All Medically-accepted Indications. |
| <b>Off Label Uses</b>                |                                     |
| <b>Part B Prerequisite</b>           | No                                  |
| <b>Prerequisite Therapy Required</b> | No                                  |

Formulary ID: 26382  
Effective: 05/01/2026

# GOSERELIN

## Products Affected

- ZOLADEX

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.                                |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.  |
| <b>Coverage Duration</b>             | STAGE B2-C PROSTATIC CARCINOMA: 4 MOS.<br>ENDOMETRIOSIS: 6 MOS PER LIFETIME. ALL OTHERS: 12 MONTHS.   |
| <b>Other Criteria</b>                | ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 6 MONTHS OF TREATMENT PER LIFETIME. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# GUSELKUMAB

## Products Affected

- TREMFYA INTRAVENOUS
- TREMFYA ONE-PRESS SUBCUTANEOUS SOLUTION PEN-INJECTOR
- TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML
- TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- TREMFYA-CD/UC INDUCTION

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS  |
| <b>Other Criteria</b>               | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION. |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | Yes                           |

# HIGH CONCENTRATION ORAL OPIOID SOLUTIONS

## Products Affected

- *morphine sulfate (concentrate) oral solution 100 mg/5ml*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | OPIOID TOLERANT: 12 MONTHS. HOSPICE, PALLIATIVE CARE OR END OF LIFE CARE: LIFETIME.   |
| Other Criteria                | 1) OPIOID TOLERANT (I.E. PREVIOUS USE OF 60 MG ORAL MORPHINE PER DAY, 25 MCG TRANSDERMAL FENTANYL PER HOUR, 30 MG ORAL OXYCODONE PER DAY, 8 MG ORAL HYDROMORPHONE PER DAY, 25 MG ORAL OXYMORPHONE PER DAY, 60 MG ORAL HYDROCODONE PER DAY, OR AN EQUIANALGESIC DOSE OF ANOTHER OPIOID) AND HAS TROUBLE SWALLOWING OPIOID TABLETS, CAPSULES, OR LARGE VOLUMES OF LIQUID, OR 2) ENROLLED IN HOSPICE OR PALLIATIVE CARE OR END OF LIFE CARE. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# IBRUTINIB

## Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | CHRONIC GRAFT VS HOST DISEASE (CGVHD): NO CONCURRENT USE WITH JAKAFI, NIKTIMVO, OR REZUROCK. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# ICATIBANT

## Products Affected

- *icatibant acetate*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | HEREDITARY ANGIOEDEMA (HAE): INITIAL: 1) TYPE III HAE, OR 2) TYPE I OR II HAE CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTS: C1-INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, HEMATOLOGIST OR PULMONOLOGIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS   |
| <b>Other Criteria</b>                | HAE: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER MEDICATIONS FOR THE TREATMENT OF ACUTE HAE ATTACKS.   |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# IDELALISIB

---

## Products Affected

- ZYDELIG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# IMATINIB

## Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.  |
| Other Criteria                | PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# IMATINIB SOLUTION

## Products Affected

- IMKELDI

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.   |
| Other Criteria                | PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. ALL INDICATIONS: UNABLE TO SWALLOW GENERIC IMATINIB TABLETS. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# IMETELSTAT

---

## Products Affected

- RYTELO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# IMLUNESTRANT

---

## Products Affected

- INLURIYO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# INAVOLISIB

---

## Products Affected

- ITOVEBI ORAL TABLET 3 MG, 9 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# INFLIXIMAB

## Products Affected

- *infliximab*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE.  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, SKYRIZI, TREMFYA, OTEZLA. AS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ. |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
|                                      | <p>MODERATE TO SEVERE CD: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, RINVOQ, SKYRIZI, TREMFYA. UC: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, XELJANZ, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, RINVOQ, SKYRIZI, TREMFYA. INITIAL/RENEWAL: RA, PSA, AS, PSO, MODERATE TO SEVERE CD, UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# INSULIN SUPPLIES PAYMENT DETERMINATION

---

## Products Affected

- ABOUTTIME PEN NEEDLE 30G X 8 MM
- ABOUTTIME PEN NEEDLE 31G X 5 MM
- ABOUTTIME PEN NEEDLE 31G X 8 MM
- ABOUTTIME PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM
- ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 1 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 1 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 1 ML
- ALCOHOL PREP PAD
- ALCOHOL PREP PAD 70 %
- ALCOHOL PREP PADS PAD 70 %
- ALCOHOL SWABS PAD
- ALCOHOL SWABS PAD 70 %
- AQ INSULIN SYRINGE 31G X 5/16" 1 ML
- AQINJECT PEN NEEDLE 31G X 5 MM
- AQINJECT PEN NEEDLE 32G X 4 MM
- ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 0.5 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 1 ML
- ASSURE ID PRO PEN NEEDLES 30G X 5 MM
- AUM ALCOHOL PREP PADS PAD 70 %
- AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM
- AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 6 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 8 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 6 MM
- AUM PEN NEEDLE 32G X 4 MM
- AUM PEN NEEDLE 32G X 5 MM
- AUM PEN NEEDLE 32G X 6 MM

Formulary ID: 26382

Effective: 05/01/2026

- AUM PEN NEEDLE 33G X 4 MM
- AUM PEN NEEDLE 33G X 5 MM
- AUM PEN NEEDLE 33G X 6 MM
- AUM READYGARD DUO PEN NEEDLE 32G X 4 MM
- AUM SAFETY PEN NEEDLE 31G X 4 MM
- BD AUTOSHIELD DUO 30G X 5 MM
- BD ECLIPSE SYRINGE 30G X 1/2" 1 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.3 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.5 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 1 ML
- BD INSULIN SYRINGE 27.5G X 5/8" 2 ML
- BD INSULIN SYRINGE 27G X 1/2" 1 ML
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (RX)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE HALF-UNIT 31G X 5/16" 0.3 ML
- BD INSULIN SYRINGE MICROFINE 27G X 5/8" 1 ML
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE U-100 1 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.5 ML
- BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM
- BD PEN NEEDLE MINI U/F 31G X 5 MM
- BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM
- BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM
- BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM
- BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM
- BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 1 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8" 1 ML
- BD SWAB SINGLE USE REGULAR PAD
- BD SWABS SINGLE USE BUTTERFLY PAD
- BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.5 ML

Formulary ID: 26382

Effective: 05/01/2026

- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 1 ML
- CAREFINE PEN NEEDLES 29G X 12MM
- CAREFINE PEN NEEDLES 30G X 8 MM
- CAREFINE PEN NEEDLES 31G X 6 MM
- CAREFINE PEN NEEDLES 31G X 8 MM
- CAREFINE PEN NEEDLES 32G X 4 MM
- CAREFINE PEN NEEDLES 32G X 5 MM
- CAREFINE PEN NEEDLES 32G X 6 MM
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.3 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 1 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH ALCOHOL PREP PAD 70 %
- CARETOUCH INSULIN SYRINGE 28G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 29G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH PEN NEEDLES 29G X 12MM
- CARETOUCH PEN NEEDLES 31G X 5 MM
- CARETOUCH PEN NEEDLES 31G X 6 MM
- CARETOUCH PEN NEEDLES 31G X 8 MM
- CARETOUCH PEN NEEDLES 32G X 4 MM
- CARETOUCH PEN NEEDLES 32G X 5 MM
- CARETOUCH PEN NEEDLES 33G X 4 MM
- CLEVER CHOICE COMFORT EZ 29G X 12MM
- CLEVER CHOICE COMFORT EZ 33G X 4 MM
- CLICKFINE PEN NEEDLES 31G X 8 MM
- CLICKFINE PEN NEEDLES 32G X 4 MM
- COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT ASSIST INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 27G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 1 ML

Formulary ID: 26382  
 Effective: 05/01/2026

- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 1 ML
- COMFORT EZ PEN NEEDLES 31G X 5 MM
- COMFORT EZ PEN NEEDLES 31G X 6 MM
- COMFORT EZ PEN NEEDLES 31G X 8 MM
- COMFORT EZ PEN NEEDLES 32G X 4 MM
- COMFORT EZ PEN NEEDLES 32G X 5 MM
- COMFORT EZ PEN NEEDLES 32G X 6 MM
- COMFORT EZ PEN NEEDLES 32G X 8 MM
- COMFORT EZ PEN NEEDLES 33G X 4 MM
- COMFORT EZ PEN NEEDLES 33G X 5 MM
- COMFORT EZ PEN NEEDLES 33G X 6 MM
- COMFORT EZ PEN NEEDLES 33G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 30G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 4 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM
- CURITY ALCOHOL PREPS PAD 70 %
- CURITY ALL PURPOSE SPONGES PAD 2"X2"
- CURITY GAUZE PAD 2"X2"
- CURITY GAUZE SPONGE PAD 2"X2"
- CURITY SPONGES PAD 2"X2"
- CVS ALCOHOL PREP PADS PAD 70 %
- CVS GAUZE PAD 2"X2"
- CVS GAUZE STERILE PAD 2"X2"
- *cvs isopropyl alcohol wipes*
- CVS PREP PAD 70 %
- DERMACEA GAUZE SPONGE PAD 2"X2"
- DERMACEA IV DRAIN SPONGES PAD 2"X2"
- DERMACEA NON-WOVEN SPONGES PAD 2"X2"
- DERMACEA TYPE VII GAUZE PAD 2"X2"
- DIATHRIVE PEN NEEDLE 31G X 5 MM
- DIATHRIVE PEN NEEDLE 31G X 6 MM
- DIATHRIVE PEN NEEDLE 31G X 8 MM
- DIATHRIVE PEN NEEDLE 32G X 4 MM

Formulary ID: 26382  
Effective: 05/01/2026

- DROPLET INSULIN SYRINGE 29G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 1 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 1 ML
- DROPLET MICRON 34G X 3.5 MM
- DROPLET PEN NEEDLES 29G X 10MM
- DROPLET PEN NEEDLES 29G X 12MM
- DROPLET PEN NEEDLES 30G X 8 MM
- DROPLET PEN NEEDLES 31G X 5 MM
- DROPLET PEN NEEDLES 31G X 6 MM
- DROPLET PEN NEEDLES 31G X 8 MM
- DROPLET PEN NEEDLES 32G X 4 MM
- DROPLET PEN NEEDLES 32G X 5 MM
- DROPLET PEN NEEDLES 32G X 6 MM
- DROPLET PEN NEEDLES 32G X 8 MM
- DROPSAFE ALCOHOL PREP PAD 70 %
- DROPSAFE AUTOPROTECT DUO 31G X 4 MM
- DROPSAFE AUTOPROTECT DUO 31G X 8 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM
- DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 1 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 0.3 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 1 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 0.5 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 1 ML
- DRUG MART UNIFINE PENTIPS 31G X 5 MM
- EASY COMFORT ALCOHOL PADS PAD
- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 0.5 ML

Formulary ID: 26382

Effective: 05/01/2026

- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 31G X 1/2" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- EASY COMFORT PEN NEEDLES 29G X 4MM
- EASY COMFORT PEN NEEDLES 29G X 5MM
- EASY COMFORT PEN NEEDLES 31G X 5 MM
- EASY COMFORT PEN NEEDLES 31G X 6 MM
- EASY COMFORT PEN NEEDLES 31G X 8 MM
- EASY COMFORT PEN NEEDLES 32G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 5 MM
- EASY COMFORT PEN NEEDLES 33G X 6 MM
- EASY GLIDE PEN NEEDLES 33G X 4 MM
- EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 %
- EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 31G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2" 1 ML
- EASY TOUCH INSULIN BARRELS U-100 1 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 27G X 5/8" 1 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML

Formulary ID: 26382  
 Effective: 05/01/2026

- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY TOUCH PEN NEEDLES 29G X 12MM
- EASY TOUCH PEN NEEDLES 30G X 5 MM
- EASY TOUCH PEN NEEDLES 30G X 6 MM
- EASY TOUCH PEN NEEDLES 30G X 8 MM
- EASY TOUCH PEN NEEDLES 31G X 5 MM
- EASY TOUCH PEN NEEDLES 31G X 6 MM
- EASY TOUCH PEN NEEDLES 31G X 8 MM
- EASY TOUCH PEN NEEDLES 32G X 4 MM
- EASY TOUCH PEN NEEDLES 32G X 5 MM
- EASY TOUCH PEN NEEDLES 32G X 6 MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM
- EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM
- EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16" 1 ML
- EMBECTA AUTOSHIELD DUO 30G X 5 MM
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64" 0.3 ML
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 1 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- EMBECTA INSULIN SYRINGE U-100 27G X 5/8" 1 ML
- EMBECTA INSULIN SYRINGE U-500
- EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM
- EMBECTA PEN NEEDLE NANO 32G X 4 MM
- EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM
- EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM
- EMBRACE PEN NEEDLES 29G X 12MM
- EMBRACE PEN NEEDLES 30G X 5 MM
- EMBRACE PEN NEEDLES 30G X 8 MM
- EMBRACE PEN NEEDLES 31G X 5 MM

Formulary ID: 26382  
Effective: 05/01/2026

- EMBRACE PEN NEEDLES 31G X 6 MM
- EMBRACE PEN NEEDLES 31G X 8 MM
- EMBRACE PEN NEEDLES 32G X 4 MM
- EQL ALCOHOL SWABS PAD 70 %
- EQL GAUZE PAD 2"X2"
- EQL INSULIN SYRINGE 30G X 5/16" 1 ML
- EXEL COMFORT POINT INSULIN SYR 29G X 1/2" 0.3 ML
- EXEL COMFORT POINT INSULIN SYR 30G X 5/16" 0.3 ML
- EXEL COMFORT POINT PEN NEEDLE 29G X 12MM
- FIFTY50 PEN NEEDLES 31G X 5 MM
- FIFTY50 PEN NEEDLES 31G X 8 MM
- FIFTY50 PEN NEEDLES 32G X 4 MM
- FIFTY50 PEN NEEDLES 32G X 6 MM
- GAUZE PADS PAD 2"X2"
- GAUZE TYPE VII MEDI-PAK PAD 2"X2"
- GLOBAL ALCOHOL PREP EASE
- GLOBAL EASE INJECT PEN NEEDLES 29G X 12MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 5 MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 8 MM
- GLOBAL EASE INJECT PEN NEEDLES 32G X 4 MM
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.3 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.5 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 1 ML
- GNP ALCOHOL SWABS PAD
- GNP CLICKFINE PEN NEEDLES 31G X 6 MM
- GNP CLICKFINE PEN NEEDLES 31G X 8 MM
- GNP INSULIN SYRINGE 28G X 1/2" 1 ML
- GNP INSULIN SYRINGE 29G X 1/2" 1 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 1 ML
- GNP INSULIN SYRINGES 30G X 5/16" 1 ML
- GNP INSULIN SYRINGES 30GX5/16" 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGES 31GX5/16" 31G X 5/16" 0.3 ML
- GNP PEN NEEDLES 31G X 5 MM
- GNP PEN NEEDLES 32G X 4 MM
- GNP PEN NEEDLES 32G X 6 MM
- GNP STERILE GAUZE PAD 2"X2"
- GNP ULTRA COM INSULIN SYRINGE 29G X 1/2" 0.5 ML
- GNP ULTRA COM INSULIN SYRINGE 30G X 5/16" 1 ML

Formulary ID: 26382  
Effective: 05/01/2026

- GOODSENSE ALCOHOL SWABS PAD 70 %
- GOODSENSE CLICKFINE PEN NEEDLE 31G X 5 MM
- GOODSENSE PEN NEEDLE PENFINE 31G X 8 MM
- H-E-B INCONTROL ALCOHOL PAD
- H-E-B INCONTROL PEN NEEDLES 29G X 12MM
- H-E-B INCONTROL PEN NEEDLES 31G X 5 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 6 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 8 MM
- H-E-B INCONTROL PEN NEEDLES 32G X 4 MM
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 1 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 1 ML
- HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM
- HM STERILE ALCOHOL PREP PAD
- HM STERILE PADS PAD 2"X2"
- HM ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML
- HM ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM
- INSULIN SYRINGE 29G X 1/2" 0.3 ML
- INSULIN SYRINGE 29G X 1/2" 0.5 ML
- INSULIN SYRINGE 29G X 1/2" 1 ML
- INSULIN SYRINGE 30G X 5/16" 0.3 ML
- INSULIN SYRINGE 30G X 5/16" 0.5 ML
- INSULIN SYRINGE 30G X 5/16" 1 ML
- INSULIN SYRINGE 31G X 5/16" 0.3 ML
- INSULIN SYRINGE 31G X 5/16" 0.5 ML
- INSULIN SYRINGE 31G X 5/16" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.3 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.5 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 5/16" 0.5 ML (OTC)

Formulary ID: 26382

Effective: 05/01/2026

- INSULIN SYRINGE/NEEDLE 27G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 1 ML
- INSUPEN PEN NEEDLES 29G X 12MM
- INSUPEN PEN NEEDLES 31G X 5 MM
- INSUPEN PEN NEEDLES 31G X 8 MM
- INSUPEN PEN NEEDLES 32G X 4 MM
- INSUPEN PEN NEEDLES 33G X 4 MM
- INSUPEN SENSITIVE 32G X 6 MM
- INSUPEN SENSITIVE 32G X 8 MM
- INSUPEN ULTRAFIN 30G X 8 MM
- INSUPEN ULTRAFIN 31G X 6 MM
- INSUPEN ULTRAFIN 31G X 8 MM
- INSUPEN32G EXTR3ME 32G X 6 MM
- J & J GAUZE PAD 2"X2"
- KENDALL HYDROPHILIC FOAM DRESS PAD 2"X2"
- KENDALL HYDROPHILIC FOAM PLUS PAD 2"X2"
- KINRAY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- KMART VALU INSULIN SYRINGE 29G U-100 1 ML
- KMART VALU INSULIN SYRINGE 30G U-100 0.3 ML
- KMART VALU INSULIN SYRINGE 30G U-100 1 ML
- KROGER INSULIN SYRINGE 30G X 5/16" 0.5 ML
- KROGER PEN NEEDLES 29G X 12MM
- KROGER PEN NEEDLES 31G X 6 MM
- LEADER INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LEADER INSULIN SYRINGE 28G X 1/2" 1 ML
- LEADER UNIFINE PENTIPS 31G X 5 MM
- LEADER UNIFINE PENTIPS 32G X 4 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 5 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 8 MM
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.3 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- LITETOUCH PEN NEEDLES 29G X 12.7MM
- LITETOUCH PEN NEEDLES 31G X 5 MM
- LITETOUCH PEN NEEDLES 31G X 6 MM
- LITETOUCH PEN NEEDLES 31G X 8 MM
- LITETOUCH PEN NEEDLES 32G X 4 MM
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 1 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.5 ML

Formulary ID: 26382  
Effective: 05/01/2026

- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 1 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM
- MAXICOMFORT II PEN NEEDLE 31G X 6 MM
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 0.5 ML
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 1 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.5 ML
- MEDICINE SHOPPE PEN NEEDLES 29G X 12MM
- MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM
- MEDPURA ALCOHOL PADS 70 % EXTERNAL
- MEIJER ALCOHOL SWABS PAD 70 %
- MEIJER PEN NEEDLES 29G X 12MM
- MEIJER PEN NEEDLES 31G X 6 MM
- MEIJER PEN NEEDLES 31G X 8 MM
- MICRODOT PEN NEEDLE 31G X 6 MM
- MICRODOT PEN NEEDLE 32G X 4 MM
- MICRODOT PEN NEEDLE 33G X 4 MM
- MIRASORB SPONGES 2"X2"
- MM PEN NEEDLES 31G X 6 MM
- MM PEN NEEDLES 32G X 4 MM
- MONOJECT INSULIN SYRINGE 25G X 5/8" 1 ML
- MONOJECT INSULIN SYRINGE 27G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 31G X 5/16" 1 ML
- MONOJECT INSULIN SYRINGE U-100 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.5 ML (RX)
- MS INSULIN SYRINGE 31G X 5/16" 0.3 ML
- MS INSULIN SYRINGE 31G X 5/16" 0.5 ML
- NOVOFINE AUTOCOVER 30G X 8 MM
- NOVOFINE PEN NEEDLE 32G X 6 MM
- NOVOFINE PLUS PEN NEEDLE 32G X 4 MM

Formulary ID: 26382  
Effective: 05/01/2026

- NOVOTWIST PEN NEEDLE 32G X 5 MM
- PC UNIFINE PENTIPS 31G X 5 MM
- PC UNIFINE PENTIPS 31G X 6 MM
- PC UNIFINE PENTIPS 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 32G X 4 MM
- PEN NEEDLES 30G X 5 MM (OTC)
- PEN NEEDLES 30G X 8 MM
- PEN NEEDLES 32G X 5 MM
- PENTIPS 29G X 12MM (RX)
- PENTIPS 31G X 5 MM (RX)
- PENTIPS 31G X 8 MM (RX)
- PENTIPS 32G X 4 MM (RX)
- PENTIPS GENERIC PEN NEEDLES 29G X 12MM
- PENTIPS GENERIC PEN NEEDLES 31G X 6 MM
- PENTIPS GENERIC PEN NEEDLES 32G X 6 MM
- PHARMACIST CHOICE ALCOHOL PAD
- PIP PEN NEEDLES 31G X 5MM 31G X 5 MM
- PIP PEN NEEDLES 32G X 4MM 32G X 4 MM
- PRECISION SURE-DOSE SYRINGE 30G X 5/16" 0.3 ML
- PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 1 ML
- PREFERRED PLUS INSULIN SYRINGE 30G X 5/16" 1 ML
- PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM
- PREVENT SAFETY PEN NEEDLES 31G X 6 MM
- PREVENT SAFETY PEN NEEDLES 31G X 8 MM
- PRO COMFORT ALCOHOL PAD 70 %
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- PRO COMFORT PEN NEEDLES 32G X 4 MM
- PRO COMFORT PEN NEEDLES 32G X 5 MM
- PRO COMFORT PEN NEEDLES 32G X 6 MM
- PRO COMFORT PEN NEEDLES 32G X 8 MM
- PRODIGY INSULIN SYRINGE 28G X 1/2" 1 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.3 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PURE COMFORT ALCOHOL PREP PAD
- PURE COMFORT PEN NEEDLE 32G X 4 MM
- PURE COMFORT PEN NEEDLE 32G X 5 MM
- PURE COMFORT PEN NEEDLE 32G X 6 MM
- PURE COMFORT PEN NEEDLE 32G X 8 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM

Formulary ID: 26382  
 Effective: 05/01/2026

- PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM
- PX SHORTLENGTH PEN NEEDLES 31G X 8 MM
- QC ALCOHOL
- QC ALCOHOL SWABS PAD 70 %
- QC BORDER ISLAND GAUZE PAD 2"X2"
- QUICK TOUCH INSULIN PEN NEEDLE 29G X 12.7MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM
- RA ALCOHOL SWABS PAD 70 %
- RA INSULIN SYRINGE 29G X 1/2" 0.5 ML
- RA INSULIN SYRINGE 29G X 1/2" 1 ML
- RA INSULIN SYRINGE 30G X 5/16" 0.5 ML
- RA INSULIN SYRINGE 30G X 5/16" 1 ML
- *ra isopropyl alcohol wipes*
- RA PEN NEEDLES 31G X 5 MM
- RA PEN NEEDLES 31G X 8 MM
- RA STERILE PAD 2"X2"
- RAYA SURE PEN NEEDLE 29G X 12MM
- RAYA SURE PEN NEEDLE 31G X 4 MM
- RAYA SURE PEN NEEDLE 31G X 5 MM
- RAYA SURE PEN NEEDLE 31G X 6 MM
- REALITY INSULIN SYRINGE 28G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 28G X 1/2" 1 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 1 ML
- REALITY SWABS PAD
- RELI-ON INSULIN SYRINGE 29G 0.3 ML
- RELION ALCOHOL SWABS PAD
- RELION ALCOHOL SWABS PAD 70 %
- RELION INSULIN SYRINGE 31G X 15/64" 0.3 ML
- RELION INSULIN SYRINGE 31G X 15/64" 0.5 ML
- RELION INSULIN SYRINGE 31G X 15/64" 1 ML
- RELION MINI PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 29G X 12MM
- RELION PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 8 MM
- RESTORE CONTACT LAYER PAD 2"X2"
- SAFETY INSULIN SYRINGES 29G X 1/2" 0.5 ML
- SAFETY INSULIN SYRINGES 29G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 5/16" 0.5 ML
- SAFETY PEN NEEDLES 30G X 5 MM

Formulary ID: 26382

Effective: 05/01/2026

- SAFETY PEN NEEDLES 30G X 8 MM
- SB ALCOHOL PREP PAD 70 %
- SB INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SB INSULIN SYRINGE 29G X 1/2" 1 ML
- SB INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SB INSULIN SYRINGE 30G X 5/16" 1 ML
- SB INSULIN SYRINGE 31G X 5/16" 1 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 1 ML
- SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM
- SM ALCOHOL PREP PAD
- SM ALCOHOL PREP PAD 6-70 % EXTERNAL
- SM ALCOHOL PREP PAD 70 %
- SM GAUZE PAD 2"X2"
- STERILE GAUZE PAD 2"X2"
- SURE COMFORT ALCOHOL PREP PAD 70 %
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE COMFORT PEN NEEDLES 29G X 12.7MM
- SURE COMFORT PEN NEEDLES 30G X 8 MM
- SURE COMFORT PEN NEEDLES 31G X 5 MM
- SURE COMFORT PEN NEEDLES 31G X 6 MM
- SURE COMFORT PEN NEEDLES 31G X 8 MM
- SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)
- SURE COMFORT PEN NEEDLES 32G X 4 MM (RX)
- SURE COMFORT PEN NEEDLES 32G X 6 MM
- SURGICAL GAUZE SPONGE PAD 2"X2"
- TECHLITE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- THERAGA UZE PAD 2"X2"
- TODAY'S HEALTH PEN NEEDLES 29G X 12MM
- TODAY'S HEALTH SHORT PEN NEEDLE 31G X 8 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM

Formulary ID: 26382  
Effective: 05/01/2026

- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 1 ML
- TRUE COMFORT ALCOHOL PREP PADS PAD 70 %
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- TRUE COMFORT PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO ALCOHOL PREP PAD 70 %
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 1 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 1 ML
- TRUE COMFORT PRO PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 8 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM
- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML

Formulary ID: 26382  
Effective: 05/01/2026

- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 1 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 1 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUEPLUS PEN NEEDLES 29G X 12MM
- TRUEPLUS PEN NEEDLES 31G X 5 MM
- TRUEPLUS PEN NEEDLES 31G X 6 MM
- TRUEPLUS PEN NEEDLES 31G X 8 MM
- TRUEPLUS PEN NEEDLES 32G X 4 MM
- ULTICARE INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- ULTICARE INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 28G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 28G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (OTC)
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- ULTICARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 0.3 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 0.5 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 1 ML
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (OTC)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (RX)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (OTC)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (RX)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTICARE MICRO PEN NEEDLES 32G X 4 MM
- ULTICARE MINI PEN NEEDLES 30G X 5 MM
- ULTICARE MINI PEN NEEDLES 31G X 6 MM
- ULTICARE MINI PEN NEEDLES 32G X 6 MM
- ULTICARE PEN NEEDLES 29G X 12.7MM (OTC)
- ULTICARE PEN NEEDLES 29G X 12.7MM (RX)
- ULTICARE PEN NEEDLES 31G X 5 MM

Formulary ID: 26382  
Effective: 05/01/2026

- ULTICARE SHORT PEN NEEDLES 30G X 8 MM
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC)
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX)
- ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 1 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 1 ML
- ULTILET ALCOHOL SWABS PAD
- ULTILET PEN NEEDLE 29G X 12.7MM
- ULTILET PEN NEEDLE 31G X 5 MM
- ULTILET PEN NEEDLE 31G X 8 MM
- ULTILET PEN NEEDLE 32G X 4 MM
- ULTRA COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM
- ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM
- ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM
- ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRA THIN PEN NEEDLES 32G X 4 MM
- ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 1 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.5 ML

Formulary ID: 26382  
Effective: 05/01/2026

- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 1 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM
- ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM
- ULTRA-THIN II PEN NEEDLES 29G X 12.7MM
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRACARE PEN NEEDLES 31G X 5 MM
- ULTRACARE PEN NEEDLES 31G X 6 MM
- ULTRACARE PEN NEEDLES 31G X 8 MM
- ULTRACARE PEN NEEDLES 32G X 4 MM
- ULTRACARE PEN NEEDLES 32G X 5 MM
- ULTRACARE PEN NEEDLES 32G X 6 MM
- ULTRACARE PEN NEEDLES 33G X 4 MM
- UNIFINE OTC PEN NEEDLES 31G X 5 MM
- UNIFINE OTC PEN NEEDLES 32G X 4 MM
- UNIFINE PEN NEEDLES 32G X 4 MM
- UNIFINE PENTIPS 29G X 12MM
- UNIFINE PENTIPS 31G X 6 MM
- UNIFINE PENTIPS 31G X 8 MM
- UNIFINE PENTIPS 32G X 4 MM
- UNIFINE PENTIPS PLUS 29G X 12MM
- UNIFINE PENTIPS PLUS 31G X 6 MM
- UNIFINE PENTIPS PLUS 32G X 4 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 5 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 8 MM
- UNIFINE PROTECT PEN NEEDLE 32G X 4 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 5 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 6 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 8 MM
- UNIFINE ULTRA PEN NEEDLE 32G X 4 MM
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 1 ML
- VANISHPOINT INSULIN SYRINGE 29G X 5/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 0.5 ML

Formulary ID: 26382  
 Effective: 05/01/2026

- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN PEN NEEDLE 29G X 12MM
- VERIFINE INSULIN PEN NEEDLE 31G X 5 MM
- VERIFINE INSULIN PEN NEEDLE 32G X 6 MM
- VERIFINE INSULIN SYRINGE 28G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 30G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 1 ML
- VERIFINE PLUS PEN NEEDLE 31G X 5 MM
- VERIFINE PLUS PEN NEEDLE 31G X 8 MM
- VERIFINE PLUS PEN NEEDLE 32G X 4 MM
- VP INSULIN SYRINGE 29G X 1/2" 0.3 ML
- WEBCOL ALCOHOL PREP LARGE PAD 70 %
- WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM
- ZEVRX STERILE ALCOHOL PREP PAD PAD 70 %

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN. |
| <b>Required Medical Information</b> |  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | LIFETIME   |
| <b>Other Criteria</b>               |  |
| <b>Indications</b>                  | All FDA-approved Indications.                                  |
| <b>Off Label Uses</b>               |  |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                           | <b>Criteria Details</b> |
|--|-------------------------|
| <b>Part B<br/>Prerequisite</b>               | No                      |
| <b>Prerequisite<br/>Therapy<br/>Required</b> | No                      |

Formulary ID: 26382  
Effective: 05/01/2026

# INTERFERON FOR MS-AVONEX

## Products Affected

- AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT
- AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# INTERFERON FOR MS-BETASERON

---

## Products Affected

- BETASERON SUBCUTANEOUS KIT

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# INTERFERON FOR MS-PLEGRIDY

## Products Affected

- PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
 Effective: 05/01/2026

# INTERFERON GAMMA-1B

## Products Affected

- ACTIMMUNE

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | INITIAL: CHRONIC GRANULOMATOUS DISEASE (CGD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, INFECTIOUS DISEASE SPECIALIST, OR IMMUNOLOGIST. SEVERE MALIGNANT OSTEOPETROSIS (SMO): PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR HEMATOLOGIST. |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS   |
| Other Criteria                | RENEWAL: CGD, SMO: 1) DEMONSTRATED CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) HAS NOT RECEIVED HEMATOPOIETIC CELL TRANSPLANTATION.   |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# IPILIMUMAB

## Products Affected

- YERVOY

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | INITIAL: UNRESECT/MET MEL: 4MO, RCC/CRC/HCC: 3MO, ALL OTHERS: 12MO. INITIAL/RENEWAL: CUTAN MEL: 6MO   |
| Other Criteria                | RENEWAL: ADJUVANT CUTANEOUS MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS). |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# ISAVUCONAZONIUM

## Products Affected

- CRESEMBA ORAL

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | INVASIVE ASPERGILLOSIS, INVASIVE MUCORMYCOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.                             |
| Coverage Duration             | 6 MONTHS   |
| Other Criteria                | INVASIVE ASPERGILLOSIS: TRIAL OF OR CONTRAINDICATION TO VORICONAZOLE. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# IVACAFTOR

## Products Affected

- KALYDECO

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  |   |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT  |
| <b>Coverage Duration</b>             | INITIAL: 12 MONTHS. RENEWAL: LIFETIME   |
| <b>Other Criteria</b>                | CF: INITIAL: 1) NOT HOMOZYGOUS FOR F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# IVOSIDENIB

---

## Products Affected

- TIBSOVO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# IXAZOMIB

---

## Products Affected

- NINLARO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LAMOTRIGINE

## Products Affected

- SUBVENITE ORAL SUSPENSION

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | ALL INDICATIONS: CONTRAINDICATION TO OR UNABLE TO SWALLOW LAMOTRIGINE TABLETS. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# LANREOTIDE

## Products Affected

- LANREOTIDE ACETATE
- SOMATULINE DEPOT  
SUBCUTANEOUS SOLUTION 60  
MG/0.2ML, 90 MG/0.3ML

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | ACROMEGALY: INITIAL: THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.   |
| Coverage Duration             | ACROMEGALY: INITIAL/RENEWAL: 12 MOS. GEP-NETS, CARCINOID SYNDROME: 12 MOS.  |
| Other Criteria                | ACROMEGALY: RENEWAL: 1) REDUCTION, NORMALIZATION, OR MAINTENANCE OF IGF-1 LEVELS BASED ON AGE AND GENDER, AND 2) IMPROVEMENT OR SUSTAINED REMISSION OF CLINICAL SYMPTOMS. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# LAPATINIB

---

## Products Affected

- *lapatinib ditosylate*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LAROTRECTINIB

## Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | VITRAKVI ORAL SOLUTION: 1) TRIAL OF VITRAKVI CAPSULES, OR 2) UNABLE TO TAKE CAPSULE FORMULATION. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# LAZERTINIB

---

## Products Affected

- LAZCLUZE ORAL TABLET 240 MG,  
80 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LEDIPASVIR-SOFOSBUVIR

## Products Affected

- HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG
- HARVONI ORAL TABLET

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  | HCV RNA LEVEL WITHIN PAST 6 MONTHS.  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.  |
| Other Criteria                | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, AND 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, TIPRANAVIR/RITONAVIR, SOFOSBUVIR (AS A SINGLE AGENT), EPCLUSA, ZEPATIER, MAVYRET, OR VOSEVI. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
 Effective: 05/01/2026

# LENALIDOMIDE

---

## Products Affected

- *lenalidomide*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LENVATINIB

## Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
 Effective: 05/01/2026

# LETERMOVIR

## Products Affected

- PREVYMIS ORAL TABLET

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | HSCT: NOT AT RISK FOR LATE CMV: 4 MOS, AT RISK FOR LATE CMV: 7 MOS. KIDNEY TRANSPLANT: 7 MOS.  |
| Other Criteria                | HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 28 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 100 DAYS POST TRANSPLANT IF NOT AT RISK FOR LATE CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE, OR BEYOND 200 DAYS POST TRANSPLANT IF AT RISK FOR LATE CMV INFECTION AND DISEASE. KIDNEY TRANSPLANT: 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 7 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 200 DAYS POST TRANSPLANT. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# LEUPROLIDE

---

## Products Affected

- *leuprolide acetate injection*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | PROSTATE CANCER: 12 MONTHS.   |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LEUPROLIDE DEPOT

---

## Products Affected

- LEUPROLIDE ACETATE (3 MONTH)
- LUTRATE DEPOT

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LEUPROLIDE MESYLATE

---

## Products Affected

- CAMCEVI

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LEUPROLIDE-ELIGARD

---

## Products Affected

- ELIGARD

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS.                    |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LEUPROLIDE-LUPRON DEPOT

## Products Affected

- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.  |
| <b>Coverage Duration</b>            | PROSTATE CA: 12 MOS. UTERINE FIBROIDS: 3 MOS.<br>ENDOMETRIOSIS: INITIAL/RENEWAL: 6 MOS.  |
| <b>Other Criteria</b>               | INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. RENEWAL: ENDOMETRIOSIS: 1) IMPROVEMENT OF PAIN RELATED TO ENDOMETRIOSIS WHILE ON THERAPY, 2) RECEIVING CONCOMITANT ADD-BACK THERAPY (I.E., COMBINATION ESTROGEN-PROGESTIN OR PROGESTIN-ONLY CONTRACEPTIVE PREPARATION), 3) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 4) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# LEUPROLIDE-LUPRON DEPOT-PED

## Products Affected

- LUPRON DEPOT-PED (3-MONTH)
- LUPRON DEPOT-PED (6-MONTH)

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | CENTRAL PRECOCIOUS PUBERTY (CPP): INITIAL: FEMALES: ELEVATED LEVEL OF LUTEINIZING HORMONE (LH) LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. MALES: ELEVATED LEVEL OF LH LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS.   |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | CPP: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.  |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>                | CPP: INITIAL: FEMALES: 1) YOUNGER THAN 8 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR BREAST DEVELOPMENT AND PUBIC HAIR GROWTH. MALES: 1) YOUNGER THAN 9 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR GENITAL DEVELOPMENT AND PUBIC HAIR GROWTH. RENEWAL: 1) TANNER STAGING AT INITIAL DIAGNOSIS HAS STABILIZED OR REGRESSED DURING THREE SEPARATE MEDICAL VISITS IN THE PREVIOUS YEAR, AND 2) HAS NOT REACHED ACTUAL AGE WHICH CORRESPONDS TO CURRENT PUBERTAL AGE. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# L-GLUTAMINE

## Products Affected

- *l-glutamine oral packet*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | SICKLE CELL DISEASE(SCD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST  |
| Coverage Duration             | INITIAL: 12 MONTHS. RENEWAL: LIFETIME.   |
| Other Criteria                | SCD: INITIAL: AGES 18 YEARS OR OLDER: 1) AT LEAST 2 SICKLE CELL CRISES IN THE PAST YEAR, 2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING, OR 3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME. AGES 5 TO 17 YEARS: APPROVED WITHOUT ADDITIONAL CRITERIA. RENEWAL: MAINTAINED OR EXPERIENCED A REDUCTION IN ACUTE COMPLICATIONS OF SCD. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
 Effective: 05/01/2026

# LIDOCAINE OINTMENT

## Products Affected

- *lidocaine external ointment 5 %*

| PA Criteria                   | Criteria Details                    |
|-------------------------------|-------------------------------------|
| Exclusion Criteria            |                                     |
| Required Medical Information  |                                     |
| Age Restrictions              |                                     |
| Prescriber Restrictions       |                                     |
| Coverage Duration             | 12 MONTHS                           |
| Other Criteria                |                                     |
| Indications                   | All Medically-accepted Indications. |
| Off Label Uses                |                                     |
| Part B Prerequisite           | No                                  |
| Prerequisite Therapy Required | No                                  |

Formulary ID: 26382  
Effective: 05/01/2026

# LIDOCAINE PATCH

## Products Affected

- *lidocaine external patch 5 %*
- *lidocan*
- *tridacaine ii*
- ZTLIDO

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | 1) PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA, 2) NEUROPATHY DUE TO DIABETES MELLITUS, 3) CHRONIC BACK PAIN, OR 4) OSTEOARTHRITIS OF THE KNEE OR HIP. |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       |   |
| <b>Coverage Duration</b>             | 12 MONTHS   |
| <b>Other Criteria</b>                |   |
| <b>Indications</b>                   | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# LIDOCAINE PRILOCAINE

## Products Affected

- *lidocaine-prilocaine external cream*

| PA Criteria                   | Criteria Details                    |
|-------------------------------|-------------------------------------|
| Exclusion Criteria            |                                     |
| Required Medical Information  |                                     |
| Age Restrictions              |                                     |
| Prescriber Restrictions       |                                     |
| Coverage Duration             | 12 MONTHS                           |
| Other Criteria                |                                     |
| Indications                   | All Medically-accepted Indications. |
| Off Label Uses                |                                     |
| Part B Prerequisite           | No                                  |
| Prerequisite Therapy Required | No                                  |

Formulary ID: 26382  
Effective: 05/01/2026

# LINVOSELTAMAB-GCPT

## Products Affected

- LYNOZYFIC INTRAVENOUS SOLUTION 200 MG/10ML, 5 MG/2.5ML

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LONCASTUXIMAB TESIRINE-LPYL

---

## Products Affected

- ZYNLONTA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LORLATINIB

---

## Products Affected

- LORBRENA ORAL TABLET 100 MG,  
25 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# LOTILANER

---

## Products Affected

- XDEMVIY

| PA Criteria                   | Criteria Details                              |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              | DEMODEX BLEPHARITIS: 18 YEARS OF AGE OR OLDER |
| Prescriber Restrictions       |   |
| Coverage Duration             | 6 WEEKS                                       |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.                 |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# LUMACAFITOR-IVACAFITOR

## Products Affected

- ORKAMBI ORAL TABLET

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CF EXPERT.  |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: LIFETIME.   |
| Other Criteria                | CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# MACITENTAN

## Products Affected

- OPSUMIT

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>                |  |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# MARGETUXIMAB-CMKB

---

## Products Affected

- MARGENZA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# MARIBAVIR

---

## Products Affected

- LIVTENCITY

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# MAVACAMTEN

## Products Affected

- CAMZYOS

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY(HCM): INITIAL: LEFT VENTRICULAR OUTFLOW TRACK (LVOT) GRADIENT OF 50 MMHG OR HIGHER   |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | OBSTRUCTIVE HCM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>                | OBSTRUCTIVE HCM: INITIAL: TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO A BETA-BLOCKER OR A NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER. RENEWAL: CONTINUED CLINICAL BENEFIT (E.G., REDUCTION OF SYMPTOMS, NYHA CLASSIFICATION IMPROVEMENT). |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# MECASERMIN

## Products Affected

- INCRELEX

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  |   |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | GROWTH FAILURE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR NEPHROLOGIST.  |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>                | GROWTH FAILURE: INITIAL: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF WRIST AND HAND. INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER GROWTH HORMONE MEDICATION. RENEWAL: IMPROVEMENT WHILE ON THERAPY (INCREASE IN HEIGHT OR INCREASE IN HEIGHT VELOCITY). |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# MECHLORETHAMINE

---

## Products Affected

- VALCHLOR

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# MEPOLIZUMAB

## Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY OR ALLERGY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOSINOPHILIC COPD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: CRSWNP: 6 MO. OTHERS: 12 MO. RENEWAL: CRSWNP, ASTHMA, COPD, EGPA, HES: 12 MO.  |
| <b>Other Criteria</b>               | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                | Criteria Details   |
|----------------------------|--|
|                            | <p>THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 3) INADEQUATELY CONTROLLED DISEASE. EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. RENEWAL: ASTHMA: 1) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): 1) REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS, OR (C) INCREASE IN FEV1 OF AT LEAST 5 PERCENT FROM PRETREATMENT BASELINE.</p> |
| <b>Indications</b>         | All FDA-approved Indications.  |
| <b>Off Label Uses</b>      |  |
| <b>Part B Prerequisite</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# METYROSINE

## Products Affected

- *metirosine*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | PHEOCHROMOCYTOMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, ENDOCRINE SURGEON, OR HEMATOLOGIST-ONCOLOGIST.   |
| Coverage Duration             | PREOPERATIVE PREPARATION FOR SURGERY: 30 DAYS.<br>MALIGNANT PHEOCHROMOCYTOMA: INITIAL/RENEWAL:12 MOS.   |
| Other Criteria                | PHEOCHROMOCYTOMA: INITIAL: HAS NON-METASTATIC PHEOCHROMOCYTOMA. PREOPERATIVE PREPARATION FOR SURGERY: USE IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR BLOCKER. RENEWAL: MALIGNANT PHEOCHROMOCYTOMA: STABLE OR CLINICAL IMPROVEMENT WHILE ON THERAPY. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# MIDOSTAURIN

---

## Products Affected

- RYDAPT

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# MIFEPRISTONE

## Products Affected

- *mifepristone oral tablet 300 mg*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | CUSHINGS SYNDROME (CS): INITIAL: DIAGNOSIS CONFIRMED BY: 1) 24-HR URINE FREE CORTISOL (AT LEAST 2 TESTS TO CONFIRM), 2) OVERNIGHT 1MG DEXAMETHASONE TEST, OR 3) LATE NIGHT SALIVARY CORTISOL (AT LEAST 2 TESTS TO CONFIRM).  |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | CS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS   |
| <b>Other Criteria</b>                | CS: INITIAL: HYPERCORTISOLISM IS NOT A RESULT OF CHRONIC GLUCOCORTICOIDS. RENEWAL: 1) CONTINUES TO HAVE IMPROVEMENT OF GLUCOSE TOLERANCE OR STABLE GLUCOSE TOLERANCE (E.G., REDUCED A1C, IMPROVED FASTING GLUCOSE), 2) CONTINUES TO HAVE TOLERABILITY TO THERAPY, AND 3) CONTINUES TO NOT BE A CANDIDATE FOR SURGICAL TREATMENT OR HAS FAILED SURGERY. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# MILTEFOSINE

---

## Products Affected

- IMPAVIDO

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# MIRDAMETINIB

## Products Affected

- GOMEKLI ORAL CAPSULE 1 MG, 2 MG
- GOMEKLI ORAL TABLET SOLUBLE MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
 Effective: 05/01/2026

# MIRVETUXIMAB SORAVTANSINE-GYNX

## Products Affected

- ELAHERE

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: AN OPHTHALMIC EXAM, INCLUDING VISUAL ACUITY AND SLIT LAMP EXAM, WILL BE COMPLETED PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | 12 MONTHS  |
| <b>Other Criteria</b>                |  |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
 Effective: 05/01/2026

# MOMELOTINIB

---

## Products Affected

- OJAARA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# MOSUNETUZUMAB-AXGB

## Products Affected

- LUNSUMIO
- LUNSUMIO VELO

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: INITIAL: 6 MONTHS. RENEWAL: 7 MONTHS.  |
| Other Criteria                | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: RENEWAL: 1) HAS ACHIEVED A PARTIAL RESPONSE TO TREATMENT, AND 2) HAS NOT PREVIOUSLY RECEIVED MORE THAN 17 CYCLES OF TREATMENT. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
 Effective: 05/01/2026

# NARCOLEPSY AGENTS

## Products Affected

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

| PA Criteria                   | Criteria Details                    |
|-------------------------------|-------------------------------------|
| Exclusion Criteria            |                                     |
| Required Medical Information  |                                     |
| Age Restrictions              |                                     |
| Prescriber Restrictions       |                                     |
| Coverage Duration             | 12 MONTHS                           |
| Other Criteria                |                                     |
| Indications                   | All Medically-accepted Indications. |
| Off Label Uses                |                                     |
| Part B Prerequisite           | No                                  |
| Prerequisite Therapy Required | No                                  |

Formulary ID: 26382  
Effective: 05/01/2026

# NAXITAMAB-GQGK

---

**Products Affected**

- DANYELZA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# NERATINIB

## Products Affected

- NERLYNX

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | EARLY-STAGE (STAGE I-III) BREAST CANCER: MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# NILOTINIB - TASIGNA

## Products Affected

- *nilotinib hcl oral capsule 150 mg, 200 mg, 50 mg*
- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND MEDICATION IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | 12 MONTHS  |
| <b>Other Criteria</b>                |  |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# NILOTINIB-DANZITEN

## Products Affected

- DANZITEN

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  | PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): 1) PERFORMED MUTATIONAL ANALYSIS PRIOR TO INITIATION OF THERAPY, AND 2) THERAPY IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# NINTEDANIB

## Products Affected

- OFEV

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 40% OF PREDICTED VALUE. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD): AT LEAST 10% FIBROSIS ON A CHEST HRCT.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. SSC-ILD, PF-ILD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: SSC-ILD: 6 MOS. IPF, PF-ILD: 12 MOS. RENEWAL (ALL INDICATIONS): 12 MOS.   |
| <b>Other Criteria</b>               | INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ESBRIET (PIRFENIDONE). SSC-ILD: DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., HEART FAILURE/FLUID OVERLOAD, DRUG-INDUCED LUNG TOXICITY, RECURRENT ASPIRATION). PF-ILD: LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE WORSENERED/PROGRESSED DESPITE TREATMENT WITH MEDICATIONS USED IN CLINICAL PRACTICE FOR ILL (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION, |

Formulary ID: 26382

Effective: 05/01/2026

|                                      |  |
|--------------------------------------|--|
| <b>PA Criteria</b>                   | <b>Criteria Details</b>  |
|                                      | HEART FAILURE). RENEWAL: IPF, SSC-ILD, PF-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# NIRAPARIB

## Products Affected

- ZEJULA ORAL CAPSULE
- ZEJULA ORAL TABLET

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: 1) ZEJULA WILL BE USED AS MONOTHERAPY, AND 2) ZEJULA IS STARTED NO LATER THAN 8 WEEKS AFTER THE MOST RECENT PLATINUM-CONTAINING REGIMEN. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
 Effective: 05/01/2026

# NIRAPARIB-ABIRATERONE

## Products Affected

- AKEEGA

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# NIROGACESTAT

## Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# NITISINONE

## Products Affected

- *nitisinone*
- ORFADIN ORAL SUSPENSION

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | HEREDITARY TYROSINEMIA TYPE 1 (HT-1): INITIAL: DIAGNOSIS CONFIRMED BY ELEVATED URINARY OR PLASMA SUCCINYLACETONE LEVELS OR A MUTATION IN THE FUMARYLACETOACETATE HYDROLASE GENE. RENEWAL: URINARY OR PLASMA SUCCINYLACETONE LEVELS HAVE DECREASED FROM BASELINE WHILE ON TREATMENT WITH NITISINONE. |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | HT-1: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PRESCRIBER SPECIALIZING IN INHERITED METABOLIC DISEASES.   |
| <b>Coverage Duration</b>             | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>                | HT-1: INITIAL: ORFADIN SUSPENSION: TRIAL OF OR CONTRAINDICATION TO PREFERRED NITISINONE TABLETS OR CAPSULES.  |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# NIVOLUMAB

---

## Products Affected

- OPDIVO

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS). |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# NIVOLUMAB-HYALURONIDASE-NVHY

---

## Products Affected

- OPDIVO QVANTIG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# NIVOLUMAB-RELATLIMAB-RMBW

---

## Products Affected

- OPDUALAG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# NOGAPENDEKIN ALFA

---

## Products Affected

- ANKTIVA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 40 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# OFATUMUMAB SQ

## Products Affected

- KESIMPTA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# OLAPARIB

## Products Affected

- LYNPARZA ORAL TABLET

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER: MEDICATION WILL BE USED AS MONOTHERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# OLUTASIDENIB

---

**Products Affected**

- REZLIDHIA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# OMACETAXINE

---

## Products Affected

- SYNRIBO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# OMALIZUMAB

## Products Affected

- XOLAIR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL OF AT LEAST 30 IU/ML. FOOD ALLERGY: 1) IGE SERUM LEVEL OF AT LEAST 30 IU/ML, AND 2) POSITIVE SKIN PRICK TEST TO AT LEAST ONE FOOD, OR POSITIVE MEDICALLY MONITORED FOOD CHALLENGE TO AT LEAST ONE FOOD.   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL/RENEWAL: CHRONIC SPONTANEOUS URTICARIA (CSU): PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. INITIAL: CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. FOOD ALLERGY: PRESCRIBED BY OR IN CONSULTATION WITH ALLERGIST OR IMMUNOLOGIST.                                 |
| <b>Coverage Duration</b>            | INITIAL/RENEWAL: ASTHMA 12 MO/12 MO, CSU 6 MO/12 MO, CRSWNP 6 MO/12 MO, FOOD ALLERGY 12 MO/24 MO  |
| <b>Other Criteria</b>               | INITIAL: CSU: 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE, 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA ON MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS, AND 3) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: DUPIXENT. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: NUCALA, DUPIXENT, 3) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, |

Formulary ID: 26382

Effective: 05/01/2026

| PA Criteria                | Criteria Details  |
|----------------------------|---|
|                            | <p>AND 4) INADEQUATELY CONTROLLED DISEASE. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA. FOOD ALLERGY: CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION .</p> <p>INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. CRSWNP: CLINICAL BENEFIT COMPARED TO BASELINE. ASTHMA: 1) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. FOOD ALLERGY: 1) PERSISTENT IGE-MEDIATED FOOD ALLERGY, AND 2) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION.</p> |
| <b>Indications</b>         | All FDA-approved Indications.   |
| <b>Off Label Uses</b>      |   |
| <b>Part B Prerequisite</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# OSIMERTINIB

---

## Products Affected

- TAGRISSO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# OXANDROLONE

## Products Affected

- *oxandrolone oral*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 6 MONTHS   |
| Other Criteria                | PROTEIN CATABOLISM, BONE PAIN: 1) MONITORED FOR PELIOSIS HEPATIS, LIVER CELL TUMORS, AND BLOOD LIPID CHANGES, 2) DOES NOT HAVE KNOWN OR SUSPECTED: CARCINOMA OF THE PROSTATE OR BREAST IN MALE PATIENTS, CARCINOMA OF THE BREAST IN FEMALES WITH HYPERCALCEMIA, NEPHROSIS (THE NEPHROTIC PHASE OF NEPHRITIS), OR HYPERCALCEMIA, AND 3) DOES NOT HAVE SEVERE HEPATIC DYSFUNCTION. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# PACRITINIB

## Products Affected

- VONJO

| <b>PA Criteria</b>                   | <b>Criteria Details</b>  |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  |  |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS                            |
| <b>Other Criteria</b>                | MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION |
| <b>Indications</b>                   | All FDA-approved Indications.                                    |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# PALBOCICLIB

---

## Products Affected

- IBRANCE

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# PASIREOTIDE DIASPARTATE

## Products Affected

- SIGNIFOR

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | CUSHINGS DISEASE (CD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.              |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS.  |
| Other Criteria                | CD: RENEWAL: 1) CONTINUED IMPROVEMENT OF CUSHINGS DISEASE, AND 2) MAINTAINED TOLERABILITY TO SIGNIFOR. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
 Effective: 05/01/2026

# PAZOPANIB

## Products Affected

- *pazopanib hcl oral tablet 200 mg, 400 mg*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | ADVANCED SOFT TISSUE SARCOMA (STS): NOT USED FOR ADIPOCYTIC STS OR GASTROINTESTINAL STROMAL TUMORS (GIST) |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# PEGFILGRASTIM - APGF

---

## Products Affected

- NYVEPRIA

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.                                       |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# PEGFILGRASTIM - CBQV

## Products Affected

- UDENYCA ONBODY

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | NON MYELOID MALIGNANCY: UDENYCA: TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT NYVEPRIA. UDENYCA ONBODY: 1) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT NYVEPRIA, OR 2) BARRIER TO ACCESS (E.G., TRAVEL BARRIERS, UNABLE TO RETURN TO CLINIC FOR INJECTIONS). |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# PEGINTERFERON ALFA-2A

## Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | HEPATITIS B: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, OR PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G., HEPATOLOGIST). |
| Coverage Duration             | HEP B/HEP C: 48 WEEKS.  |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# PEGVISOMANT

---

## Products Affected

- SOMAVERT

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# PEMBROLIZUMAB

## Products Affected

- KEYTRUDA INTRAVENOUS SOLUTION

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS). |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# PEMBROLIZUMAB-BERAHYALURONIDASE ALFA-PMPH

## Products Affected

- KEYTRUDA QLEX

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# PEMIGATINIB

## Products Affected

- PEMAZYRE

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | CHOLANGIOCARCINOMA, MYELOID/LYMPHOID NEOPLASMS: COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), WILL BE COMPLETED PRIOR TO INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# PENICILLAMINE TABLET

## Products Affected

- *penicillamine oral tablet*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: CYSTINURIA: HAS NEPHROLITHIASIS AND ONE OF THE FOLLOWING: 1) STONE ANALYSIS SHOWING PRESENCE OF CYSTINE, 2) PRESENCE OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, OR 3) FAMILY HISTORY OF CYSTINURIA AND POSITIVE CYANIDE-NITROPRUSSIDE SCREENING.   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: WILSONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. CYSTINURIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL: 12 MONTHS, RENEWAL: LIFETIME.  |
| <b>Other Criteria</b>               | INITIAL: WILSONS DISEASE: 1) LEIPZIG SCORE OF 4 OR GREATER. RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) EXPERIENCED OR MAINTAINED IMPROVEMENT IN TENDER JOINT COUNT OR SWOLLEN JOINT COUNT COMPARED TO BASELINE. WILSONS DISEASE, CYSTINURIA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.   |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Off Label Uses</b>                |                         |
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# PEXIDARTINIB

---

## Products Affected

- TURALIO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# PIMAVANSERIN

## Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              | PSYCHOSIS IN PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OR OLDER   |
| Prescriber Restrictions       | PSYCHOSIS IN PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (E.G., PSYCHIATRIST). |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS.  |
| Other Criteria                | PSYCHOSIS IN PD: RENEWAL: IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT.                           |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# PIRFENIDONE

## Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | IDIOPATHIC PULMONARY FIBROSIS (IPF): INITIAL: A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | IPF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | IPF: INITIAL: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, OR CANCER). RENEWAL: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | No                      |

Formulary ID: 26382  
Effective: 05/01/2026

# PIRTOBRUTINIB

## Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# POMALIDOMIDE

---

## Products Affected

- *pomalidomide*
- POMALYST

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# PONATINIB

---

## Products Affected

- ICLUSIG

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  | CHRONIC MYELOID LEUKEMIA (CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND ICLUSIG IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# POSACONAZOLE TABLET

## Products Affected

- *posaconazole oral tablet delayed release*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE, PROPHYLAXIS: 6 MONTHS. TREATMENT: 12 WEEKS. |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# PRALSETINIB

---

## Products Affected

- GAVRETO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# PYRIMETHAMINE

## Products Affected

- *pyrimethamine oral*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | TOXOPLASMOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.  |
| Coverage Duration             | TOXOPLASMOSIS: INITIAL: 8 WEEKS, RENEWAL: 6 MOS.   |
| Other Criteria                | TOXOPLASMOSIS: RENEWAL: ONE OF THE FOLLOWING: (1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING), OR (2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENTLY TAKING AN ANTI-RETROVIRAL THERAPY IF HIV POSITIVE. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# QUININE

---

## Products Affected

- *quinine sulfate oral*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# QUIZARTINIB

---

## Products Affected

- VANFLYTA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# REGORAFENIB

---

## Products Affected

- STIVARGA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# RELUGOLIX

---

## Products Affected

- ORGOVYX

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# REPOTRECTINIB

## Products Affected

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# RESMETIROM

## Products Affected

- REZDIFFRA

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | NONALCOHOLIC STEATOHEPATITIS (NASH): INITIAL: DIAGNOSIS CONFIRMED BY BIOPSY OR NONINVASIVE TESTING, OBTAINED IN THE PAST 12 MONTHS, DEMONSTRATING: 1) LIVER FIBROSIS STAGE 2 OR 3, OR 2) NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACTIVITY SCORE OF 4 OR MORE. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | NASH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST, GASTROENTEROLOGIST, OR ENDOCRINOLOGIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS   |
| <b>Other Criteria</b>                | NASH: RENEWAL: CONTINUES TO HAVE NONCIRRHOTIC NASH WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS).  |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# RETIFANLIMAB-DLWR

---

## Products Affected

- ZYNYZ

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# REVUMENIB

---

## Products Affected

- REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# RIBOCICLIB

## Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
 Effective: 05/01/2026

# RIBOCICLIB-LETROZOLE

## Products Affected

- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# RIFAXIMIN

## Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | TRAVELERS DIARRHEA, HEPATIC ENCEPHALOPATHY (HE): 12 MOS. IBS-D: 8 WKS.         |
| Other Criteria                | HE: TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# RILONACEPT

## Products Affected

- ARCALYST

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | <p>CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES.</p> <p>DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS.</p> <p>RECURRENT PERICARDITIS (RP): TWO OF THE FOLLOWING: CHEST PAIN CONSISTENT WITH PERICARDITIS, PERICARDIAL FRICTION RUB, ECG SHOWING DIFFUSE ST-SEGMENT ELEVATION OR PR-SEGMENT DEPRESSION, NEW OR WORSENING PERICARDIAL EFFUSION.</p> |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | CAPS, DIRA: LIFETIME. RP: 12 MONTHS.  |
| <b>Other Criteria</b>               | CAPS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR CAPS. DIRA: 1) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR  |

Formulary ID: 26382

Effective: 05/01/2026

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
|                                      | TARGETED SMALL MOLECULES FOR DIRA, AND 2) TRIAL OF THE PREFERRED AGENT: KINERET. RP: 1) HAD AN EPISODE OF ACUTE PERICARDITIS, 2) SYMPTOM-FREE FOR 4 TO 6 WEEKS, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR RP. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# RIMEGEPANT

## Products Affected

- NURTEC

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> |  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | ACUTE MIGRAINE TREATMENT: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN). INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR 2) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS. EPISODIC MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# RIOCIQUAT

## Products Affected

- ADEMPAS

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH): DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) (WHO GROUP 4): WHO FUNCTIONAL CLASS II-IV SYMPTOMS.  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: PAH, CTEPH: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: PAH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE (PDE) INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. CTEPH: 1) NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS, AND 2) NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH OR HAS PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. RENEWAL: PAH, CTEPH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | No                      |

# RIPRETINIB

---

## Products Affected

- QINLOCK

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# RISANKIZUMAB-RZAA

## Products Affected

- SKYRIZI
- SKYRIZI PEN

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PLAQUE PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS  |
| <b>Other Criteria</b>               | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# RITUXIMAB AND HYALURONIDASE HUMAN-SQ

## Products Affected

- RITUXAN HYCELA

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | FOLLICULAR LYMPHOMA (FL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 1) HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# RITUXIMAB-ABBS

## Products Affected

- TRUXIMA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> |  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.  |
| <b>Coverage Duration</b>            | RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA, PV: 12 MO. CLL: 6 MO.  |
| <b>Other Criteria</b>               | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: RA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

# ROPEGINTERFERON ALFA-2B-NJFT

## Products Affected

- BESREMI

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# RUCAPARIB

## Products Affected

- RUBRACA

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# RUXOLITINIB

## Products Affected

- JAKAFI

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | MYELOFIBROSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. POLYCYTHEMIA VERA, GVHD: 12 MONTHS.  |
| Other Criteria                | INITIAL: CHRONIC GRAFT VS HOST DISEASE (CGVHD): NO CONCURRENT USE WITH REZUROCK, NIKTIMVO, OR IMBRUVICA. RENEWAL: MYELOFIBROSIS: CONTINUES TO BENEFIT FROM THE MEDICATION. CGVHD: NO CONCURRENT USE WITH REZUROCK, NIKTIMVO, OR IMBRUVICA. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# SAPROPTERIN

## Products Affected

- *javygtor oral tablet*
- *sapropterin dihydrochloride oral tablet*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | INITIAL: 2 MONTHS, RENEWAL 12 MONTHS.   |
| Other Criteria                | HYPERPHENYLALANINEMIA (HPA): INITIAL: NO CONCURRENT USE WITH PALYNZIQ. RENEWAL: 1) CONTINUES TO BENEFIT FROM TREATMENT, AND 2) NO CONCURRENT USE WITH PALYNZIQ. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
 Effective: 05/01/2026

# SECUKINUMAB SQ

## Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, ENTHESITIS-RELATED ARTHRITIS (ERA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL: HS: 12 MONTHS, ALL OTHER INDICATIONS: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. AS, NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. ERA: TRIAL OF OR CONTRAINDICATION TO ONE NSAID, SULFASALAZINE, OR METHOTREXATE. INITIAL/RENEWAL: |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
|                                      | ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# SELEXIPAG

## Products Affected

- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI TITRATION

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS   |
| <b>Other Criteria</b>                | PAH: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: 1) FORMULARY VERSION OF AN ORAL ENDOTHELIN RECEPTOR ANTAGONIST, 2) FORMULARY VERSION OF AN ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, 3) FORMULARY VERSION OF AN ORAL CGMP STIMULATOR.                                    |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# SELINEXOR

## Products Affected

- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG, 40 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG, 80 MG
- XPOVIO (80 MG TWICE WEEKLY)

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# SELPERCATINIB

## Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# SELUMETINIB

## Products Affected

- KOSELUGO ORAL CAPSULE 10 MG, 25 MG
- KOSELUGO ORAL CAPSULE SPRINKLE 5 MG, 7.5 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# SEVABERTINIB

---

## Products Affected

- HYRNUO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# SILDENAFIL TABLET

## Products Affected

- *sildenafil citrate oral tablet 20 mg*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: AGES 18 YEARS OR OLDER: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. AGES 1 TO 17 YEARS: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PAP GREATER THAN 20 MMHG, 2) PCWP OF 15 MMHG OR LESS, AND 3) PVR OF 3 WOOD UNITS OR GREATER. |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL/RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | No                      |

Formulary ID: 26382  
Effective: 05/01/2026

# SIPONIMOD

---

## Products Affected

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER PACK

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# SIROLIMUS PROTEIN-BOUND

---

## Products Affected

- FYARRO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# SODIUM OXYBATE-XYREM

## Products Affected

- *sodium oxybate*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> |   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: CATAPLEXY IN NARCOLEPSY, EXCESSIVE DAYTIME SLEEPINESS (EDS) IN NARCOLEPSY: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR SPECIALIST IN SLEEP MEDICINE  |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS   |
| <b>Other Criteria</b>               | INITIAL: EDS IN NARCOLEPSY: 1) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT, AND 2) AGES 18 YEARS OR OLDER: TRIAL, FAILURE OF, OR CONTRAINDICATION TO A FORMULARY VERSION OF MODAFINIL, ARMODAFINIL, OR SUNOSI AND ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY. CATAPLEXY IN NARCOLEPSY: NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. RENEWAL: CATAPLEXY IN NARCOLEPSY, EDS IN NARCOLEPSY: 1) SUSTAINED IMPROVEMENT OF SYMPTOMS COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. |
| <b>Indications</b>                  | All FDA-approved Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

# SOFOSBUVIR/VELPATASVIR

## Products Affected

- EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG
- EPCLUSA ORAL TABLET

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | HCV RNA LEVEL WITHIN PAST 6 MONTHS.   |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       |   |
| <b>Coverage Duration</b>             | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.   |
| <b>Other Criteria</b>                | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANA VIR/RITONAVIR, TOPOTECAN, SOVALDI (AS A SINGLE AGENT), HARVONI, ZEPATIER, MAVYRET, OR VOSEVI, AND 3) PATIENTS WITH DECOMPENSATED CIRRHOSIS REQUIRE CONCURRENT RIBAVIRIN UNLESS RIBAVIRIN INELIGIBLE. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

## Products Affected

- VOSEVI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | HCV RNA LEVEL WITHIN PAST 6 MONTHS   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.  |
| <b>Other Criteria</b>               | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR, TIPRANAVIR/RITONAVIR, SOVALDI (AS A SINGLE AGENT), EPCLUSA, HARVONI, ZEPATIER, OR MAVYRET, AND 3) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C). |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | No                      |

Formulary ID: 26382  
Effective: 05/01/2026

# SOMATROPIN - NORDITROPIN

## Products Affected

- NORDITROPIN FLEXPRO  
SUBCUTANEOUS SOLUTION PEN-  
INJECTOR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES.   |
| <b>Required Medical Information</b> | INITIAL: PEDIATRIC GROWTH HORMONE DEFICIENCY (GHD), IDIOPATHIC SHORT STATURE (ISS), SMALL FOR GESTATIONAL AGE (SGA), NOONAN SYNDROME: HEIGHT AT LEAST 2 STANDARD DEVIATIONS BELOW THE MEAN HEIGHT FOR CHILDREN OF THE SAME AGE AND GENDER. TURNER SYNDROME (TS): CONFIRMED BY CHROMOSOMAL ANALYSIS (KARYOTYPING). PRADER WILLI SYNDROME (PWS): CONFIRMED GENETIC DIAGNOSIS OF PWS. ADULT GHD: 1) HAS A CONGENITAL, GENETIC, OR ORGANIC DISEASE (E.G., CRANIOPHARYNGIOMA, PITUITARY HYPOPLASIA, ECTOPIC POSTERIOR PITUITARY, PREVIOUS CRANIAL IRRADIATION), OR 2) GHD CONFIRMED BY ONE OF THE FOLLOWING GROWTH HORMONE (GH) STIMULATION TESTS: (A) INSULIN TOLERANCE TEST (PEAK GH OF 5 NG/ML OR LESS), (B) GLUCAGON-STIMULATION TEST (ONE OF THE FOLLOWING: (I) PEAK RESPONSE OF 3 NG/ML OR LESS AND BMI LESS THAN 25 KG/M2, (II) PEAK RESPONSE OF 3 NG/ML OR LESS AND BMI IS BETWEEN 25 - 30 KG/M2 WITH A PRE-TEST PROBABILITY, (III) PEAK RESPONSE OF 1 NG/ML OR LESS AND BMI IS BETWEEN 25 - 30 KG/M2 WITH LOW TEST PROBABILITY, OR (IV) PEAK RESPONSE OF 1 NG/ML OR LESS AND BMI IS GREATER THAN 30 KG/M2), OR (C) MACIMORELIN TEST (PEAK GH OF 2.8 NG/ML OR LESS). |
| <b>Age Restrictions</b>             | SGA: 2 YEARS OF AGE OR OLDER.   |
| <b>Prescriber Restrictions</b>      | INITIAL/RENEWAL: ALL INDICATIONS: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL/RENEWAL: 12 MONTHS.   |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Other Criteria</b>                | <p>INITIAL: PEDIATRIC GHD, ISS, SGA, TS, NOONAN SYNDROME: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. INITIAL/RENEWAL: ADULT GHD, PEDIATRIC GHD, SGA, TS, PWS, NOONAN SYNDROME: NO CONCURRENT USE WITH INCRELEX. RENEWAL: ISS: 1) IMPROVEMENT WHILE ON THERAPY (INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. PEDIATRIC GHD, SGA, TS, NOONAN SYNDROME: 1) IMPROVEMENT WHILE ON THERAPY (INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND OR HAS NOT COMPLETED PREPUBERTAL GROWTH. PWS: IMPROVEMENT IN BODY COMPOSITION.</p> |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

# SOMATROPIN - SEROSTIM

## Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            | INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES   |
| <b>Required Medical Information</b>  | INITIAL: HIV/WASTING: ONE OF THE FOLLOWING FOR WEIGHT LOSS: 1) 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS OR 5% WEIGHT LOSS OVER 6 MONTHS, 2) 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, 3) BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, 4) BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND BMI LESS THAN 27 KG PER METER SQUARED, OR 5) BMI LESS THAN 20 KG PER METER SQUARED. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | HIV/WASTING: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST, OR INFECTIOUS DISEASE SPECIALIST.  |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 9 MONTHS.   |
| <b>Other Criteria</b>                | HIV/WASTING: RENEWAL: 1) CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT.   |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# SONIDEGIB

---

## Products Affected

- ODOMZO

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  | LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC):<br>BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# SORAFENIB

---

## Products Affected

- *sorafenib tosylate*

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# SOTATERCEPT-CSRK

## Products Affected

- WINREVAIR

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | PAH: INITIAL: 1) ON BACKGROUND PAH THERAPY (FOR AT LEAST 3 MONTHS) WITH AT LEAST TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: A) ORAL ENDOTHELIN RECEPTOR ANTAGONIST, B) ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, C) ORAL CGMP STIMULATOR, D) IV/SQ PROSTACYCLIN, OR 2) ON ONE AGENT FROM ONE OF THE ABOVE DRUG CLASSES, AND HAS A CONTRAINDICATION OR INTOLERANCE TO ALL OF THE OTHER DRUG CLASSES. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# SOTORASIB

---

## Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# STIRIPENTOL

## Products Affected

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | DRAVET SYNDROME: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS.  |
| Other Criteria                |  |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# SUNITINIB

## Products Affected

- *sunitinib malate*

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO IMATINIB. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
 Effective: 05/01/2026

# TADALAFIL - ADCIRCA, ALYQ

## Products Affected

- *alyq*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>                | PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM, AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.  |
| <b>Indications</b>                   | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# TADALAFIL-CIALIS

## Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            | ERECTILE DYSFUNCTION WITHOUT DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH).  |
| <b>Required Medical Information</b>  |  |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | 12 MONTHS  |
| <b>Other Criteria</b>                | BPH: 1) TRIAL OF ONE ALPHA BLOCKER (E.G., DOXAZOSIN, TERAZOSIN, TAMSULOSIN, ALFUZOSIN), AND 2) TRIAL OF ONE 5-ALPHA-REDUCTASE INHIBITOR (E.G., FINASTERIDE, DUTASTERIDE). APPLIES TO 2.5MG AND 5MG STRENGTHS ONLY. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# TAFAMIDIS

## Products Affected

- VYNDAMAX

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | CARDIOMYOPATHY ASSOCIATED WITH WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM): INITIAL: 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS I, II, OR III HEART FAILURE, AND 2) DIAGNOSIS CONFIRMED BY (A) BONE SCAN (SCINTIGRAPHY) STRONGLY POSITIVE FOR MYOCARDIAL UPTAKE OF TC-99M-PYP, OR (B) BIOPSY OF TISSUE OF AFFECTED ORGAN(S) (CARDIAC AND POSSIBLY NON-CARDIAC SITES) TO CONFIRM AMYLOID PRESENCE AND CHEMICAL TYPING TO CONFIRM PRESENCE OF TRANSTHYRETIN (TTR) PROTEIN. |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | ATTR-CM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ATTR SPECIALIST, OR MEDICAL GENETICIST.   |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS  |
| <b>Other Criteria</b>                | ATTR-CM: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER ATTR-CM TTR STABILIZERS (E.G., ACORAMIDIS)   |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# TALAZOPARIB

## Products Affected

- TALZENNA

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | ADVANCED OR METASTATIC BREAST CANCER: 1) HAS BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND 2) IF HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER, RECEIVED PRIOR TREATMENT WITH ENDOCRINE THERAPY OR IS CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# TALETRECTINIB

## Products Affected

- IBTROZI

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TALQUETAMAB-TGVS

---

## Products Affected

- TALVEY

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TARLATAMAB-DLLE

---

## Products Affected

- IMDELLTRA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TAZEMETOSTAT

---

## Products Affected

- TAZVERIK

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TEBENTAFUSP-TEBN

---

## Products Affected

- KIMMTRAK

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TECLISTAMAB-CQYV

## Products Affected

- TECVAYLI

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TELISOTUZUMAB VEDOTIN-TLLV

---

## Products Affected

- EMRELIS

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TELOTRISTAT

## Products Affected

- XERMELO

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | CARCINOID SYNDROME DIARRHEA: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST OR GASTROENTEROLOGIST |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                |  |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# TEPOTINIB

---

## Products Affected

- TEPMETKO

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TERIPARATIDE

## Products Affected

- *teriparatide subcutaneous solution pen-injector 560 mcg/2.24ml*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 24 MONTHS  |
| Other Criteria                | OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY, UNLESS REMAINS AT OR HAS RETURNED TO HAVING A HIGH RISK FOR FRACTURE. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# TESTOSTERONE

## Products Affected

- *testosterone gel 1.62 % transdermal*
- *testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.  |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS   |
| <b>Other Criteria</b>                | MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# TESTOSTERONE CYPIONATE - DEPO

## Products Affected

- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.  |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: 12 MONTHS   |
| <b>Other Criteria</b>                | MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# TESTOSTERONE ENANTHATE

## Products Affected

- *testosterone enanthate intramuscular solution*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.  |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | INITIAL/RENEWAL: MALE DELAYED PUBERTY: 6MO, MALE HYPOGONADISM: 12 MO. OTHER INDICATIONS: 12 MO.  |
| <b>Other Criteria</b>                | INITIAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. MALE DELAYED PUBERTY: HAS NOT RECEIVED MORE THAN TWO 6-MONTH COURSES OF TESTOSTERONE REPLACEMENT THERAPY |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# TETRABENAZINE

## Products Affected

- *tetrabenazine*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                |  |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# THALIDOMIDE

---

## Products Affected

- THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TISLELIZUMAB-JSGR

---

## Products Affected

- TEVIMBRA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TISOTUMAB VEDOTIN-TFTV

## Products Affected

- TIVDAK

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TIVOZANIB

---

## Products Affected

- FOTIVDA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TOCILIZUMAB-AAZG IV

## Products Affected

- TYENNE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS   |
| <b>Required Medical Information</b> |  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: RA, PJIA, SJIA, GCA: 6 MONTHS. CRS: 1 MONTH. RENEWAL: RA, PJIA, SJIA, GCA: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. GIANT CELL ARTERITIS (GCA): 1) HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICIDS, AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: RINVOQ. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ IR, ORENCIA, RINVOQ. RENEWAL: RA, PJIA, SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. GCA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
|                                      | BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. |
| <b>Indications</b>                   | All FDA-approved Indications.                                 |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# TOCILIZUMAB-AAZG SQ

## Products Affected

- TYENNE

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> |   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.  |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS   |
| <b>Other Criteria</b>               | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. GIANT CELL ARTERITIS (GCA): 1) HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOIDS, AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: RINVOQ. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PJIA, SJIA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.   |
| <b>Off Label Uses</b>               |   |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# TOFACITINIB

## Products Affected

- XELJANZ
- XELJANZ XR

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Exclusion Criteria           |   |
| Required Medical Information |   |
| Age Restrictions             |   |
| Prescriber Restrictions      | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.   |
| Coverage Duration            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| Other Criteria               | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, PCJIA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications                  | All FDA-approved Indications.   |
| Off Label Uses               |   |

Formulary ID: 26382  
Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# TOLVAPTAN

## Products Affected

- JYNARQUE ORAL TABLET
- tolvaptan oral tablet therapy pack*

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  | AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD); INITIAL: CONFIRMED POLYCYSTIC KIDNEY DISEASE VIA CT, MRI, OR ULTRASOUND. |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       | ADPKD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST.  |
| <b>Coverage Duration</b>             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>                | ADPKD: INITIAL: DOES NOT HAVE ESRD (I.E., RECEIVING DIALYSIS). RENEWAL: HAS NOT PROGRESSED TO ESRD/DIALYSIS.                   |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# TOPICAL TRETINOIN

## Products Affected

- ALTRENO
- *tretinoin external cream*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            | COSMETIC INDICATIONS SUCH AS WRINKLES, PHOTOAGING, MELASMA.  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | ACNE VULGARIS: BRAND TOPICAL TRETINOIN REQUIRES TRIAL OF OR CONTRAINDICATION TO A GENERIC TOPICAL TRETINOIN PRODUCT. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
 Effective: 05/01/2026

# TORIPALIMAB-TPZI

## Products Affected

- LOQTORZI

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | NASOPHARYNGEAL CARCINOMA (NPC): FIRST LINE TREATMENT: 24 MOS, PREVIOUSLY TREATED: LIFETIME. |
| Other Criteria                |   |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# TOVORAFENIB

## Products Affected

- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TRAMETINIB SOLUTION

## Products Affected

- MEKINIST ORAL SOLUTION RECONSTITUTED

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | UNRESECTABLE OR METASTATIC MELANOMA, MELANOMA, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC), UNRESECTABLE OR METASTATIC SOLID TUMOR, LOW-GRADE GLIOMA (LGG): UNABLE TO SWALLOW MEKINIST TABLETS. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# TRAMETINIB TABLET

---

## Products Affected

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TRASTUZUMAB-DKST

---

## Products Affected

- OGIVRI

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TRASTUZUMAB-HYALURONIDASE-OYSK

## Products Affected

- HERCEPTIN HYLECTA

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | ADJUVANT BREAST CANCER, METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: HERZUMA, OGIVRI, ONTRUZANT, TRAZIMERA. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# TRAZODONE

---

## Products Affected

- RALDESY

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | MAJOR DEPRESSIVE DISORDER (MDD): CONTRAINDICATION TO OR UNABLE TO SWALLOW TRAZODONE TABLETS. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# TREMELIMUMAB-ACTL

## Products Affected

- IMJUDO

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | UHCC: 30 DAYS. METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): 5 MONTHS.   |
| Other Criteria                | UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): HAS NOT RECEIVED PRIOR TREATMENT WITH IMJUDO. NSCLC: HAS NOT RECEIVED A TOTAL OF 5 DOSES OF IMJUDO. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# TRIENTINE CAPSULE

## Products Affected

- *trientine hcl oral capsule 250 mg*

| PA Criteria                          | Criteria Details  |
|--------------------------------------|---|
| <b>Exclusion Criteria</b>            |   |
| <b>Required Medical Information</b>  | WILSONS DISEASE: INITIAL: LEIPZIG SCORE OF 4 OR GREATER.  |
| <b>Age Restrictions</b>              |   |
| <b>Prescriber Restrictions</b>       | WILSONS DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST.   |
| <b>Coverage Duration</b>             | INITIAL: 12 MONTHS, RENEWAL: LIFETIME.  |
| <b>Other Criteria</b>                | WILSONS DISEASE: INITIAL: TRIAL OF OR CONTRAINDICATION TO FORMULARY VERSION OF PENICILLAMINE TABLET. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                   | All FDA-approved Indications.   |
| <b>Off Label Uses</b>                |   |
| <b>Part B Prerequisite</b>           | No  |
| <b>Prerequisite Therapy Required</b> | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# TRIFLURIDINE/TIPIRACIL

## Products Affected

- LONSURF ORAL TABLET 15-6.14 MG,  
20-8.19 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TRIPTORELIN-TRELSTAR

---

## Products Affected

- TRELSTAR MIXJECT

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS.                    |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# TUCATINIB

---

## Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# UBROGEPANT

## Products Affected

- UBRELVY

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| Other Criteria                | ACUTE MIGRAINE TREATMENT: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# UPADACITINIB

## Products Affected

- RINVOQ
- RINVOQ LQ

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. AD: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST, OR IMMUNOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.  |
| <b>Other Criteria</b>               | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, AND 2) TRIAL OF OR CONTRAINDICATION TO A TOPICAL CORTICOSTEROID, TOPICAL CALCINEURIN INHIBITOR, TOPICAL PDE4 INHIBITOR, OR TOPICAL JAK INHIBITOR. AS, NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG). GIANT CELL |

Formulary ID: 26382  
Effective: 05/01/2026

| PA Criteria                          | Criteria Details   |
|--------------------------------------|--|
|                                      | <p>ARTERITIS (GCA): HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOIDS.</p> <p>INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM THE MEDICATION. AD: IMPROVEMENT WHILE ON THERAPY.</p> |
| <b>Indications</b>                   | All FDA-approved Indications.  |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# USTEKINUMAB-AAUZ SQ

## Products Affected

- *ustekinumab-aauz*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | Yes                     |

# USTEKINUMAB-AEKN IV

## Products Affected

- SELARSDI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | Yes                     |

Formulary ID: 26382  
Effective: 05/01/2026

# USTEKINUMAB-AEKN SQ

## Products Affected

- SELARSDI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | Yes                     |

# USTEKINUMAB-KFCE IV

## Products Affected

- YESINTEK

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | Yes                     |

# USTEKINUMAB-KFCE SQ

## Products Affected

- YESINTEK

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.   |
| <b>Coverage Duration</b>            | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.   |
| <b>Other Criteria</b>               | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| <b>Indications</b>                  | All FDA-approved Indications.  |
| <b>Off Label Uses</b>               |  |

Formulary ID: 26382

Effective: 05/01/2026

| <b>PA Criteria</b>                   | <b>Criteria Details</b> |
|--------------------------------------|-------------------------|
| <b>Part B Prerequisite</b>           | No                      |
| <b>Prerequisite Therapy Required</b> | Yes                     |

# VALBENAZINE

## Products Affected

- INGREZZA ORAL CAPSULE
- INGREZZA ORAL CAPSULE SPRINKLE
- INGREZZA ORAL CAPSULE THERAPY PACK

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | TARDIVE DYSKINESIA (TD): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | TD: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.  |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# VANDETANIB

---

## Products Affected

- CAPRELSA ORAL TABLET 100 MG,  
300 MG

| <b>PA Criteria</b>                   | <b>Criteria Details</b>                                  |
|--------------------------------------|--|
| <b>Exclusion Criteria</b>            |  |
| <b>Required Medical Information</b>  |  |
| <b>Age Restrictions</b>              |  |
| <b>Prescriber Restrictions</b>       |  |
| <b>Coverage Duration</b>             | 12 MONTHS  |
| <b>Other Criteria</b>                | CURRENTLY STABLE ON CAPRELSA REQUIRES NO EXTRA CRITERIA. |
| <b>Indications</b>                   | All FDA-approved Indications.                            |
| <b>Off Label Uses</b>                |  |
| <b>Part B Prerequisite</b>           | No   |
| <b>Prerequisite Therapy Required</b> | No   |

Formulary ID: 26382  
Effective: 05/01/2026

# VANZACAFTOR-TEZACAFTOR- DEUTIVACAFTOR

## Products Affected

- ALYFTREK ORAL TABLET 10-50-125  
MG, 4-20-50 MG

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       | CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.   |
| Coverage Duration             | INITIAL: 6 MONTHS. RENEWAL: LIFETIME.   |
| Other Criteria                | CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# VEMURAFENIB

## Products Affected

- ZELBORAF

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | 12 MONTHS   |
| Other Criteria                | MELANOMA: ZELBORAF WILL BE USED ALONE OR IN COMBINATION WITH COTELLIC |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | No  |

Formulary ID: 26382  
Effective: 05/01/2026

# VENETOCLAX

## Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# VERICIGUAT

## Products Affected

- VERQUVO

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | INITIAL/RENEWAL:12 MONTHS.  |
| Other Criteria                | HEART FAILURE (HF): INITIAL: 1) TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO ONE PREFERRED SGLT-2 INHIBITOR, AND 2) TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO ONE AGENT FROM ANY OF THE FOLLOWING STANDARD OF CARE CLASSES: (A) ACE INHIBITOR, ARB, OR ARNI, (B) BETA BLOCKER (BISOPROLOL, CARVEDILOL, METOPROLOL SUCCINATE), OR (C) ALDOSTERONE ANTAGONIST (SPIRONOLACTONE, EPLERENONE). INITIAL/RENEWAL: NO CONCURRENT USE WITH RIOCIGUAT OR PDE-5 INHIBITORS. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# VIGABATRIN

## Products Affected

- *vigabatrín*
- *vigadrone*
- *vigpoder*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       | INITIAL: REFRACTORY COMPLEX PARTIAL SEIZURES (CPS), INFANTILE SPASMS: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration             | INITIAL/RENEWAL: 12 MONTHS   |
| Other Criteria                | INITIAL: CPS: TRIAL OF OR CONTRAINDICATION TO TWO ANTIPILEPTIC AGENTS.   |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
 Effective: 05/01/2026

# VIMSELTINIB

---

## Products Affected

- ROMVIMZA

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# VISMODEGIB

---

## Products Affected

- ERIVEDGE

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# VONOPRAZAN

## Products Affected

- VOQUEZNA

| PA Criteria                   | Criteria Details  |
|-------------------------------|---|
| Exclusion Criteria            |   |
| Required Medical Information  |   |
| Age Restrictions              |   |
| Prescriber Restrictions       |   |
| Coverage Duration             | INITIAL: H PYLORI: 30 DAYS. EE: 8 WEEKS. NERD: 4 WEEKS. RENEWAL: EE: 24 WEEKS.  |
| Other Criteria                | INITIAL: EROSIIVE ESOPHAGITIS (EE): TRIAL OF OR CONTRAINDICATION TO TWO PROTON PUMP INHIBITORS AT MAXIMUM DOSE FOR 8 WEEKS EACH. NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (NERD): 1) NO PREVIOUS TREATMENT FAILURE WITH VOQUEZNA IN THE LAST 12 MONTHS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE PROTON PUMP INHIBITOR AT MAXIMUM DOSE FOR 8 WEEKS. RENEWAL: EE: MAINTAINED A CLINICAL RESPONSE ON VOQUEZNA. |
| Indications                   | All FDA-approved Indications.   |
| Off Label Uses                |   |
| Part B Prerequisite           | No  |
| Prerequisite Therapy Required | Yes   |

Formulary ID: 26382  
Effective: 05/01/2026

# VORASIDENIB

---

## Products Affected

- VORANIGO

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# VORICONAZOLE SUSPENSION

## Products Affected

- *voriconazole oral suspension reconstituted*

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | CANDIDA INFECTIONS: 3 MOS. CONTINUATION OF THERAPY, ALL OTHER INDICATIONS: 6 MOS.  |
| Other Criteria                | CANDIDA INFECTIONS: CONTRAINDICATION TO OR UNABLE TO SWALLOW FLUCONAZOLE TABLETS. ALL INDICATIONS EXCEPT ESOPHAGEAL CANDIDIASIS: UNABLE TO SWALLOW TABLETS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
Effective: 05/01/2026

# ZANIDATAMAB-HRII

---

## Products Affected

- ZIIHERA

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ZANUBRUTINIB

## Products Affected

- BRUKINSA ORAL CAPSULE
- BRUKINSA ORAL TABLET

| PA Criteria                   | Criteria Details   |
|-------------------------------|--|
| Exclusion Criteria            |  |
| Required Medical Information  |  |
| Age Restrictions              |  |
| Prescriber Restrictions       |  |
| Coverage Duration             | 12 MONTHS  |
| Other Criteria                | MANTLE CELL LYMPHOMA: INTOLERANCE TO CALQUENCE. CHRONIC LYMPHOCYTIC LEUKEMIA, SMALL LYMPHOCYTIC LYMPHOMA: INTOLERANCE TO CALQUENCE OR IMBRUVICA. WALDENSTROMS MACROGLOBULINEMIA: NO STEP REQUIRED. |
| Indications                   | All FDA-approved Indications.  |
| Off Label Uses                |  |
| Part B Prerequisite           | No   |
| Prerequisite Therapy Required | Yes  |

Formulary ID: 26382  
 Effective: 05/01/2026

# ZENOCUTUZUMAB-ZBCO

## Products Affected

- BIZENGRI (750 MG DOSE)

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ZIFTOMENIB

---

## Products Affected

- KOMZIFTI

| <b>PA Criteria</b>                   | <b>Criteria Details</b>       |
|--------------------------------------|-------------------------------|
| <b>Exclusion Criteria</b>            |                               |
| <b>Required Medical Information</b>  |                               |
| <b>Age Restrictions</b>              |                               |
| <b>Prescriber Restrictions</b>       |                               |
| <b>Coverage Duration</b>             | 12 MONTHS                     |
| <b>Other Criteria</b>                |                               |
| <b>Indications</b>                   | All FDA-approved Indications. |
| <b>Off Label Uses</b>                |                               |
| <b>Part B Prerequisite</b>           | No                            |
| <b>Prerequisite Therapy Required</b> | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ZOLBETUXIMAB-CLZB

## Products Affected

- VYLOY

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ZONGERTINIB

---

## Products Affected

- HERNEXEOS

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 12 MONTHS                     |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

# ZURANOLONE

## Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

| PA Criteria                   | Criteria Details              |
|-------------------------------|-------------------------------|
| Exclusion Criteria            |                               |
| Required Medical Information  |                               |
| Age Restrictions              |                               |
| Prescriber Restrictions       |                               |
| Coverage Duration             | 14 DAYS                       |
| Other Criteria                |                               |
| Indications                   | All FDA-approved Indications. |
| Off Label Uses                |                               |
| Part B Prerequisite           | No                            |
| Prerequisite Therapy Required | No                            |

Formulary ID: 26382  
Effective: 05/01/2026

## INDEX

### A

- abiraterone acetate ..... 7
- ABIRATERONE ACETATE  
MICRONIZED ..... 8
- abirtega..... 7
- ABOUTTIME PEN NEEDLE 30G X 8 MM  
..... 163, 181, 182
- ABOUTTIME PEN NEEDLE 31G X 5 MM  
..... 163, 181, 182
- ABOUTTIME PEN NEEDLE 31G X 8 MM  
..... 163, 181, 182
- ABOUTTIME PEN NEEDLE 32G X 4 MM  
..... 163, 181, 182
- ACTIMMUNE..... 186
- adalimumab-aaty (1 pen) auto-injector kit 40  
mg/0.4ml subcutaneous..... 14, 15
- adalimumab-aaty (1 pen) subcutaneous auto-  
injector kit 80 mg/0.8ml..... 14, 15
- adalimumab-aaty (2 pen) ..... 14, 15
- adalimumab-aaty (2 syringe) ..... 14, 15
- adalimumab-aaty cd/uc/hs start..... 14, 15
- ADEMPAS ..... 296, 297
- ADVOCATE INSULIN PEN NEEDLE 32G  
X 4 MM..... 163, 181, 182
- ADVOCATE INSULIN PEN NEEDLES  
29G X 12.7MM..... 163, 181, 182
- ADVOCATE INSULIN PEN NEEDLES  
31G X 5 MM..... 163, 181, 182
- ADVOCATE INSULIN PEN NEEDLES  
31G X 8 MM..... 163, 181, 182
- ADVOCATE INSULIN PEN NEEDLES  
33G X 4 MM..... 163, 181, 182
- ADVOCATE INSULIN SYRINGE 29G X  
1/2 ..... 163, 181, 182
- ADVOCATE INSULIN SYRINGE 30G X  
5/16 ..... 163, 181, 182
- ADVOCATE INSULIN SYRINGE 31G X  
5/16 ..... 163, 181, 182
- AIMOVIG..... 120
- AKEEGA ..... 242
- ALCOHOL PREP PAD..... 163, 181, 182
- ALCOHOL PREP PAD 70 %. 163, 181, 182
- ALCOHOL PREP PADS PAD 70 % .... 163,  
181, 182
- ALCOHOL SWABS PAD..... 163, 181, 182
- ALCOHOL SWABS PAD 70 % ... 163, 181,  
182
- ALECENSA..... 21
- ALTRENO..... 363
- ALUNBRIG ORAL TABLET 180 MG, 30  
MG, 90 MG..... 59
- ALUNBRIG ORAL TABLET THERAPY  
PACK..... 59
- ALVAIZ..... 107
- ALYFTREK ORAL TABLET 10-50-125  
MG, 4-20-50 MG..... 391
- alyq..... 334
- ANKTIVA ..... 248
- AQ INSULIN SYRINGE 31G X 5/16... 163,  
181, 182
- AQINJECT PEN NEEDLE 31G X 5 MM  
..... 163, 181, 182
- AQINJECT PEN NEEDLE 32G X 4 MM  
..... 163, 181, 182
- ARCALYST ..... 292, 293
- ARIKAYCE..... 23
- armodafinil..... 234
- ASSURE ID DUO PRO PEN NEEDLES  
31G X 5 MM..... 163, 181, 182
- ASSURE ID INSULIN SAFETY SYR 29G  
X 1/2..... 163, 181, 182
- ASSURE ID INSULIN SAFETY SYR 31G  
X 15/64..... 163, 181, 182
- ASSURE ID PRO PEN NEEDLES 30G X 5  
MM ..... 163, 181, 182
- ATTRUBY..... 10
- AUGTYRO ORAL CAPSULE 160 MG, 40  
MG ..... 285
- AUM ALCOHOL PREP PADS PAD 70 %  
..... 163, 181, 182
- AUM INSULIN SAFETY PEN NEEDLE  
31G X 4 MM..... 163, 181, 182
- AUM INSULIN SAFETY PEN NEEDLE  
31G X 5 MM..... 163, 181, 182
- AUM MINI INSULIN PEN NEEDLE 32G  
X 4 MM..... 163, 181, 182
- AUM MINI INSULIN PEN NEEDLE 32G  
X 5 MM..... 163, 181, 182

AUM MINI INSULIN PEN NEEDLE 32G X 6 MM..... 163, 181, 182  
 AUM MINI INSULIN PEN NEEDLE 32G X 8 MM..... 163, 181, 182  
 AUM MINI INSULIN PEN NEEDLE 33G X 4 MM..... 163, 181, 182  
 AUM MINI INSULIN PEN NEEDLE 33G X 5 MM..... 163, 181, 182  
 AUM MINI INSULIN PEN NEEDLE 33G X 6 MM..... 163, 181, 182  
 AUM PEN NEEDLE 32G X 4 MM ..... 163, 181, 182  
 AUM PEN NEEDLE 32G X 5 MM ..... 163, 181, 182  
 AUM PEN NEEDLE 32G X 6 MM ..... 163, 181, 182  
 AUM PEN NEEDLE 33G X 4 MM ..... 164, 181, 182  
 AUM PEN NEEDLE 33G X 5 MM ..... 164, 181, 182  
 AUM PEN NEEDLE 33G X 6 MM ..... 164, 181, 182  
 AUM READYGARD DUO PEN NEEDLE 32G X 4 MM..... 164, 181, 182  
 AUM SAFETY PEN NEEDLE 31G X 4 MM ..... 164, 181, 182  
 AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG ..... 89  
 AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG ..... 89  
 AUSTEDO XR PATIENT TITRATION . 89  
 AVMAPKI FAKZYNJA CO-PACK..... 40  
 AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT..... 183  
 AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT..... 183  
 AYVAKIT ..... 39  
**B**  
 BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG..... 119  
 BD AUTOSHIELD DUO 30G X 5 MM 164, 181, 182  
 BD ECLIPSE SYRINGE 30G X 1/2 ..... 164, 181, 182  
 BD INSULIN SYR ULTRAFINE II 31G X 5/16 ..... 164, 181, 182  
 BD INSULIN SYRINGE 27.5G X 5/8.. 164, 181, 182  
 BD INSULIN SYRINGE 27G X 1/2..... 164, 181, 182  
 BD INSULIN SYRINGE 29G X 1/2..... 164, 181, 182  
 BD INSULIN SYRINGE HALF-UNIT 31G X 5/16..... 164, 181, 182  
 BD INSULIN SYRINGE MICROFINE 27G X 5/8..... 164, 181, 182  
 BD INSULIN SYRINGE MICROFINE 28G X 1/2..... 164, 181, 182  
 BD INSULIN SYRINGE U-100 1 ML . 164, 181, 182  
 BD INSULIN SYRINGE ULTRAFINE 29G X 1/2..... 164, 181, 182  
 BD INSULIN SYRINGE ULTRAFINE 30G X 1/2..... 164, 181, 182  
 BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM..... 164, 181, 182  
 BD PEN NEEDLE MINI U/F 31G X 5 MM ..... 164, 181, 182  
 BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM..... 164, 181, 182  
 BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM..... 164, 181, 182  
 BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM..... 164, 181, 182  
 BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM..... 164, 181, 182  
 BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM..... 164, 181, 182  
 BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2..... 164, 181, 182  
 BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16..... 164, 181, 182  
 BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64..... 164, 181, 182  
 BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16..... 164, 181, 182  
 BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8..... 164, 181, 182

|   |                    |   |               |
|---|--------------------|---|---------------|
| BD SWAB SINGLE USE REGULAR PAD<br>.....                           | 164, 181, 182      | CAREFINE PEN NEEDLES 31G X 6 MM<br>.....      | 165, 181, 182 |
| BD SWABS SINGLE USE BUTTERFLY<br>PAD.....                         | 164, 181, 182      | CAREFINE PEN NEEDLES 31G X 8 MM<br>.....      | 165, 181, 182 |
| BD VEO INSULIN SYR U/F 1/2UNIT 31G<br>X 15/64.....                | 164, 181, 182      | CAREFINE PEN NEEDLES 32G X 4 MM<br>.....      | 165, 181, 182 |
| BD VEO INSULIN SYR ULTRAFINE 31G<br>X 15/64.....                  | 164, 181, 182      | CAREFINE PEN NEEDLES 32G X 5 MM<br>.....      | 165, 181, 182 |
| BD VEO INSULIN SYRINGE U/F 31G X<br>15/64 .....                   | 164, 165, 181, 182 | CAREFINE PEN NEEDLES 32G X 6 MM<br>.....      | 165, 181, 182 |
| BENDAMUSTINE HCL INTRAVENOUS<br>SOLUTION.....                     | 49                 | CAREONE INSULIN SYRINGE 30G X<br>1/2 .....    | 165, 181, 182 |
| bendamustine hcl intravenous solution<br>reconstituted.....       | 49                 | CAREONE INSULIN SYRINGE 31G X<br>5/16 .....   | 165, 181, 182 |
| BENDEKA .....   | 49                 | CARETOUCH ALCOHOL PREP PAD 70<br>% .....      | 165, 181, 182 |
| BENLYSTA SUBCUTANEOUS.....  | 46                 | CARETOUCH INSULIN SYRINGE 28G X<br>5/16 ..... | 165, 181, 182 |
| BESREMI .....   | 304                | CARETOUCH INSULIN SYRINGE 29G X<br>5/16 ..... | 165, 181, 182 |
| betaine.....  | 52                 | CARETOUCH INSULIN SYRINGE 30G X<br>5/16 ..... | 165, 181, 182 |
| BETASERON SUBCUTANEOUS KIT  | 184                | CARETOUCH INSULIN SYRINGE 31G X<br>5/16 ..... | 165, 181, 182 |
| bexarotene .....  | 54                 | CARETOUCH PEN NEEDLES 29G X<br>12MM .....     | 165, 181, 182 |
| BIZENGRI (750 MG DOSE) .....                                      | 403                | CARETOUCH PEN NEEDLES 31G X 5<br>MM .....     | 165, 181, 182 |
| BORTEZOMIB INJECTION SOLUTION<br>RECONSTITUTED 1 MG, 2.5 MG ..... | 56                 | CARETOUCH PEN NEEDLES 31G X 6<br>MM .....     | 165, 181, 182 |
| bortezomib injection solution reconstituted<br>3.5 mg .....       | 56                 | CARETOUCH PEN NEEDLES 31G X 8<br>MM .....     | 165, 181, 182 |
| BORUZU .....  | 56                 | CARETOUCH PEN NEEDLES 32G X 4<br>MM .....     | 165, 181, 182 |
| bosentan oral tablet .....  | 57                 | CARETOUCH PEN NEEDLES 32G X 5<br>MM .....     | 165, 181, 182 |
| BOSULIF ORAL CAPSULE 100 MG, 50<br>MG .....                       | 58                 | CARETOUCH PEN NEEDLES 33G X 4<br>MM .....     | 165, 181, 182 |
| BOSULIF ORAL TABLET 100 MG, 400<br>MG, 500 MG.....                | 58                 | carglumic acid oral tablet soluble .....      | 66            |
| BRAFTOVI ORAL CAPSULE 75 MG .                                     | 111                | CAYSTON.....                                  | 44            |
| BRUKINSA ORAL CAPSULE .....                                       | 402                | CIMZIA (1 SYRINGE) .....                      | 68, 69        |
| BRUKINSA ORAL TABLET .....  | 402                | CIMZIA (2 SYRINGE) .....                      | 68, 69        |
| <b>C</b>  |                    | CIMZIA SUBCUTANEOUS KIT 2 X 200<br>MG .....   | 68, 69        |
| CABOMETYX ORAL TABLET 20 MG, 40<br>MG, 60 MG.....                 | 62                 | CIMZIA-STARTER .....                          | 68, 69        |
| CALQUENCE .....   | 9                  |   |               |
| CAMCEVI .....   | 203                |   |               |
| CAMZYOS .....   | 220                |   |               |
| CAPRELSA ORAL TABLET 100 MG, 300<br>MG .....                      | 390                |   |               |
| CAREFINE PEN NEEDLES 29G X 12MM<br>.....                          | 165, 181, 182      |   |               |
| CAREFINE PEN NEEDLES 30G X 8 MM<br>.....                          | 165, 181, 182      |   |               |

|   |               |  |               |
|---|---------------|--|---------------|
| CLEVER CHOICE COMFORT EZ 29G X 12MM .....                     | 165, 181, 182 | COMFORT EZ PEN NEEDLES 33G X 4 MM .....                            | 166, 181, 182 |
| CLEVER CHOICE COMFORT EZ 33G X 4 MM .....                     | 165, 181, 182 | COMFORT EZ PEN NEEDLES 33G X 5 MM .....                            | 166, 181, 182 |
| CLICKFINE PEN NEEDLES 31G X 8 MM .....                        | 165, 181, 182 | COMFORT EZ PEN NEEDLES 33G X 6 MM .....                            | 166, 181, 182 |
| CLICKFINE PEN NEEDLES 32G X 4 MM .....                        | 165, 181, 182 | COMFORT EZ PEN NEEDLES 33G X 8 MM .....                            | 166, 181, 182 |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG .....        | 61            | COMFORT EZ PRO PEN NEEDLES 30G X 8 MM.....                         | 166, 181, 182 |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG ..... | 61            | COMFORT EZ PRO PEN NEEDLES 31G X 4 MM.....                         | 166, 181, 182 |
| COMETRIQ (60 MG DAILY DOSE).....                              | 61            | COMFORT EZ PRO PEN NEEDLES 31G X 5 MM.....                         | 166, 181, 182 |
| COMFORT ASSIST INSULIN SYRINGE 29G X 1/2.....                 | 165, 181, 182 | COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM.....                     | 166, 181, 182 |
| COMFORT ASSIST INSULIN SYRINGE 31G X 5/16.....                | 165, 181, 182 | COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM.....                     | 166, 181, 182 |
| COMFORT EZ INSULIN SYRINGE 27G X 1/2.....                     | 165, 181, 182 | COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM.....                     | 166, 181, 182 |
| COMFORT EZ INSULIN SYRINGE 28G X 1/2.....                     | 165, 181, 182 | COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM.....                     | 166, 181, 182 |
| COMFORT EZ INSULIN SYRINGE 29G X 1/2.....                     | 165, 181, 182 | COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM.....                     | 166, 181, 182 |
| COMFORT EZ INSULIN SYRINGE 30G X 1/2.....                     | 165, 181, 182 | COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM.....                     | 166, 181, 182 |
| COMFORT EZ INSULIN SYRINGE 30G X 5/16.....                    | 166, 181, 182 | COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM.....                     | 166, 181, 182 |
| COMFORT EZ INSULIN SYRINGE 31G X 15/64.....                   | 166, 181, 182 | COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM.....                     | 166, 181, 182 |
| COMFORT EZ INSULIN SYRINGE 31G X 5/16.....                    | 166, 181, 182 | COPIKTRA.....  | 99            |
| COMFORT EZ PEN NEEDLES 31G X 5 MM .....                       | 166, 181, 182 | CORTROPHIN .....   | 74, 75        |
| COMFORT EZ PEN NEEDLES 31G X 6 MM .....                       | 166, 181, 182 | COSENTYX (300 MG DOSE).....  | 308, 309      |
| COMFORT EZ PEN NEEDLES 31G X 8 MM .....                       | 166, 181, 182 | COSENTYX SENSOREADY (300 MG) .....                                 | 308, 309      |
| COMFORT EZ PEN NEEDLES 32G X 4 MM .....                       | 166, 181, 182 | COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML ..... | 308, 309      |
| COMFORT EZ PEN NEEDLES 32G X 5 MM .....                       | 166, 181, 182 | COSENTYX UNOREADY .....  | 308, 309      |
| COMFORT EZ PEN NEEDLES 32G X 6 MM .....                       | 166, 181, 182 | COTELLIC .....   | 73            |
| COMFORT EZ PEN NEEDLES 32G X 8 MM .....                       | 166, 181, 182 | CRESEMBA ORAL .....  | 188           |
|   |               | CURITY ALCOHOL PREPS PAD 70 % .....                                | 166, 181, 182 |
|   |               | CURITY ALL PURPOSE SPONGES PAD 2.....                              | 166, 181, 182 |
|   |               | CURITY GAUZE PAD 2 .....   | 166, 181, 182 |

CURITY GAUZE SPONGE PAD 2..... 166, 181, 182  
 CURITY SPONGES PAD 2... 166, 181, 182  
 CVS ALCOHOL PREP PADS PAD 70 %  
 ..... 166, 181, 182  
 CVS GAUZE PAD 2 ..... 166, 181, 182  
 CVS GAUZE STERILE PAD 2 .... 166, 181, 182  
 cvs isopropyl alcohol wipes .... 166, 181, 182  
 CVS PREP PAD 70 %..... 166, 181, 182  
 CYLTEZO (2 PEN) ..... 16, 17  
 CYLTEZO (2 SYRINGE) ..... 16, 17  
 CYLTEZO-CD/UC/HS STARTER.... 16, 17  
 CYLTEZO-PSORIASIS/UV STARTER 16, 17

**D**

dalfampridine er ..... 81  
 DANYELZA..... 235  
 DANZITEN ..... 238  
 dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg ..... 83  
 DATROWAY ..... 84  
 DAURISMO ORAL TABLET 100 MG, 25 MG ..... 144  
 deferasirox granules ..... 86, 87  
 deferasirox oral tablet ..... 86, 87  
 DERMACEA GAUZE SPONGE PAD 2  
 ..... 166, 181, 182  
 DERMACEA IV DRAIN SPONGES PAD 2..... 166, 181, 182  
 DERMACEA NON-WOVEN SPONGES PAD 2..... 166, 181, 182  
 DERMACEA TYPE VII GAUZE PAD 2  
 ..... 166, 181, 182  
 DIACOMIT ORAL CAPSULE 250 MG, 500 MG ..... 332  
 DIACOMIT ORAL PACKET 250 MG, 500 MG ..... 332  
 DIATHRIVE PEN NEEDLE 31G X 5 MM  
 ..... 166, 181, 182  
 DIATHRIVE PEN NEEDLE 31G X 6 MM  
 ..... 166, 181, 182  
 DIATHRIVE PEN NEEDLE 31G X 8 MM  
 ..... 166, 181, 182  
 DIATHRIVE PEN NEEDLE 32G X 4 MM  
 ..... 166, 181, 182

diclofenac epolamine external ..... 91  
 diclofenac sodium external solution 2 %.. 90  
 dimethyl fumarate oral capsule delayed release 120 mg, 240 mg ..... 92  
 dimethyl fumarate starter pack oral capsule delayed release therapy pack ..... 92  
 dronabinol ..... 96  
 DROPLET INSULIN SYRINGE 29G X 1/2 ..... 167, 181, 182  
 DROPLET INSULIN SYRINGE 30G X 1/2 ..... 167, 181, 182  
 DROPLET INSULIN SYRINGE 30G X 15/64 ..... 167, 181, 182  
 DROPLET INSULIN SYRINGE 30G X 5/16 ..... 167, 181, 182  
 DROPLET INSULIN SYRINGE 31G X 15/64 ..... 167, 181, 182  
 DROPLET INSULIN SYRINGE 31G X 5/16 ..... 167, 181, 182  
 DROPLET MICRON 34G X 3.5 MM... 167, 181, 182  
 DROPLET PEN NEEDLES 29G X 10MM ..... 167, 181, 182  
 DROPLET PEN NEEDLES 29G X 12MM ..... 167, 181, 182  
 DROPLET PEN NEEDLES 30G X 8 MM ..... 167, 181, 182  
 DROPLET PEN NEEDLES 31G X 5 MM ..... 167, 181, 182  
 DROPLET PEN NEEDLES 31G X 6 MM ..... 167, 181, 182  
 DROPLET PEN NEEDLES 31G X 8 MM ..... 167, 181, 182  
 DROPLET PEN NEEDLES 32G X 4 MM ..... 167, 181, 182  
 DROPLET PEN NEEDLES 32G X 5 MM ..... 167, 181, 182  
 DROPLET PEN NEEDLES 32G X 6 MM ..... 167, 181, 182  
 DROPLET PEN NEEDLES 32G X 8 MM ..... 167, 181, 182  
 DROPSAFE ALCOHOL PREP PAD 70 % ..... 167, 181, 182  
 DROPSAFE AUTOPROTECT DUO 31G X 4 MM ..... 167, 181, 182

DROPSAFE AUTOPROTECT DUO 31G X  
 8 MM ..... 167, 181, 182  
 DROPSAFE SAFETY PEN NEEDLES 31G  
 X 5 MM..... 167, 181, 182  
 DROPSAFE SAFETY PEN NEEDLES 31G  
 X 6 MM..... 167, 181, 182  
 DROPSAFE SAFETY SYRINGE/NEEDLE  
 29G X 1/2..... 167, 181, 182  
 DROPSAFE SAFETY SYRINGE/NEEDLE  
 31G X 15/64..... 167, 181, 182  
 DROPSAFE SAFETY SYRINGE/NEEDLE  
 31G X 5/16..... 167, 181, 182  
 droxidopa ..... 97  
 DRUG MART ULTRA COMFORT SYR  
 29G X 1/2..... 167, 181, 182  
 DRUG MART ULTRA COMFORT SYR  
 30G X 5/16..... 167, 181, 182  
 DRUG MART UNIFINE PENTIPS 31G X  
 5 MM ..... 167, 181, 182  
 DUPIXENT SUBCUTANEOUS  
 SOLUTION AUTO-INJECTOR ..... 98  
 DUPIXENT SUBCUTANEOUS  
 SOLUTION PREFILLED SYRINGE .. 98  
**E**  
 EASY COMFORT ALCOHOL PADS PAD  
 ..... 167, 181, 182  
 EASY COMFORT INSULIN SYRINGE  
 29G X 5/16..... 167, 168, 181, 182  
 EASY COMFORT INSULIN SYRINGE  
 30G X 1/2..... 168, 181, 182  
 EASY COMFORT INSULIN SYRINGE  
 30G X 5/16..... 168, 181, 182  
 EASY COMFORT INSULIN SYRINGE  
 31G X 1/2..... 168, 181, 182  
 EASY COMFORT INSULIN SYRINGE  
 31G X 5/16..... 168, 181, 182  
 EASY COMFORT INSULIN SYRINGE  
 32G X 5/16..... 168, 181, 182  
 EASY COMFORT PEN NEEDLES 29G X  
 4MM ..... 168, 181, 182  
 EASY COMFORT PEN NEEDLES 29G X  
 5MM ..... 168, 181, 182  
 EASY COMFORT PEN NEEDLES 31G X  
 5 MM ..... 168, 181, 182  
 EASY COMFORT PEN NEEDLES 31G X  
 6 MM ..... 168, 181, 182

EASY COMFORT PEN NEEDLES 31G X  
 8 MM ..... 168, 181, 182  
 EASY COMFORT PEN NEEDLES 32G X  
 4 MM ..... 168, 181, 182  
 EASY COMFORT PEN NEEDLES 33G X  
 4 MM ..... 168, 181, 182  
 EASY COMFORT PEN NEEDLES 33G X  
 5 MM ..... 168, 181, 182  
 EASY COMFORT PEN NEEDLES 33G X  
 6 MM ..... 168, 181, 182  
 EASY GLIDE PEN NEEDLES 33G X 4  
 MM ..... 168, 181, 182  
 EASY TOUCH ALCOHOL PREP  
 MEDIUM PAD 70 %..... 168, 181, 182  
 EASY TOUCH FLIPLOCK INSULIN SY  
 29G X 1/2..... 168, 181, 182  
 EASY TOUCH FLIPLOCK INSULIN SY  
 30G X 1/2..... 168, 181, 182  
 EASY TOUCH FLIPLOCK INSULIN SY  
 30G X 5/16..... 168, 181, 182  
 EASY TOUCH FLIPLOCK INSULIN SY  
 31G X 5/16..... 168, 181, 182  
 EASY TOUCH FLIPLOCK SAFETY SYR  
 27G X 1/2..... 168, 181, 182  
 EASY TOUCH INSULIN BARRELS U-  
 100 1 ML..... 168, 181, 182  
 EASY TOUCH INSULIN SAFETY SYR  
 29G X 1/2..... 168, 181, 182  
 EASY TOUCH INSULIN SAFETY SYR  
 30G X 1/2..... 168, 181, 182  
 EASY TOUCH INSULIN SAFETY SYR  
 30G X 5/16..... 168, 181, 182  
 EASY TOUCH INSULIN SYRINGE 27G  
 X 1/2..... 168, 181, 182  
 EASY TOUCH INSULIN SYRINGE 27G  
 X 5/8..... 168, 181, 182  
 EASY TOUCH INSULIN SYRINGE 28G  
 X 1/2..... 168, 181, 182  
 EASY TOUCH INSULIN SYRINGE 29G  
 X 1/2..... 168, 181, 182  
 EASY TOUCH INSULIN SYRINGE 30G  
 X 1/2..... 168, 181, 182  
 EASY TOUCH INSULIN SYRINGE 30G  
 X 5/16..... 168, 169, 181, 182  
 EASY TOUCH INSULIN SYRINGE 31G  
 X 5/16..... 169, 181, 182

EASY TOUCH PEN NEEDLES 29G X 12MM ..... 169, 181, 182  
EASY TOUCH PEN NEEDLES 30G X 5 MM ..... 169, 181, 182  
EASY TOUCH PEN NEEDLES 30G X 6 MM ..... 169, 181, 182  
EASY TOUCH PEN NEEDLES 30G X 8 MM ..... 169, 181, 182  
EASY TOUCH PEN NEEDLES 31G X 5 MM ..... 169, 181, 182  
EASY TOUCH PEN NEEDLES 31G X 6 MM ..... 169, 181, 182  
EASY TOUCH PEN NEEDLES 31G X 8 MM ..... 169, 181, 182  
EASY TOUCH PEN NEEDLES 32G X 4 MM ..... 169, 181, 182  
EASY TOUCH PEN NEEDLES 32G X 5 MM ..... 169, 181, 182  
EASY TOUCH PEN NEEDLES 32G X 6 MM ..... 169, 181, 182  
EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM..... 169, 181, 182  
EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM..... 169, 181, 182  
EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM..... 169, 181, 182  
EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2..... 169, 181, 182  
EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2..... 169, 181, 182  
EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16..... 169, 181, 182  
EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16..... 169, 181, 182  
ELAHERE ..... 231  
ELIGARD ..... 204  
ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML ..... 106  
eltrombopag olamine oral packet 12.5 mg, 25 mg ..... 108, 109  
eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg ..... 108, 109  
EMBECTA AUTOSHIELD DUO 30G X 5 MM ..... 169, 181, 182

EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64 ..... 169, 181, 182  
EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16 ..... 169, 181, 182  
EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2..... 169, 181, 182  
EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64..... 169, 181, 182  
EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16..... 169, 181, 182  
EMBECTA INSULIN SYRINGE 28G X 1/2 ..... 169, 181, 182  
EMBECTA INSULIN SYRINGE U-100 27G X 5/8..... 169, 181, 182  
EMBECTA INSULIN SYRINGE U-500 ..... 169, 181, 182  
EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM..... 169, 181, 182  
EMBECTA PEN NEEDLE NANO 32G X 4 MM ..... 169, 181, 182  
EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM..... 169, 181, 182  
EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM..... 169, 181, 182  
EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM..... 169, 181, 182  
EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM..... 169, 181, 182  
EMBRACE PEN NEEDLES 29G X 12MM ..... 169, 181, 182  
EMBRACE PEN NEEDLES 30G X 5 MM ..... 169, 181, 182  
EMBRACE PEN NEEDLES 30G X 8 MM ..... 169, 181, 182  
EMBRACE PEN NEEDLES 31G X 5 MM ..... 169, 181, 182  
EMBRACE PEN NEEDLES 31G X 6 MM ..... 170, 181, 182  
EMBRACE PEN NEEDLES 31G X 8 MM ..... 170, 181, 182  
EMBRACE PEN NEEDLES 32G X 4 MM ..... 170, 181, 182  
EMGALITY ..... 139  
EMGALITY (300 MG DOSE) ..... 139  
EMRELIS ..... 344  
ENBREL MINI..... 123, 124

ENBREL SUBCUTANEOUS SOLUTION  
 25 MG/0.5ML..... 123, 124  
 ENBREL SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE ..... 123, 124  
 ENBREL SURECLICK SUBCUTANEOUS  
 SOLUTION AUTO-INJECTOR 123, 124  
 ENSACOVE ORAL CAPSULE 100 MG,  
 25 MG ..... 112  
 EPCLUSA ORAL PACKET 150-37.5 MG,  
 200-50 MG..... 321  
 EPCLUSA ORAL TABLET..... 321  
 EPIDIOLEX..... 63  
 EPKINLY ..... 116  
 EQL ALCOHOL SWABS PAD 70 %... 170,  
 181, 182  
 EQL GAUZE PAD 2 ..... 170, 181, 182  
 EQL INSULIN SYRINGE 30G X 5/16. 170,  
 181, 182  
 ERBITUX ..... 70  
 ERIVEDGE..... 397  
 ERLEADA ORAL TABLET 240 MG, 60  
 MG ..... 28  
 erlotinib hcl oral tablet 100 mg, 150 mg, 25  
 mg ..... 121  
 everolimus oral tablet 10 mg, 2.5 mg, 5 mg,  
 7.5 mg ..... 125  
 everolimus oral tablet soluble ..... 126  
 EXEL COMFORT POINT INSULIN SYR  
 29G X 1/2..... 170, 181, 182  
 EXEL COMFORT POINT INSULIN SYR  
 30G X 5/16..... 170, 181, 182  
 EXEL COMFORT POINT PEN NEEDLE  
 29G X 12MM..... 170, 181, 182  
 EXXUA..... 142  
 EXXUA TITRATION PACK..... 142  
**F**  
 FASENRA ..... 50, 51  
 FASENRA PEN..... 50, 51  
 fentanyl citrate buccal lozenge on a handle  
 ..... 130  
 FIFTY50 PEN NEEDLES 31G X 5 MM  
 ..... 170, 181, 182  
 FIFTY50 PEN NEEDLES 31G X 8 MM  
 ..... 170, 181, 182  
 FIFTY50 PEN NEEDLES 32G X 4 MM  
 ..... 170, 181, 182

FIFTY50 PEN NEEDLES 32G X 6 MM  
 ..... 170, 181, 182  
 fingolimod hcl..... 135  
 FINTEPLA..... 129  
 FOTIVDA..... 355  
 FRUZAQLA ORAL CAPSULE 1 MG, 5  
 MG ..... 137  
 FYARRO ..... 318  
**G**  
 GAUZE PADS PAD 2..... 170, 181, 182  
 GAUZE TYPE VII MEDI-PAK PAD 2 170,  
 181, 182  
 GAVRETO ..... 279  
 gefitinib ..... 141  
 GILOTRIF ..... 20  
 glatiramer acetate subcutaneous solution  
 prefilled syringe 20 mg/ml, 40 mg/ml 145  
 glatopa subcutaneous solution prefilled  
 syringe 20 mg/ml, 40 mg/ml..... 145  
 GLOBAL ALCOHOL PREP EASE..... 170,  
 181, 182  
 GLOBAL EASE INJECT PEN NEEDLES  
 29G X 12MM..... 170, 181, 182  
 GLOBAL EASE INJECT PEN NEEDLES  
 31G X 5 MM..... 170, 181, 182  
 GLOBAL EASE INJECT PEN NEEDLES  
 31G X 8 MM..... 170, 181, 182  
 GLOBAL EASE INJECT PEN NEEDLES  
 32G X 4 MM..... 170, 181, 182  
 GLOBAL EASY GLIDE INSULIN SYR  
 31G X 15/64..... 170, 181, 182  
 GLOBAL INJECT EASE INSULIN SYR  
 30G X 1/2..... 170, 181, 182  
 GLUCOPRO INSULIN SYRINGE 30G X  
 1/2 ..... 170, 181, 182  
 GLUCOPRO INSULIN SYRINGE 30G X  
 5/16 ..... 170, 181, 182  
 GLUCOPRO INSULIN SYRINGE 31G X  
 5/16 ..... 170, 181, 182  
 GNP ALCOHOL SWABS PAD.... 170, 181,  
 182  
 GNP CLICKFINE PEN NEEDLES 31G X 6  
 MM ..... 170, 181, 182  
 GNP CLICKFINE PEN NEEDLES 31G X 8  
 MM ..... 170, 181, 182

GNP INSULIN SYRINGE 28G X 1/2 .. 170, 181, 182  
GNP INSULIN SYRINGE 29G X 1/2 .. 170, 181, 182  
GNP INSULIN SYRINGE 30G X 5/16 170, 181, 182  
GNP INSULIN SYRINGES 29GX1/2.. 170, 181, 182  
GNP INSULIN SYRINGES 30G X 5/16 ..... 170, 181, 182  
GNP INSULIN SYRINGES 30GX5/16 170, 181, 182  
GNP INSULIN SYRINGES 31GX5/16 170, 181, 182  
GNP PEN NEEDLES 31G X 5 MM ..... 170, 181, 182  
GNP PEN NEEDLES 32G X 4 MM ..... 170, 181, 182  
GNP PEN NEEDLES 32G X 6 MM ..... 170, 181, 182  
GNP STERILE GAUZE PAD 2.... 170, 181, 182  
GNP ULTRA COM INSULIN SYRINGE 29G X 1/2..... 170, 181, 182  
GNP ULTRA COM INSULIN SYRINGE 30G X 5/16..... 170, 181, 182  
GOMEKLI ORAL CAPSULE 1 MG, 2 MG ..... 230  
GOMEKLI ORAL TABLET SOLUBLE230  
GOODSENSE ALCOHOL SWABS PAD 70 % ..... 171, 181, 182  
GOODSENSE CLICKFINE PEN NEEDLE 31G X 5 MM..... 171, 181, 182  
GOODSENSE PEN NEEDLE PENFINE 31G X 8 MM..... 171, 181, 182

**H**  
HADLIMA..... 18, 19  
HADLIMA PUSHTOUCH..... 18, 19  
HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT ..... 60  
HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG ..... 197  
HARVONI ORAL TABLET ..... 197  
HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16..... 171, 181, 182

HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16..... 171, 181, 182  
HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM..... 171, 181, 182  
HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM..... 171, 181, 182  
HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM..... 171, 181, 182  
HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM..... 171, 181, 182  
HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM..... 171, 181, 182  
HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM..... 171, 181, 182  
HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM..... 171, 181, 182  
HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM..... 171, 181, 182  
H-E-B INCONTROL ALCOHOL PAD 171, 181, 182  
H-E-B INCONTROL PEN NEEDLES 29G X 12MM..... 171, 181, 182  
H-E-B INCONTROL PEN NEEDLES 31G X 5 MM..... 171, 181, 182  
H-E-B INCONTROL PEN NEEDLES 31G X 6 MM..... 171, 181, 182  
H-E-B INCONTROL PEN NEEDLES 31G X 8 MM..... 171, 181, 182  
H-E-B INCONTROL PEN NEEDLES 32G X 4 MM..... 171, 181, 182  
HERCEPTIN HYLECTA..... 369  
HERNEXEOS..... 406  
HM STERILE ALCOHOL PREP PAD 171, 181, 182  
HM STERILE PADS PAD 2.. 171, 181, 182  
HM ULTICARE INSULIN SYRINGE 30G X 1/2..... 171, 181, 182  
HM ULTICARE INSULIN SYRINGE 31G X 5/16..... 171, 181, 182  
HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM..... 171, 181, 182  
HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT..... 12, 13  
HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20

MG/0.2ML, 40 MG/0.4ML, 40  
 MG/0.8ML ..... 12, 13  
 HUMIRA-CD/UC/HS STARTER  
 SUBCUTANEOUS AUTO-INJECTOR  
 KIT ..... 12, 13  
 HUMIRA-PED<40KG CROHNS  
 STARTER..... 12, 13  
 HUMIRA-PED>=40KG CROHNS START  
 ..... 12, 13  
 HUMIRA-PED>=40KG UC STARTER  
 SUBCUTANEOUS AUTO-INJECTOR  
 KIT ..... 12, 13  
 HUMIRA-PS/UV/ADOL HS STARTER  
 SUBCUTANEOUS AUTO-INJECTOR  
 KIT ..... 12, 13  
 HUMIRA-PSORIASIS/UEVIT STARTER  
 SUBCUTANEOUS AUTO-INJECTOR  
 KIT ..... 12, 13  
 HYRNUO ..... 314  
**I**  
 IBRANCE ..... 259  
 IBTROZI ..... 338  
 icatibant acetate ..... 154  
 ICLUSIG ..... 277  
 IDHIFA ..... 110  
 imatinib mesylate oral tablet 100 mg, 400  
 mg ..... 156  
 IMBRUVICA ORAL CAPSULE 140 MG,  
 70 MG ..... 153  
 IMBRUVICA ORAL SUSPENSION..... 153  
 IMBRUVICA ORAL TABLET ..... 153  
 IMDELLTRA ..... 340  
 IMJUDO ..... 371  
 IMKELDI ..... 157  
 IMPAVIDO ..... 229  
 INCONTROL ULTICARE PEN NEEDLES  
 31G X 6 MM..... 171, 181, 182  
 INCONTROL ULTICARE PEN NEEDLES  
 31G X 8 MM..... 171, 181, 182  
 INCONTROL ULTICARE PEN NEEDLES  
 32G X 4 MM..... 171, 181, 182  
 INCRELEX ..... 221  
 infliximab ..... 161, 162  
 INGREGZA ORAL CAPSULE ..... 389  
 INGREGZA ORAL CAPSULE SPRINKLE  
 ..... 389

INGREGZA ORAL CAPSULE THERAPY  
 PACK ..... 389  
 INLURIYO ..... 159  
 INLYTA ORAL TABLET 1 MG, 5 MG.. 42  
 INQOVI ..... 85  
 INREBIC..... 128  
 INSULIN SYRINGE 29G X 1/2 ... 171, 181,  
 182  
 INSULIN SYRINGE 30G X 5/16 . 171, 181,  
 182  
 INSULIN SYRINGE 31G X 5/16 . 171, 181,  
 182  
 INSULIN SYRINGE/NEEDLE 27G X 1/2  
 ..... 172, 181, 182  
 INSULIN SYRINGE/NEEDLE 28G X 1/2  
 ..... 172, 181, 182  
 INSULIN SYRINGE-NEEDLE U-100 27G  
 X 1/2..... 171, 181, 182  
 INSULIN SYRINGE-NEEDLE U-100 28G  
 X 1/2..... 171, 181, 182  
 INSULIN SYRINGE-NEEDLE U-100 30G  
 X 5/16..... 171, 181, 182  
 INSULIN SYRINGE-NEEDLE U-100 31G  
 X 1/4..... 171, 181, 182  
 INSULIN SYRINGE-NEEDLE U-100 31G  
 X 5/16..... 171, 181, 182  
 INSUPEN PEN NEEDLES 29G X 12MM  
 ..... 172, 181, 182  
 INSUPEN PEN NEEDLES 31G X 5 MM  
 ..... 172, 181, 182  
 INSUPEN PEN NEEDLES 31G X 8 MM  
 ..... 172, 181, 182  
 INSUPEN PEN NEEDLES 32G X 4 MM  
 ..... 172, 181, 182  
 INSUPEN PEN NEEDLES 33G X 4 MM  
 ..... 172, 181, 182  
 INSUPEN SENSITIVE 32G X 6 MM .. 172,  
 181, 182  
 INSUPEN SENSITIVE 32G X 8 MM .. 172,  
 181, 182  
 INSUPEN ULTRAFIN 30G X 8 MM... 172,  
 181, 182  
 INSUPEN ULTRAFIN 31G X 6 MM... 172,  
 181, 182  
 INSUPEN ULTRAFIN 31G X 8 MM... 172,  
 181, 182

INSUPEN32G EXTR3ME 32G X 6 MM  
 ..... 172, 181, 182  
 ITOVEBI ORAL TABLET 3 MG, 9 MG  
 ..... 160  
 IWILFIN ..... 100  
**J**  
 J & J GAUZE PAD 2..... 172, 181, 182  
 JAKAFI..... 306  
 javygtor oral tablet ..... 307  
 JAYPIRCA ORAL TABLET 100 MG, 50  
 MG ..... 275  
 JEMPERLI..... 95  
 JYNARQUE ORAL TABLET ..... 362  
**K**  
 KALYDECO..... 189  
 KENDALL HYDROPHILIC FOAM  
 DRESS PAD 2 ..... 172, 181, 182  
 KENDALL HYDROPHILIC FOAM PLUS  
 PAD 2..... 172, 181, 182  
 KERENDIA ..... 134  
 KESIMPTA..... 249  
 KEYTRUDA INTRAVENOUS  
 SOLUTION..... 266  
 KEYTRUDA QLEX..... 267  
 KIMMTRAK ..... 342  
 KINERET SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE ..... 26, 27  
 KINRAY INSULIN SYRINGE 29G X 1/2  
 ..... 172, 181, 182  
 KISQALI (200 MG DOSE) ..... 289  
 KISQALI (400 MG DOSE) ..... 289  
 KISQALI (600 MG DOSE) ..... 289  
 KISQALI FEMARA (200 MG DOSE) .. 290  
 KISQALI FEMARA (400 MG DOSE) .. 290  
 KISQALI FEMARA (600 MG DOSE) .. 290  
 KMART VALU INSULIN SYRINGE 29G  
 U-100 1 ML ..... 172, 181, 182  
 KMART VALU INSULIN SYRINGE 30G  
 U-100 0.3 ML ..... 172, 181, 182  
 KMART VALU INSULIN SYRINGE 30G  
 U-100 1 ML ..... 172, 181, 182  
 KOMZIFTI ..... 404  
 KOSELUGO ORAL CAPSULE 10 MG, 25  
 MG ..... 313  
 KOSELUGO ORAL CAPSULE  
 SPRINKLE 5 MG, 7.5 MG..... 313

KRAZATI..... 11  
 KROGER INSULIN SYRINGE 30G X 5/16  
 ..... 172, 181, 182  
 KROGER PEN NEEDLES 29G X 12MM  
 ..... 172, 181, 182  
 KROGER PEN NEEDLES 31G X 6 MM  
 ..... 172, 181, 182  
 KYNMOBI ..... 30  
**L**  
 LANREOTIDE ACETATE ..... 193  
 lapatinib ditosylate ..... 194  
 LAZCLUZE ORAL TABLET 240 MG, 80  
 MG ..... 196  
 LEADER INSULIN SYRINGE 28G X 1/2  
 ..... 172, 181, 182  
 LEADER UNIFINE PENTIPS 31G X 5  
 MM ..... 172, 181, 182  
 LEADER UNIFINE PENTIPS 32G X 4  
 MM ..... 172, 181, 182  
 LEADER UNIFINE PENTIPS PLUS 31G  
 X 5 MM..... 172, 181, 182  
 LEADER UNIFINE PENTIPS PLUS 31G  
 X 8 MM..... 172, 181, 182  
 lenalidomide..... 198  
 LENVIMA (10 MG DAILY DOSE) ..... 199  
 LENVIMA (12 MG DAILY DOSE) ..... 199  
 LENVIMA (14 MG DAILY DOSE) ..... 199  
 LENVIMA (18 MG DAILY DOSE) ..... 199  
 LENVIMA (20 MG DAILY DOSE) ..... 199  
 LENVIMA (24 MG DAILY DOSE) ..... 199  
 LENVIMA (4 MG DAILY DOSE) ..... 199  
 LENVIMA (8 MG DAILY DOSE) ..... 199  
 LEUPROLIDE ACETATE (3 MONTH) 202  
 leuprolide acetate injection ..... 201  
 l-glutamine oral packet ..... 208  
 lidocaine external ointment 5 % ..... 209  
 lidocaine external patch 5 %..... 210  
 lidocaine-prilocaine external cream ..... 211  
 lidocan..... 210  
 LITETOUCH INSULIN SYRINGE 28G X  
 1/2 ..... 172, 181, 182  
 LITETOUCH INSULIN SYRINGE 29G X  
 1/2 ..... 172, 181, 182  
 LITETOUCH INSULIN SYRINGE 30G X  
 5/16 ..... 172, 181, 182

|  |                    |   |               |
|--|--------------------|---|---------------|
| LITETOUCH INSULIN SYRINGE 31G X 5/16 .....                   | 172, 181, 182      | MAVENCLAD (7 TABS) .....                      | 71            |
| LITETOUCH PEN NEEDLES 29G X 12.7MM .....                     | 172, 181, 182      | MAVENCLAD (8 TABS) .....                      | 71            |
| LITETOUCH PEN NEEDLES 31G X 5 MM .....                       | 172, 181, 182      | MAVENCLAD (9 TABS) .....                      | 71            |
| LITETOUCH PEN NEEDLES 31G X 6 MM .....                       | 172, 181, 182      | MAXICOMFORT II PEN NEEDLE 31G X 6 MM .....    | 173, 181, 182 |
| LITETOUCH PEN NEEDLES 31G X 8 MM .....                       | 172, 181, 182      | MAXI-COMFORT INSULIN SYRINGE 28G X 1/2.....   | 173, 181, 182 |
| LITETOUCH PEN NEEDLES 32G X 4 MM .....                       | 172, 181, 182      | MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM..... | 173, 181, 182 |
| LIVTENCITY.....  | 219                | MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM..... | 173, 181, 182 |
| LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG.....              | 373                | MAXICOMFORT SYR 27G X 1/2.....                | 173, 181, 182 |
| LOQTORZI.....  | 364                | MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG.....  | 317           |
| LORBRENA ORAL TABLET 100 MG, 25 MG .....                     | 214                | MAYZENT STARTER PACK.....                     | 317           |
| LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG.....             | 331                | MEDIC INSULIN SYRINGE 30G X 5/16 .....        | 173, 181, 182 |
| LUNSUMIO .....   | 233                | MEDICINE SHOPPE PEN NEEDLES 29G X 12MM.....   | 173, 181, 182 |
| LUNSUMIO VELO.....   | 233                | MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM.....   | 173, 181, 182 |
| LUPRON DEPOT (1-MONTH).....                                  | 205, 206           | MEDPURA ALCOHOL PADS 70 % EXTERNAL .....      | 173, 181, 182 |
| LUPRON DEPOT (3-MONTH).....                                  | 205, 206           | MEIJER ALCOHOL SWABS PAD 70 % .....           | 173, 181, 182 |
| LUPRON DEPOT (4-MONTH).....                                  | 205, 206           | MEIJER PEN NEEDLES 29G X 12MM .....           | 173, 181, 182 |
| LUPRON DEPOT (6-MONTH).....                                  | 205, 206           | MEIJER PEN NEEDLES 31G X 6 MM .....           | 173, 181, 182 |
| LUPRON DEPOT-PED (3-MONTH)....                               | 207                | MEIJER PEN NEEDLES 31G X 8 MM .....           | 173, 181, 182 |
| LUPRON DEPOT-PED (6-MONTH)....                               | 207                | MEKINIST ORAL SOLUTION RECONSTITUTED.....     | 366           |
| LUTRATE DEPOT .....  | 202                | MEKINIST ORAL TABLET 0.5 MG, 2 MG .....       | 367           |
| LYNOZYFIC INTRAVENOUS SOLUTION 200 MG/10ML, 5 MG/2.5ML ..... | 212                | MEKTOVI .....                                 | 55            |
| LYNPARZA ORAL TABLET .....                                   | 250                | metyrosine.....                               | 226           |
| LYTGObI (12 MG DAILY DOSE).....                              | 138                | MICRODOT PEN NEEDLE 31G X 6 MM .....          | 173, 181, 182 |
| LYTGObI (16 MG DAILY DOSE).....                              | 138                | MICRODOT PEN NEEDLE 32G X 4 MM .....          | 173, 181, 182 |
| LYTGObI (20 MG DAILY DOSE).....                              | 138                | MICRODOT PEN NEEDLE 33G X 4 MM .....          | 173, 181, 182 |
| <b>M</b>   |                    | mifepristone oral tablet 300 mg .....         | 228           |
| MAGELLAN INSULIN SAFETY SYR 29G X 1/2.....                   | 172, 181, 182      | MIPLYFFA.....                                 | 33            |
| MAGELLAN INSULIN SAFETY SYR 30G X 5/16.....                  | 172, 173, 181, 182 |   |               |
| MARGENZA.....  | 218                |   |               |
| MAVENCLAD (10 TABS) .....                                    | 71                 |   |               |
| MAVENCLAD (4 TABS) .....                                     | 71                 |   |               |
| MAVENCLAD (5 TABS) .....                                     | 71                 |   |               |
| MAVENCLAD (6 TABS) .....                                     | 71                 |   |               |

MIRASORB SPONGES 2..... 173, 181, 182  
MM PEN NEEDLES 31G X 6 MM ..... 173,  
181, 182  
MM PEN NEEDLES 32G X 4 MM ..... 173,  
181, 182  
modafinil oral tablet 100 mg, 200 mg..... 234  
MODEYSO..... 94  
MONOJECT INSULIN SYRINGE 25G X  
5/8 ..... 173, 181, 182  
MONOJECT INSULIN SYRINGE 27G X  
1/2 ..... 173, 181, 182  
MONOJECT INSULIN SYRINGE 28G X  
1/2 ..... 173, 181, 182  
MONOJECT INSULIN SYRINGE 29G X  
1/2 ..... 173, 181, 182  
MONOJECT INSULIN SYRINGE 30G X  
5/16 ..... 173, 181, 182  
MONOJECT INSULIN SYRINGE 31G X  
5/16 ..... 173, 181, 182  
MONOJECT INSULIN SYRINGE U-100 1  
ML..... 173, 181, 182  
MONOJECT ULTRA COMFORT  
SYRINGE 28G X 1/2 ..... 173, 181, 182  
MONOJECT ULTRA COMFORT  
SYRINGE 29G X 1/2 ..... 173, 181, 182  
MONOJECT ULTRA COMFORT  
SYRINGE 30G X 5/16 ..... 173, 181, 182  
morphine sulfate (concentrate) oral solution  
100 mg/5ml..... 152  
MOUNJARO SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR ..... 148  
MS INSULIN SYRINGE 31G X 5/16... 173,  
181, 182  
**N**  
NERLYNX ..... 236  
NIKTIMVO ..... 41  
nilotinib hcl oral capsule 150 mg, 200 mg,  
50 mg ..... 237  
NINLARO..... 191  
nitisinone..... 244  
NIVESTYM..... 133  
NORDITROPIN FLEXPRO  
SUBCUTANEOUS SOLUTION PEN-  
INJECTOR..... 324, 325  
NOVOFINE AUTOCOVER 30G X 8 MM  
..... 173, 181, 182

NOVOFINE PEN NEEDLE 32G X 6 MM  
..... 173, 181, 182  
NOVOFINE PLUS PEN NEEDLE 32G X 4  
MM ..... 173, 181, 182  
NOVOTWIST PEN NEEDLE 32G X 5 MM  
..... 174, 181, 182  
NUBEQA..... 82  
NUCALA SUBCUTANEOUS SOLUTION  
AUTO-INJECTOR ..... 223, 224, 225  
NUCALA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE 100 MG/ML, 40  
MG/0.4ML ..... 223, 224, 225  
NUCALA SUBCUTANEOUS SOLUTION  
RECONSTITUTED ..... 223, 224, 225  
NUPLAZID ORAL CAPSULE ..... 272  
NUPLAZID ORAL TABLET 10 MG.... 272  
NURTEC..... 294, 295  
NYVEPRIA ..... 262  
**O**  
ODOMZO ..... 327  
OFEV ..... 239, 240  
OGIVRI..... 368  
OGSIVEO ORAL TABLET 100 MG, 150  
MG, 50 MG..... 243  
OJEMDA ORAL SUSPENSION  
RECONSTITUTED ..... 365  
OJEMDA ORAL TABLET ..... 365  
OJJAARA ..... 232  
ONAPGO ..... 29  
ONUREG ..... 43  
OPDIVO ..... 245  
OPDIVO QVANTIG ..... 246  
OPDUALAG..... 247  
OPSUMIT ..... 217  
ORENCIA CLICKJECT..... 4, 5  
ORENCIA INTRAVENOUS ..... 2, 3  
ORENCIA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE ..... 4, 5  
ORFADIN ORAL SUSPENSION..... 244  
ORGOVYX..... 284  
ORILISSA ORAL TABLET 150 MG, 200  
MG ..... 102, 103  
ORKAMBI ORAL TABLET ..... 216  
ORSERDU ORAL TABLET 345 MG, 86  
MG ..... 101  
OSENVELT ..... 88

OTEZLA ..... 31, 32  
 OTEZLA XR ..... 31, 32  
 OTEZLA/OTEZLA XR INITIATION PK  
 ..... 31, 32  
 oxandrolone oral ..... 257  
 OZEMPIC (0.25 OR 0.5 MG/DOSE)..... 147  
 OZEMPIC (1 MG/DOSE)  
 SUBCUTANEOUS SOLUTION PEN-  
 INJECTOR 4 MG/3ML ..... 147  
 OZEMPIC (2 MG/DOSE) ..... 147  
**P**  
 pazopanib hcl oral tablet 200 mg, 400 mg  
 ..... 261  
 PC UNIFINE PENTIPS 31G X 5 MM.. 174,  
 181, 182  
 PC UNIFINE PENTIPS 31G X 6 MM.. 174,  
 181, 182  
 PC UNIFINE PENTIPS 31G X 8 MM.. 174,  
 181, 182  
 PEGASYS SUBCUTANEOUS SOLUTION  
 180 MCG/ML ..... 264  
 PEGASYS SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE ..... 264  
 PEMAZYRE ..... 268  
 PEN NEEDLE/5-BEVEL TIP 31G X 8 MM  
 ..... 174, 181, 182  
 PEN NEEDLE/5-BEVEL TIP 32G X 4 MM  
 ..... 174, 181, 182  
 PEN NEEDLES 30G X 5 MM (OTC)... 174,  
 181, 182  
 PEN NEEDLES 30G X 8 MM 174, 181, 182  
 PEN NEEDLES 32G X 5 MM 174, 181, 182  
 penicillamine oral tablet..... 269, 270  
 PENTIPS 29G X 12MM (RX) 174, 181, 182  
 PENTIPS 31G X 5 MM (RX). 174, 181, 182  
 PENTIPS 31G X 8 MM (RX). 174, 181, 182  
 PENTIPS 32G X 4 MM (RX). 174, 181, 182  
 PENTIPS GENERIC PEN NEEDLES 29G  
 X 12MM..... 174, 181, 182  
 PENTIPS GENERIC PEN NEEDLES 31G  
 X 6 MM..... 174, 181, 182  
 PENTIPS GENERIC PEN NEEDLES 32G  
 X 6 MM..... 174, 181, 182  
 PHARMACIST CHOICE ALCOHOL PAD  
 ..... 174, 181, 182

PIP PEN NEEDLES 31G X 5MM 31G X 5  
 MM ..... 174, 181, 182  
 PIP PEN NEEDLES 32G X 4MM 32G X 4  
 MM ..... 174, 181, 182  
 PIQRAY (200 MG DAILY DOSE)..... 22  
 PIQRAY (250 MG DAILY DOSE)..... 22  
 PIQRAY (300 MG DAILY DOSE)..... 22  
 pirfenidone oral capsule..... 273, 274  
 pirfenidone oral tablet 267 mg, 534 mg, 801  
 mg ..... 273, 274  
 PLEGRIDY STARTER PACK  
 SUBCUTANEOUS SOLUTION AUTO-  
 INJECTOR..... 185  
 PLEGRIDY STARTER PACK  
 SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE ..... 185  
 PLEGRIDY SUBCUTANEOUS  
 SOLUTION AUTO-INJECTOR ..... 185  
 PLEGRIDY SUBCUTANEOUS  
 SOLUTION PREFILLED SYRINGE 185  
 pomalidomide ..... 276  
 POMALYST ..... 276  
 posaconazole oral tablet delayed release 278  
 PRECISION SURE-DOSE SYRINGE 30G  
 X 5/16..... 174, 181, 182  
 PREFERRED PLUS INSULIN SYRINGE  
 28G X 1/2..... 174, 181, 182  
 PREFERRED PLUS INSULIN SYRINGE  
 29G X 1/2..... 174, 181, 182  
 PREFERRED PLUS INSULIN SYRINGE  
 30G X 5/16..... 174, 181, 182  
 PREFERRED PLUS UNIFINE PENTIPS  
 29G X 12MM..... 174, 181, 182  
 PREVENT DROPSAFE PEN NEEDLES  
 31G X 6 MM..... 174, 181, 182  
 PREVENT DROPSAFE PEN NEEDLES  
 31G X 8 MM..... 174, 181, 182  
 PREVENT SAFETY PEN NEEDLES 31G  
 X 6 MM..... 174, 181, 182  
 PREVENT SAFETY PEN NEEDLES 31G  
 X 8 MM..... 174, 181, 182  
 PREVYMIS ORAL TABLET ..... 200  
 PRO COMFORT ALCOHOL PAD 70 %  
 ..... 174, 181, 182  
 PRO COMFORT INSULIN SYRINGE 30G  
 X 1/2..... 174, 181, 182

PRO COMFORT INSULIN SYRINGE 30G X 5/16..... 174, 181, 182  
 PRO COMFORT INSULIN SYRINGE 31G X 5/16..... 174, 181, 182  
 PRO COMFORT PEN NEEDLES 32G X 4 MM ..... 174, 181, 182  
 PRO COMFORT PEN NEEDLES 32G X 5 MM ..... 174, 181, 182  
 PRO COMFORT PEN NEEDLES 32G X 6 MM ..... 174, 181, 182  
 PRO COMFORT PEN NEEDLES 32G X 8 MM ..... 174, 181, 182  
 PRODIGY INSULIN SYRINGE 28G X 1/2 ..... 174, 181, 182  
 PRODIGY INSULIN SYRINGE 31G X 5/16 ..... 174, 181, 182  
 PURE COMFORT ALCOHOL PREP PAD ..... 174, 181, 182  
 PURE COMFORT PEN NEEDLE 32G X 4 MM ..... 174, 181, 182  
 PURE COMFORT PEN NEEDLE 32G X 5 MM ..... 174, 181, 182  
 PURE COMFORT PEN NEEDLE 32G X 6 MM ..... 174, 181, 182  
 PURE COMFORT PEN NEEDLE 32G X 8 MM ..... 174, 181, 182  
 PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM..... 174, 181, 182  
 PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM..... 174, 181, 182  
 PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM..... 175, 181, 182  
 PX SHORTLENGTH PEN NEEDLES 31G X 8 MM..... 175, 181, 182  
 pyrimethamine oral ..... 280  
**Q**  
 QC ALCOHOL..... 175, 181, 182  
 QC ALCOHOL SWABS PAD 70 %..... 175, 181, 182  
 QC BORDER ISLAND GAUZE PAD 2 ..... 175, 181, 182  
 QINLOCK..... 298  
 QUICK TOUCH INSULIN PEN NEEDLE 29G X 12.7MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM..... 175, 181, 182

QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 31G X 6 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 31G X 8 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM..... 175, 181, 182  
 QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM..... 175, 181, 182  
 quinine sulfate oral..... 281  
 QULIPTA ..... 37  
**R**  
 RA ALCOHOL SWABS PAD 70 %..... 175, 181, 182  
 RA INSULIN SYRINGE 29G X 1/2..... 175, 181, 182  
 RA INSULIN SYRINGE 30G X 5/16... 175, 181, 182  
 ra isopropyl alcohol wipes ..... 175, 181, 182  
 RA PEN NEEDLES 31G X 5 MM 175, 181, 182  
 RA PEN NEEDLES 31G X 8 MM 175, 181, 182  
 RA STERILE PAD 2 ..... 175, 181, 182  
 RALDESY ..... 370  
 RAYA SURE PEN NEEDLE 29G X 12MM ..... 175, 181, 182  
 RAYA SURE PEN NEEDLE 31G X 4 MM ..... 175, 181, 182  
 RAYA SURE PEN NEEDLE 31G X 5 MM ..... 175, 181, 182  
 RAYA SURE PEN NEEDLE 31G X 6 MM ..... 175, 181, 182

|  |               |  |                    |
|--|---------------|--|--------------------|
| REALITY INSULIN SYRINGE 28G X 1/2<br>.....     | 175, 181, 182 | RYBELSUS .....                                   | 147                |
| REALITY INSULIN SYRINGE 29G X 1/2<br>.....     | 175, 181, 182 | RYBELSUS (FORMULATION R2).....                   | 147                |
| REALITY SWABS PAD.....                         | 175, 181, 182 | RYBREVANT .....                                  | 25                 |
| RELION ALCOHOL SWABS PAD .....                 | 175,          | RYBREVANT FASPRO .....                           | 24                 |
| 181, 182                                       |               | RYDAPT.....                                      | 227                |
| RELION ALCOHOL SWABS PAD 70 %<br>.....         | 175, 181, 182 | RYTELO.....                                      | 158                |
| RELI-ON INSULIN SYRINGE 29G 0.3<br>ML.....     | 175, 181, 182 | <b>S</b>   |                    |
| RELION INSULIN SYRINGE 31G X 15/64<br>.....    | 175, 181, 182 | SAFETY INSULIN SYRINGES 29G X 1/2<br>.....       | 175, 181, 182      |
| RELION MINI PEN NEEDLES 31G X 6<br>MM .....    | 175, 181, 182 | SAFETY INSULIN SYRINGES 30G X 1/2<br>.....       | 175, 181, 182      |
| RELION PEN NEEDLES 29G X 12MM<br>.....         | 175, 181, 182 | SAFETY INSULIN SYRINGES 30G X<br>5/16 .....      | 175, 181, 182      |
| RELION PEN NEEDLES 31G X 6 MM                  | 175, 182      | SAFETY PEN NEEDLES 30G X 5 MM<br>.....           | 175, 181, 182      |
| 175, 182                                       |               | SAFETY PEN NEEDLES 30G X 8 MM<br>.....           | 176, 181, 182      |
| RELION PEN NEEDLES 31G X 8 MM                  | 175, 182      | sapropterin dihydrochloride oral tablet... 307   |                    |
| 175, 182                                       |               | SB ALCOHOL PREP PAD 70 %..                       | 176, 181, 182      |
| RESTORE CONTACT LAYER PAD 2                    | 175, 181, 182 | SB INSULIN SYRINGE 29G X 1/2 .....               | 176, 181, 182      |
| RETACRIT INJECTION SOLUTION                    |               | SB INSULIN SYRINGE 30G X 5/16 ...                | 176, 181, 182      |
| 10000 UNIT/ML, 10000                           |               | SB INSULIN SYRINGE 31G X 5/16 ...                | 176, 181, 182      |
| UNIT/ML(1ML), 2000 UNIT/ML, 20000              |               | SCSEMBLIX ORAL TABLET 100 MG, 20                 |                    |
| UNIT/ML, 3000 UNIT/ML, 4000                    |               | MG, 40 MG.....                                   | 34                 |
| UNIT/ML, 40000 UNIT/ML .....                   | 117, 118      | SECURESAFE INSULIN SYRINGE 29G<br>X 1/2.....     | 176, 181, 182      |
| RETEVMO ORAL CAPSULE 40 MG, 80                 |               | SECURESAFE SAFETY PEN NEEDLES<br>30G X 8 MM..... | 176, 181, 182      |
| MG .....                                       | 312           | SELARSDI .....                                   | 381, 382, 383, 384 |
| RETEVMO ORAL TABLET 120 MG, 160                |               | SEROSTIM SUBCUTANEOUS                            |                    |
| MG, 40 MG, 80 MG .....                         | 312           | SOLUTION RECONSTITUTED 4 MG,<br>5 MG, 6 MG.....  | 326                |
| REVCovi.....                                   | 104           | SIGNIFOR .....                                   | 260                |
| REVUFORJ ORAL TABLET 110 MG, 160               |               | sildenafil citrate oral tablet 20 mg ..          | 315, 316           |
| MG, 25 MG.....                                 | 288           | SIRTURO .....                                    | 45                 |
| REZDIFFRA.....                                 | 286           | SKYRIZI.....                                     | 299, 300           |
| REZLIDHIA .....                                | 251           | SKYRIZI PEN .....                                | 299, 300           |
| REZUROCK.....                                  | 47            | SM ALCOHOL PREP PAD ...                          | 176, 181, 182      |
| RINVOQ.....                                    | 377, 378      | SM ALCOHOL PREP PAD 6-70 %<br>EXTERNAL .....     | 176, 181, 182      |
| RINVOQ LQ.....                                 | 377, 378      | SM ALCOHOL PREP PAD 70 %.                        | 176, 181, 182      |
| RITUXAN HYCELA .....                           | 301           |  |                    |
| ROMVIMZA .....                                 | 396           |  |                    |
| ROZLYTREK ORAL CAPSULE 100 MG,<br>200 MG ..... | 113           |  |                    |
| ROZLYTREK ORAL PACKET .....                    | 114           |  |                    |
| RUBRACA .....                                  | 305           |  |                    |

|   |               |
|---|---------------|
| SM GAUZE PAD 2 .....                      | 176, 181, 182 |
| sodium oxybate .....                      | 319, 320      |
| SOMATULINE DEPOT                          |               |
| SUBCUTANEOUS SOLUTION 60                  |               |
| MG/0.2ML, 90 MG/0.3ML .....               | 193           |
| SOMAVERT.....                             | 265           |
| sorafenib tosylate .....                  | 328           |
| SPRAVATO (56 MG DOSE).....                | 122           |
| SPRAVATO (84 MG DOSE).....                | 122           |
| STERILE GAUZE PAD 2 .....                 | 176, 181, 182 |
| STIVARGA .....                            | 283           |
| STRENSIQ .....                            | 35, 36        |
| SUBVENITE ORAL SUSPENSION .....           | 192           |
| sunitinib malate.....                     | 333           |
| SURE COMFORT ALCOHOL PREP PAD             |               |
| 70 % .....                                | 176, 181, 182 |
| SURE COMFORT INSULIN SYRINGE              |               |
| 28G X 1/2.....                            | 176, 181, 182 |
| SURE COMFORT INSULIN SYRINGE              |               |
| 29G X 1/2.....                            | 176, 181, 182 |
| SURE COMFORT INSULIN SYRINGE              |               |
| 30G X 1/2.....                            | 176, 181, 182 |
| SURE COMFORT INSULIN SYRINGE              |               |
| 30G X 5/16.....                           | 176, 181, 182 |
| SURE COMFORT INSULIN SYRINGE              |               |
| 31G X 1/4.....                            | 176, 181, 182 |
| SURE COMFORT INSULIN SYRINGE              |               |
| 31G X 5/16.....                           | 176, 181, 182 |
| SURE COMFORT PEN NEEDLES 29G X            |               |
| 12.7MM .....                              | 176, 181, 182 |
| SURE COMFORT PEN NEEDLES 30G X            |               |
| 8 MM .....                                | 176, 181, 182 |
| SURE COMFORT PEN NEEDLES 31G X            |               |
| 5 MM .....                                | 176, 181, 182 |
| SURE COMFORT PEN NEEDLES 31G X            |               |
| 6 MM .....                                | 176, 181, 182 |
| SURE COMFORT PEN NEEDLES 31G X            |               |
| 8 MM .....                                | 176, 181, 182 |
| SURE COMFORT PEN NEEDLES 32G X            |               |
| 4 MM (OTC).....                           | 176, 181, 182 |
| SURE COMFORT PEN NEEDLES 32G X            |               |
| 4 MM (RX).....                            | 176, 181, 182 |
| SURE COMFORT PEN NEEDLES 32G X            |               |
| 6 MM .....                                | 176, 181, 182 |
| SURGICAL GAUZE SPONGE PAD 2               | 176, 181, 182 |
| SYMPAZAN.....                             | 72            |
| SYNRIBO .....                             | 252           |
| <b>T</b>                                  |               |
| TABRECTA .....                            | 65            |
| tadalafil oral tablet 2.5 mg, 5 mg .....  | 335           |
| TAFINLAR ORAL CAPSULE .....               | 78            |
| TAFINLAR ORAL TABLET SOLUBLE              | 79            |
| TAGRISSE .....                            | 256           |
| TALVEY.....                               | 339           |
| TALZENNA .....                            | 337           |
| TASIGNA ORAL CAPSULE 150 MG, 200          |               |
| MG, 50 MG.....                            | 237           |
| TAVNEOS.....                              | 38            |
| TAZVERIK.....                             | 341           |
| TECHLITE INSULIN SYRINGE 29G X            |               |
| 1/2 .....                                 | 176, 181, 182 |
| TECVAYLI.....                             | 343           |
| TEPMETKO .....                            | 346           |
| teriparatide subcutaneous solution pen-   |               |
| injector 560 mcg/2.24ml .....             | 347           |
| testosterone cypionate intramuscular      |               |
| solution 100 mg/ml, 200 mg/ml, 200        |               |
| mg/ml (1 ml) .....                        | 349           |
| testosterone enanthate intramuscular      |               |
| solution.....                             | 350           |
| testosterone gel 1.62 % transdermal ..... | 348           |
| testosterone transdermal gel 12.5 mg/act  |               |
| (1%), 20.25 mg/act (1.62%), 25            |               |
| mg/2.5gm (1%), 50 mg/5gm (1%).....        | 348           |
| tetrabenazine .....                       | 351           |
| TEVIMBRA.....                             | 353           |
| THALOMID ORAL CAPSULE 100 MG,             |               |
| 150 MG, 200 MG, 50 MG .....               | 352           |
| THERAGAUZE PAD 2.....                     | 176, 181, 182 |
| TIBSOVO .....                             | 190           |
| TIVDAK .....                              | 354           |
| TODAYS HEALTH PEN NEEDLES 29G             |               |
| X 12MM.....                               | 176, 181, 182 |
| TODAYS HEALTH SHORT PEN                   |               |
| NEEDLE 31G X 8 MM .....                   | 176, 181, 182 |
| tolvaptan oral tablet therapy pack .....  | 362           |
| TOPCARE CLICKFINE PEN NEEDLES             |               |
| 31G X 6 MM.....                           | 176, 181, 182 |
| TOPCARE CLICKFINE PEN NEEDLES             |               |
| 31G X 8 MM.....                           | 176, 181, 182 |

|  |               |   |                    |
|--|---------------|---|--------------------|
| TOPCARE ULTRA COMFORT INS SYR<br>29G X 1/2.....                        | 177, 181, 182 | TRUE COMFORT PRO INSULIN SYR<br>30G X 5/16.....   | 177, 181, 182      |
| TOPCARE ULTRA COMFORT INS SYR<br>30G X 5/16.....                       | 177, 181, 182 | TRUE COMFORT PRO INSULIN SYR<br>31G X 5/16.....   | 177, 181, 182      |
| TOPCARE ULTRA COMFORT INS SYR<br>31G X 5/16.....                       | 177, 181, 182 | TRUE COMFORT PRO INSULIN SYR<br>32G X 5/16.....   | 177, 181, 182      |
| torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5<br>mg .....               | 125           | TRUE COMFORT PRO PEN NEEDLES<br>31G X 5 MM.....   | 177, 181, 182      |
| TRELSTAR MIXJECT .....   | 374           | TRUE COMFORT PRO PEN NEEDLES<br>31G X 6 MM.....   | 177, 181, 182      |
| TREMFYA INTRAVENOUS .....  | 150, 151      | TRUE COMFORT PRO PEN NEEDLES<br>31G X 8 MM.....   | 177, 181, 182      |
| TREMFYA ONE-PRESS<br>SUBCUTANEOUS SOLUTION PEN-<br>INJECTOR.....       | 150, 151      | TRUE COMFORT PRO PEN NEEDLES<br>32G X 4 MM.....   | 177, 181, 182      |
| TREMFYA PEN SUBCUTANEOUS<br>SOLUTION AUTO-INJECTOR 200<br>MG/2ML ..... | 150, 151      | TRUE COMFORT PRO PEN NEEDLES<br>32G X 5 MM.....   | 177, 181, 182      |
| TREMFYA SUBCUTANEOUS<br>SOLUTION PREFILLED SYRINGE                     | 150,<br>151   | TRUE COMFORT PRO PEN NEEDLES<br>32G X 6 MM.....   | 177, 181, 182      |
| TREMFYA-CD/UC INDUCTION.   | 150, 151      | TRUE COMFORT PRO PEN NEEDLES<br>33G X 4 MM.....   | 177, 181, 182      |
| tretinoin external cream .....   | 363           | TRUE COMFORT PRO PEN NEEDLES<br>33G X 5 MM.....   | 177, 181, 182      |
| tridacaine ii.....   | 210           | TRUE COMFORT PRO PEN NEEDLES<br>33G X 6 MM.....   | 177, 181, 182      |
| trientine hcl oral capsule 250 mg.....                                 | 372           | TRUEPLUS 5-BEVEL PEN NEEDLES<br>29G X 12.7MM..... | 177, 181, 182      |
| TRIKAFTA ORAL TABLET THERAPY<br>PACK.....                              | 105           | TRUEPLUS 5-BEVEL PEN NEEDLES<br>31G X 5 MM.....   | 177, 181, 182      |
| TRIKAFTA ORAL THERAPY PACK..   | 105           | TRUEPLUS 5-BEVEL PEN NEEDLES<br>31G X 6 MM.....   | 177, 181, 182      |
| TRUE COMFORT ALCOHOL PREP<br>PADS PAD 70 %.....                        | 177, 181, 182 | TRUEPLUS 5-BEVEL PEN NEEDLES<br>31G X 8 MM.....   | 177, 181, 182      |
| TRUE COMFORT INSULIN SYRINGE<br>30G X 1/2.....                         | 177, 181, 182 | TRUEPLUS 5-BEVEL PEN NEEDLES<br>32G X 4 MM.....   | 177, 181, 182      |
| TRUE COMFORT INSULIN SYRINGE<br>30G X 5/16.....                        | 177, 181, 182 | TRUEPLUS INSULIN SYRINGE 28G X<br>1/2 .....       | 177, 178, 181, 182 |
| TRUE COMFORT INSULIN SYRINGE<br>31G X 5/16.....                        | 177, 181, 182 | TRUEPLUS INSULIN SYRINGE 29G X<br>1/2 .....       | 178, 181, 182      |
| TRUE COMFORT INSULIN SYRINGE<br>32G X 5/16.....                        | 177, 181, 182 | TRUEPLUS INSULIN SYRINGE 30G X<br>5/16 .....      | 178, 181, 182      |
| TRUE COMFORT PEN NEEDLES 31G X<br>5 MM .....                           | 177, 181, 182 | TRUEPLUS INSULIN SYRINGE 31G X<br>5/16 .....      | 178, 181, 182      |
| TRUE COMFORT PEN NEEDLES 31G X<br>6 MM .....                           | 177, 181, 182 | TRUEPLUS PEN NEEDLES 29G X 12MM<br>.....          | 178, 181, 182      |
| TRUE COMFORT PEN NEEDLES 32G X<br>4 MM .....                           | 177, 181, 182 | TRUEPLUS PEN NEEDLES 31G X 5 MM<br>.....          | 178, 181, 182      |
| TRUE COMFORT PRO ALCOHOL PREP<br>PAD 70 %.....                         | 177, 181, 182 |   |                    |
| TRUE COMFORT PRO INSULIN SYR<br>30G X 1/2.....                         | 177, 181, 182 |   |                    |

|   |                    |   |               |
|---|--------------------|---|---------------|
| TRUEPLUS PEN NEEDLES 31G X 6 MM               | 178, 181, 182      | ULTICARE PEN NEEDLES 31G X 5 MM             | 178, 181, 182 |
| TRUEPLUS PEN NEEDLES 31G X 8 MM               | 178, 181, 182      | ULTICARE SHORT PEN NEEDLES 30G X 8 MM       | 179, 181, 182 |
| TRUEPLUS PEN NEEDLES 32G X 4 MM               | 178, 181, 182      | ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC) | 179, 181, 182 |
| TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR | 146                | ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX)  | 179, 181, 182 |
| TRUQAP ORAL TABLET 200 MG                     | 64                 | ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM  | 179, 181, 182 |
| TRUQAP ORAL TABLET THERAPY PACK 160 MG        | 64                 | ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM    | 179, 181, 182 |
| TRUXIMA                                       | 302, 303           | ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM    | 179, 181, 182 |
| TUKYSA ORAL TABLET 150 MG, 50 MG              | 375                | ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM    | 179, 181, 182 |
| TURALIO                                       | 271                | ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM    | 179, 181, 182 |
| TYENNE  | 356, 357, 358, 359 | ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM    | 179, 181, 182 |
| TYMLOS  | 1                  | ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2     | 179, 181, 182 |
| <b>U</b>                                      |                    | ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16    | 179, 181, 182 |
| UBRELVY                                       | 376                | ULTILET ALCOHOL SWABS PAD ...               | 179, 181, 182 |
| UDENYCA ONBODY                                | 263                | ULTILET PEN NEEDLE 29G X 12.7MM             | 179, 181, 182 |
| ULTICARE INSULIN SAFETY SYR 29G X 1/2         | 178, 181, 182      | ULTILET PEN NEEDLE 31G X 5 MM               | 179, 181, 182 |
| ULTICARE INSULIN SYRINGE 28G X 1/2            | 178, 181, 182      | ULTILET PEN NEEDLE 31G X 8 MM               | 179, 181, 182 |
| ULTICARE INSULIN SYRINGE 29G X 1/2            | 178, 181, 182      | ULTILET PEN NEEDLE 32G X 4 MM               | 179, 181, 182 |
| ULTICARE INSULIN SYRINGE 30G X 1/2            | 178, 181, 182      | ULTRA COMFORT INSULIN SYRINGE 30G X 5/16    | 179, 181, 182 |
| ULTICARE INSULIN SYRINGE 30G X 5/16           | 178, 181, 182      | ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM    | 179, 181, 182 |
| ULTICARE INSULIN SYRINGE 31G X 1/4            | 178, 181, 182      | ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM    | 179, 181, 182 |
| ULTICARE INSULIN SYRINGE 31G X 5/16           | 178, 181, 182      | ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM    | 179, 181, 182 |
| ULTICARE MICRO PEN NEEDLES 32G X 4 MM         | 178, 181, 182      | ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM    | 179, 181, 182 |
| ULTICARE MINI PEN NEEDLES 30G X 5 MM          | 178, 181, 182      | ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2    | 179, 181, 182 |
| ULTICARE MINI PEN NEEDLES 31G X 6 MM          | 178, 181, 182      |   |               |
| ULTICARE MINI PEN NEEDLES 32G X 6 MM          | 178, 181, 182      |   |               |
| ULTICARE PEN NEEDLES 29G X 12.7MM (OTC)       | 178, 181, 182      |   |               |
| ULTICARE PEN NEEDLES 29G X 12.7MM (RX)        | 178, 181, 182      |   |               |

|   |                    |   |                  |
|---|--------------------|---|------------------|
| ULTRA FLO INSULIN SYR 1/2 UNIT<br>30G X 5/16..... | 179, 181, 182      | ULTRA-THIN II PEN NEEDLES 29G X<br>12.7MM .....   | 180, 181, 182    |
| ULTRA FLO INSULIN SYR 1/2 UNIT<br>31G X 5/16..... | 179, 181, 182      | UNIFINE OTC PEN NEEDLES 31G X 5<br>MM .....       | 180, 181, 182    |
| ULTRA FLO INSULIN SYRINGE 29G X<br>1/2 .....      | 179, 181, 182      | UNIFINE OTC PEN NEEDLES 32G X 4<br>MM .....       | 180, 181, 182    |
| ULTRA FLO INSULIN SYRINGE 30G X<br>1/2 .....      | 179, 181, 182      | UNIFINE PEN NEEDLES 32G X 4 MM<br>.....           | 180, 181, 182    |
| ULTRA FLO INSULIN SYRINGE 30G X<br>5/16 .....     | 179, 181, 182      | UNIFINE PENTIPS 29G X 12MM                        | 180, 181,<br>182 |
| ULTRA FLO INSULIN SYRINGE 31G X<br>5/16 .....     | 179, 181, 182      | UNIFINE PENTIPS 31G X 6 MM                        | 180, 181,<br>182 |
| ULTRA THIN PEN NEEDLES 32G X 4<br>MM .....        | 179, 181, 182      | UNIFINE PENTIPS 31G X 8 MM                        | 180, 181,<br>182 |
| ULTRACARE INSULIN SYRINGE 30G X<br>1/2 .....      | 180, 181, 182      | UNIFINE PENTIPS 32G X 4 MM                        | 180, 181,<br>182 |
| ULTRACARE INSULIN SYRINGE 30G X<br>5/16 .....     | 180, 181, 182      | UNIFINE PENTIPS PLUS 29G X 12MM<br>.....          | 180, 181, 182    |
| ULTRACARE INSULIN SYRINGE 31G X<br>5/16 .....     | 180, 181, 182      | UNIFINE PENTIPS PLUS 31G X 6 MM<br>.....          | 180, 181, 182    |
| ULTRACARE PEN NEEDLES 31G X 5<br>MM .....         | 180, 181, 182      | UNIFINE PENTIPS PLUS 32G X 4 MM<br>.....          | 180, 181, 182    |
| ULTRACARE PEN NEEDLES 31G X 6<br>MM .....         | 180, 181, 182      | UNIFINE PROTECT PEN NEEDLE 30G X<br>5 MM .....    | 180, 181, 182    |
| ULTRACARE PEN NEEDLES 31G X 8<br>MM .....         | 180, 181, 182      | UNIFINE PROTECT PEN NEEDLE 30G X<br>8 MM .....    | 180, 181, 182    |
| ULTRACARE PEN NEEDLES 32G X 4<br>MM .....         | 180, 181, 182      | UNIFINE PROTECT PEN NEEDLE 32G X<br>4 MM .....    | 180, 181, 182    |
| ULTRACARE PEN NEEDLES 32G X 5<br>MM .....         | 180, 181, 182      | UNIFINE SAFECONTROL PEN NEEDLE<br>30G X 5 MM..... | 180, 181, 182    |
| ULTRACARE PEN NEEDLES 32G X 6<br>MM .....         | 180, 181, 182      | UNIFINE SAFECONTROL PEN NEEDLE<br>30G X 8 MM..... | 180, 181, 182    |
| ULTRACARE PEN NEEDLES 33G X 4<br>MM .....         | 180, 181, 182      | UNIFINE SAFECONTROL PEN NEEDLE<br>31G X 5 MM..... | 180, 181, 182    |
| ULTRA-COMFORT INSULIN SYRINGE<br>29G X 1/2.....   | 179, 181, 182      | UNIFINE SAFECONTROL PEN NEEDLE<br>31G X 6 MM..... | 180, 181, 182    |
| ULTRA-THIN II INS SYR SHORT 30G X<br>5/16 .....   | 179, 181, 182      | UNIFINE SAFECONTROL PEN NEEDLE<br>31G X 8 MM..... | 180, 181, 182    |
| ULTRA-THIN II INS SYR SHORT 31G X<br>5/16 .....   | 179, 180, 181, 182 | UNIFINE SAFECONTROL PEN NEEDLE<br>32G X 4 MM..... | 180, 181, 182    |
| ULTRA-THIN II INSULIN SYRINGE 29G<br>X 1/2.....   | 180, 181, 182      | UNIFINE ULTRA PEN NEEDLE 31G X 5<br>MM .....      | 180, 181, 182    |
| ULTRA-THIN II MINI PEN NEEDLE 31G<br>X 5 MM.....  | 180, 181, 182      | UNIFINE ULTRA PEN NEEDLE 31G X 6<br>MM .....      | 180, 181, 182    |
| ULTRA-THIN II PEN NEEDLE SHORT<br>31G X 8 MM..... | 180, 181, 182      | UNIFINE ULTRA PEN NEEDLE 31G X 8<br>MM .....      | 180, 181, 182    |

|   |               |  |               |
|---|---------------|--|---------------|
| UNIFINE ULTRA PEN NEEDLE 32G X 4<br>MM .....  | 180, 181, 182 | VERZENIO.....  | 6             |
| UPTRAVI ORAL TABLET 1000 MCG,<br>1200 MCG, 1400 MCG, 1600 MCG, 200<br>MCG, 400 MCG, 600 MCG, 800 MCG<br>..... | 310           | vigabatrin .....   | 395           |
| UPTRAVI TITRATION.....  | 310           | vigadrone.....   | 395           |
| ustekinumab-aauz .....  | 379, 380      | vigpoder .....   | 395           |
| <b>V</b>  |               | VITRAKVI ORAL CAPSULE 100 MG, 25<br>MG .....                           | 195           |
| VALCHLOR.....   | 222           | VITRAKVI ORAL SOLUTION .....   | 195           |
| VALUE HEALTH INSULIN SYRINGE<br>29G X 1/2.....  | 180, 181, 182 | VIVIMUSTA .....  | 49            |
| VANFLYTA .....  | 282           | VIZIMPRO .....   | 80            |
| VANISHPOINT INSULIN SYRINGE 29G<br>X 5/16.....  | 180, 181, 182 | VONJO .....  | 258           |
| VANISHPOINT INSULIN SYRINGE 30G<br>X 3/16.....  | 180, 181, 182 | VOQUEZNA .....   | 398           |
| VANISHPOINT INSULIN SYRINGE 30G<br>X 5/16.....  | 181, 182      | VORANIGO .....   | 399           |
| VENCLEXTA ORAL TABLET 10 MG,<br>100 MG, 50 MG.....  | 393           | voriconazole oral suspension reconstituted<br>.....                    | 400           |
| VENCLEXTA STARTING PACK .....   | 393           | VOSEVI.....  | 322, 323      |
| VEOZAH .....  | 131, 132      | VOWST .....  | 127           |
| VERIFINE INSULIN PEN NEEDLE 29G<br>X 12MM.....  | 181, 182      | VP INSULIN SYRINGE 29G X 1/2 .....                                     | 181,<br>182   |
| VERIFINE INSULIN PEN NEEDLE 31G<br>X 5 MM.....  | 181, 182      | VUMERITY .....   | 93            |
| VERIFINE INSULIN PEN NEEDLE 32G<br>X 6 MM.....  | 181, 182      | VYALEV SUBCUTANEOUS SOLUTION<br>12-240 MG/ML.....                      | 136           |
| VERIFINE INSULIN SYRINGE 28G X 1/2<br>.....   | 181, 182      | VYLOY.....   | 405           |
| VERIFINE INSULIN SYRINGE 29G X 1/2<br>.....   | 181, 182      | VYNDAMAX.....  | 336           |
| VERIFINE INSULIN SYRINGE 30G X 1/2<br>.....   | 181, 182      | <b>W</b>   |               |
| VERIFINE INSULIN SYRINGE 30G X<br>5/16 .....  | 181, 182      | WEBCOL ALCOHOL PREP LARGE PAD<br>70 % .....                            | 181, 182      |
| VERIFINE INSULIN SYRINGE 31G X<br>5/16 .....  | 181, 182      | WEGMANS UNIFINE PENTIPS PLUS<br>31G X 8 MM.....                        | 181, 182      |
| VERIFINE PLUS PEN NEEDLE 31G X 5<br>MM .....  | 181, 182      | WELIREG.....   | 48            |
| VERIFINE PLUS PEN NEEDLE 31G X 8<br>MM .....  | 181, 182      | WINREVAIR.....   | 329, 330      |
| VERIFINE PLUS PEN NEEDLE 32G X 4<br>MM .....  | 181, 182      | <b>X</b>   |               |
| VERQUVO .....   | 394           | XALKORI ORAL CAPSULE.....  | 76            |
|   |               | XALKORI ORAL CAPSULE SPRINKLE<br>150 MG, 20 MG, 50 MG .....            | 77            |
|   |               | XDEMVY .....   | 215           |
|   |               | XELJANZ.....   | 360, 361      |
|   |               | XELJANZ XR .....   | 360, 361      |
|   |               | XERMELO .....  | 345           |
|   |               | XIFAXAN ORAL TABLET 200 MG, 550<br>MG .....                            | 291           |
|   |               | XOLAIR .....   | 253, 254, 255 |
|   |               | XOSPATA .....  | 143           |
|   |               | XPOVIO (100 MG ONCE WEEKLY)<br>ORAL TABLET THERAPY PACK 50<br>MG ..... | 311           |

|  |                    |
|--|--------------------|
| XPOVIO (40 MG ONCE WEEKLY) ORAL<br>TABLET THERAPY PACK 10 MG, 40<br>MG ..... | 311                |
| XPOVIO (40 MG TWICE WEEKLY)<br>ORAL TABLET THERAPY PACK 40<br>MG .....       | 311                |
| XPOVIO (60 MG ONCE WEEKLY) ORAL<br>TABLET THERAPY PACK 60 MG..               | 311                |
| XPOVIO (60 MG TWICE WEEKLY)...   | 311                |
| XPOVIO (80 MG ONCE WEEKLY) ORAL<br>TABLET THERAPY PACK 40 MG, 80<br>MG ..... | 311                |
| XPOVIO (80 MG TWICE WEEKLY)...   | 311                |
| XTANDI ORAL CAPSULE.....   | 115                |
| XTANDI ORAL TABLET 40 MG, 80 MG<br>.....                                     | 115                |
| <b>Y</b>   |                    |
| YERVOY .....   | 187                |
| YESINTEK .....   | 385, 386, 387, 388 |
| YONSA.....   | 8                  |

|   |          |
|---|----------|
| YUFLYMA (1 PEN).....                              | 14, 15   |
| YUFLYMA (2 SYRINGE).....                          | 14, 15   |
| YUFLYMA-CD/UC/HS STARTER ..                       | 14, 15   |
| <b>Z</b>  |          |
| ZEJULA ORAL CAPSULE .....                         | 241      |
| ZEJULA ORAL TABLET .....                          | 241      |
| ZELBORAF .....                                    | 392      |
| ZEVRX STERILE ALCOHOL PREP PAD<br>PAD 70 % .....  | 181, 182 |
| ZIIHERA.....                                      | 401      |
| ZIRABEV .....                                     | 53       |
| ZOLADEX.....                                      | 149      |
| ZTALMY .....                                      | 140      |
| ZTLIDO .....                                      | 210      |
| ZURZUVAE ORAL CAPSULE 20 MG, 25<br>MG, 30 MG..... | 407      |
| ZYDELIG .....                                     | 155      |
| ZYKADIA ORAL TABLET .....                         | 67       |
| ZYNLONTA.....                                     | 213      |
| ZYNYZ.....  | 287      |